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Abstract 
 
The process of transcription underlies the expression of all gene profiles. Normal 
expression is caused by carefully coordinating the assembly of transcriptional 
proteins at specific genes, a procedure mediated through transcription factors 
that bind specific sequences of DNA. The glucocorticoid receptor (GR) is a 
transcription factor that influences the expression of genes involved in 
inflammation pathways. Drug-like molecules targeting GR are  capable of 
stimulating GR to bind DNA; however, these molecules are unable to exert 
complete control over the members of the transcriptional complex recruited by 
GR. As such, we are limited in our control of GR activity. My dissertation focuses 
on addressing this with new GR ligands designed to recruit specific 
transcriptional proteins to produce novel, desired expression profiles. 
 
We first conjugated a GR molecule to a ligand of the protein FKBP. This 
bifunctional ligand was capable of localizing GR to DNA, recruiting FKBP-fusions 
to the GR-regulated gene, and producing transcriptional activity dictated by the 
recruitment. This was achieved with the recruitment of both a transcriptionally 
activating protein and a repressing protein, demonstrating the adaptability of this 
system to toggle the output of a gene of interest. 
 
The design of our system benefits from its inherent modularity; expanding to new 
targets is simply achieved through synthetic conjugation to an alternative ligand.  
In a first application of this strategy, we conjugated an agonistic GR ligand to a 
selective inhibitor of the transcriptional protein BRD4. Recruitment of BRD4 to 
GR resulted in the suppression of transcription at select genes, and this 
selectivity drives a novel profile of activated and suppressed genes. In a second 
application, we conjugated a GR antagonist to the BRD4 inhibitor, allowing for 
 xii 
the further production of novel transcriptional profiles with potential 
pharmacological utility. 
 
This dissertation also includes a study aimed at introducing undergraduate 
students to the scientific principles of modern chemical biology research. To 
enhance student learning, we have developed a new guided-inquiry experimental 
module for biochemistry laboratory courses. This has been well received, and 
assessment metrics indicate that the incorporation into the University of 
Michigan’s biochemistry course has raised student cognitive abilities in analysis 
and application. 
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Chapter 1 
 
Small molecule regulation of protein complex assembly 
 
1.1 Abstract 
 
Cellular growth and maintenance are accomplished by multiprotein complexes 
assembled via protein-protein interactions. Often these are dynamic assemblies, 
with the formation of protein-protein interactions governed by post-translational 
modifications and ligand-induced allosteric changes. Anomalous formation and 
abnormal interactions within such multiprotein complexes is implicated in 
countless disease states, including several cancers and neurological disorders. 
There is thus significant effort aimed at identifying small molecules that could 
regulate the assembly of complexes such as the transcriptional machinery. A 
particular challenge in that regard has been the discovery of molecules that 
induce the assembly of specific protein complexes. The focus of this introductory 
chapter is to outline the challenges associated with developing small molecule 
activators of protein complex assembly, with a particular focus on transcription. 
Successful examples, including therapeutic applications, are also described. 
  
1.2 Introduction 
 
The assembly of multiprotein complexes is an elaborate process that plays a key 
role in numerous physiological activities1,2. Proteasomal degradation, gene 
transcription, protein synthesis, and chaperone-mediated folding, for example, 
are tasks accomplished by multi-protein machines that are dynamically 
assembled via protein-protein interactions (PPIs) (represented in Fig. 1.1). The 
! 2!
number of distinct, binary PPIs in a cell has been estimated at ~ 130,0003, and 
thus PPIs represent an attractive target for modulating the assembly and, thus, 
function of multiprotein complexes. While many efforts are currently being 
undertaken to develop small molecules that disrupt PPIs, there have been far 
fewer devoted to the chemical induction of PPIs. Here, several natural and 
engineered systems are described wherein PPIs are produced in response to or 
created through the use of small molecules. 
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Figure 1.1 Biological processes are driven by multiprotein complexation. A: The function of many 
proteins is dependent on proper folding through chaperone complexes. Chaperone proteins, in concert 
with various cochaperone partners, facilitate the proper folding of many substrates. B: Transcriptional 
regulation is mediated through extensive protein-protein interactions. Transcription factors, 
recognizing target DNA sequences through a DNA-binding domain (DBD), use a transcriptional 
activation domain (TAD) to recruit members of the transcriptional machinery, such as the Mediator 
complex (Med) and RNA polymerases, to activate the expression of genes. C: Proteasomal 
degradation is carried out through interactions of many proteins. Ubiquitin ligases recognize 
degradation targets and facilitate the enzymatic attachment of ubiquityl groups to the substrate. 
Recognizing polyubiquityl signals, the proteasome facilitates the degradation of the substrate target. 
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1.3 Naturally occurring molecular modulators of protein interactions 
 
Allosteric PPI modulators 
 
In eukaryotic systems, protein complexation often occurs as a result of allosteric 
ligand binding, such as in GPCR signaling4 or chaperone-mediated protein 
folding5. Allosteric induction of protein complexation enjoys many advantages 
relative to stimuli relying on enzymatic activity; for example, this allows protein 
partners to dictate interactions not through highly conserved active sites but 
instead through alternative binding sites, providing a mechanism for 
promiscuously binding proteins to form specific interactions in a context-
dependent manner4. Though many allosteric processes rely on protein ligand-
induced activities, hormonal signaling and gene regulation are notable for being 
particularly dependent on small molecules for the construction of correct protein 
complexes. 
 
For example, in the case of the nuclear receptors (NRs), activity is largely 
dependent on small molecule hormonal ligands6,7. Members of the NR family are 
transcription factors that effect changes in gene expression through the 
nucleation of the transcriptional machinery at specific genes.  Ligand binding 
triggers an allosteric shift in the NR, allowing for DNA binding and subsequent 
recruitment of several coregulator proteins to form a transcriptional complex that 
modulates gene transcription. Proper NR action is contingent on being able to 
correctly interact with specific coregulators out of potential partners numbering in 
the hundreds8,9. Aberrant NR interactions with coregulators has been implicated 
in the pathogenesis of several diseases, spurring numerous pharmacological 
efforts to produce synthetic hormones that produce desired transcriptional 
profiles by inducing ‘correct’ transcriptional complexes10. 
! 5!
 
An important target of this strategy is the glucocorticoid receptor (GR), owing to 
its role in important processes including inflammation and metabolism11. Similar 
to other NRs, GR is an allosterically regulated transcription factor dependent on 
the binding of endogenous corticosteroids for stimulated activity. When bound to 
the promoter of a GR-regulated gene, the receptor adopts a conformation 
capable of making specific contacts with a host of potential coregulators9,12, each 
capable of subsequent recruitment of transcriptional machinery. A complex 
transmittance of signals through GR, including properties of the bound ligand and 
promoter sequence, influence the specific conformation adopted and the 
resulting identity of recruited coregulators. Through this, a potentially 
promiscuous coregulator-binding interface13 is shaped to allow for only distinct 
complex formation and resultant transcriptional activity. 
 
Plant hormonal signaling has been less characterized than its mammalian 
counterpart, but recent discoveries have revealed that allostery plays a role in the 
transcriptional activity of many plant hormones, though in a fashion significantly 
different than for their mammalian counterparts. In the case of gibberellin 
hormones, Ueguchi-Tanaka and co-workers14 determined that the interaction of 
these molecules with their recently isolated receptor, GAD115, results in 
transcriptional modulation, but not through the formation of transcriptional 
complexes. Unlike in NR models, the gibberellin-GAD1 interaction does not 
cause DNA localization. Rather, gibberellins cause a conformational shift within 
GAD1 that triggers interaction with the constitutively active transcriptional 
repressor SLR1. The formation of this complex instigates ubuitylation of SLR1, 
resulting in the indirect upregulation of gibberellin-induced genes14. 
 
PPI stabilizers 
 
An alternative mechanism of small molecule PPI modulation occurs in scenarios 
wherein ligands act to stabilize transient PPIs. Inositol tetraphosphate (IP4) has 
! 6!
been known to play a key role in chromatin remodeling, but until recently the 
mechanism of action has been unclear16. Watson and coworkers17 identified IP4 
in a co-crystal structure of the histone deacetylase HDAC3 and the corepressor 
SMRT. IP4 acts as an ‘intermolecular glue,’ neutralizing electrostatic repulsions 
between several basic residues in the HDAC3-SMRT interaction cleft. 
 
Naturally occurring polyamines such as spermine, spermidine, and putrescine 
have also been shown to act as PPI stabilizers. Investigating the interactions 
between mitochondrial cytochrome P45011A1 and two electron transport 
partners, adrenodoxin (Adr) and adrenodoxin reductase (Adx), Berwanger and 
co-workers18 demonstrated a significant increase in association rate and binding 
strength between Adr and Adx in response to polyamine. Specific negatively 
charged residues in the Adr-Adx binding interface were identified as potential 
polyamine interaction points through docking studies and confirmed in 
subsequent mutagenesis experiments. 
 
Plant and fungal metabolites have shown to be a source of cytotoxics that act by 
stabilizing PPIs in non-native systems. Forskolin, a diterpene first isolated from 
Coleus Forskohlii19, has been used studies as a potent activator of adenylyl 
cyclase (AC), raising intracellular cyclic AMP levels20. Upon obtaining a crystal 
structure of the AC catalytic site, Zhang and coworkers21 identified a solvent-
exposed hydrophobic cavity as the forskolin binding site, allowing for a more 
energetically favorable dimerization and activation of AC, triggering the 
potentially cytotoxic event. A similar story unfolded as researchers probed the 
mechanism of action of brefeldin A, a fungal macrolactone commonly used to 
study intracellular protein transport22. Biochemical23 and structural studies24 
revealed that brefeldin A stabilizes the interaction between members of the ARF 
family of G proteins and the associated exchange factors (GEFs). The ARF-
brefeldin A-GEF complex is functionally compromised, triggering the movement 
of Golgi-associated membrane proteins to the endoplasmic reticulum. 
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Novel PPI inducers 
 
A number of natural products cause an extreme version of PPI stabilization, 
inducing the dimerization between two non-interacting proteins by first binding a 
target and then presenting a molecular surface to bind a second target. These 
are termed chemical inducers of dimerization (CIDs). Cyclosporine A (CsA) is a 
non-ribosomal cyclic peptide that has been used as an immunosuppressant for 
decades25. CsA effects this immunomodulatory action through the inhibition of 
calcineurin, a phosphatase involved in T cell activation26. Interestingly, CsA does 
not directly inhibit the calcineurin active site but instead binds a distal surface – 
inhibition occurs because CsA simultaneously binds cyclophilin A and 
recruitment of this second target render the calcineurin catalytic domain 
inaccessible27,28.  
 
Rapamycin29 and FK506 (tacrolimus) 30,31 are two fungal macrolactones that act 
as immunosuppressants through similar mechanisms of action as CsA27,28,32. 
Owing to a highly similar scaffold (Fig. 1.2), each binds the prolyl isomerase 
FKBP12 with extremely high affinity (FK506 Kd: 0.4 nM; rapamycin Kd: 0.2 nM)33. 
As with CsA, each inhibits a secondary target in addition to FKBP12. Despite 
limited structural resemblance between the two, FK506 likewise binds several of 
the same residues in calcineurin28. This FK506-induced interaction prevents 
calcineurin enzymatic activity34. Rapamycin, however, does not affect calcineurin 
activity – mechanistic studies have revealed that it targets the kinase mTOR, an 
alternative target in immunomodulatory signaling (Figure 1.2). Free energy 
binding analysis revealed that the recruitment of FKBP to mTOR is entirely 
directed through protein-rapamycin interactions, with very limited interactions 
occurring directly between the two proteins35. The ability of these two metabolites 
to induce the heterodimerization of distinct targets bears high utility, though 
limitations concerning off-target interactions necessitated further refinement for 
nuanced applications. 
 
! 8!
 
 
 
1.4 Engineering systems for chemically-inducing protein interactions 
 
Homodimerizing Molecules 
 
Following the elucidation of the mechanisms of action for FK506 and rapamycin, 
collaborators in Gerald Crabtree’s and Stuart Schreiber’s laboratories worked to 
develop a system wherein separate proteins could be localized through a 
dimerizing synthetic ligand. By connecting two molecules of FK506 through a 
hydrocarbon linker, they produced a dimeric “bifunctional” molecule, termed 
FK101236. In the first example of the utility of this strategy, Spencer and co-
workers36 stimulated cell surface receptor signaling in T-cells by expressing the 
receptors as FKBP-fusion proteins and treating with FK1012; the induced 
proximity of the receptors acted as a surrogate for natural dimerization. In 
designing FK1012, the point of conjugation was chosen to be at a key contact 
with calcineurin, interfering with its recruitment to the FKBP-FK1012 complex and 
lowering associated toxicity.  
Figure 1.2 Illustrating the similarities and differences between PPI inducers. FK506 and rapamycin 
share a common, highly similar FKBP-binding domain (blue), while differing in other portions of 
the scaffold. This is highlighted calcineurin-binding portion of FK506 (red) and the mTOR-binding 
portion of rapamycin (orange). 
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Given the ease of expressing chimeric FKBP-fusion proteins in cellular systems, 
this development spurred the investigation into the role of protein localization in 
many cellular processes; this has been described in several reviews37-42. Despite 
its broad utility, a limitation to this system is that FK1012 interacts with 
endogenous FKBP proteins, interfering with signaling. Researchers at Ariad 
Gene Therapeutics employed a two-pronged approach to this issue, developing 
a number of alternative synthetic ligands for FKBP43 and engineering mutated 
forms of the protein with unique binding profiles44,45. 
 
An alternative method for avoiding undesirable protein-ligand interactions, such 
as FK1012 with endogenous FKBPs, is to express non-native dimerization 
targets in cellular systems. Many high affinity inhibitors of bacterial proteins have 
been described, and several have been cleverly repurposed as dimerizers. A 
particularly attractive example involves the aminocoumarin family of antibiotics. 
Investigations with this class of natural products revealed an inhibition of E. coli 
DNA gyrase B activity (gyrB) 46,47. Importantly, researchers in the Maxwell 
laboratory discovered that coumermycin, a member of the family bearing a 
natural symmetry (Fig. 1.3), is capable of binding two molecules of the gyrB N-
terminal domain, inducing dimer formation48,49. Though coumermycin does not 
bind gyrB with the same high affinity as FK506 for its target (Kd: ~ 24 nM), Farrar 
and coworkers50 were able to utilize its ability to dimerize gyrB in an engineered 
signal transduction system, activating the MAP kinase cascade through the 
courmermycin-mediated dimerization of Raf1 kinase-gyrB fusion proteins.  
 
An additional limitation of FK506-based homodimerization systems is the non-
trivial nature of FK1012 synthesis and modification. Kopytek and coworkers51 
recognized the potential for a methotrexate-based dimerization system given its 
high affinity for dihydrofolate reductase (DHFR) (Kd: 8.5 nM)52. A bifunctional 
version of methotrexate, termed BisMTX, was synthetically accessible in three 
steps and, somewhat unexpectedly, promoted a cooperative binding event 
! 10!
between DHFR monomers, effecting a higher rate of complex formation than 
predicted51. 
 
Heterodimerizing Molecules 
 
The systems described heretofore provide the capability for inducing protein self-
association. However, these methods are ill equipped to localize dissimilar 
proteins. For example, in a system where proteins A and B have been expressed 
as FKBP-fusions, the introduction of FK1012 would yield a heterogeneous 
population of A–A, A–B, and B–B dimers. The identification of a small, 90 amino 
acid sub-domain capable of binding the FKBP-rapamycin complex53 aided the 
design of a system wherein rapamycin is capable of inducing gene transcription, 
allowing for a fusion moiety less intrusive than full length mTOR. Rapamycin 
potently triggered the dimerization of a DNA-binding domain fused to FKBP and 
a transcriptional activation domain-FRB chimera, stimulating the expression of a 
target gene in both cellular and in vivo mice studies54. The rapamycin-induced 
co-localization of alternative targets has been greatly expanded and has been 
reviewed recently55. 
 
Building off of the success of FK1012 (and in need of alternatives to the 
potentially toxic rapamycin), additional work on developing heterodimerizing 
systems focused on producing new bifunctional molecules that bear divergent 
chemical moieties. Following the establishment of CsA as an alternative to 
FK506 for building a bifunctional molecule56, a synthetic molecule linking FK506 
to CsA was constructed, termed FKCsA57. Employing appropriate fusion proteins, 
Belshaw and coworkers were able to use FKCsA to induce a multitude of cellular 
processes, including protein localization and transcriptional activity. 
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A 
B 
C 
Figure 1.3 Chemical homo- and heterodimerizers. A: Coumermycin contains two DNA gyrase B-
binding moieties (blue). The symmetry of this molecule allows for simultaneous binding of two gyrase 
molecules, causing effective dimerization45,46. B: The designed molecule Bis-MTX48 takes advantage of 
methotrexate’s (pink) potent binding of dihydrofolate reductase (DHFR) to localize two reductase 
molecules, causing the effective dimerization of proteins fused to DHFR. C: An assymetrical chemical 
dimerizer allows for heterodimerization. Linking dexamethasone (green) to FK506 (orange) produced 
Dex-FK50672, allowing for the cellular localization of glucocorticoid receptor ligand-binding domain 
(LBD) to FKBP, causing the functional effects of dimerizing any potential fusion partners of these 
proteins. ! 
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1.5 Refining new systems for chemical dimerization 
 
Expanding available heterodimerizers 
 
The utility of the dimerizing systems described stimulated further investigations 
into refinement and discovery of more selective and effective dimerizers (several 
depicted in Fig. 1.3). The use of natural product-based dimerizers is restricted by 
synthetic barriers, including high cost and difficulty of manipulation, and limited 
bioorthogonality, evidenced by the shared FK506/rapamycin target. Looking to 
address these issues, researchers in the Crabtree laboratory have recently 
identified a plant phytohormone as a new inducer of dimerization58. (S)Abscisic 
acid (ABA) targets the pyrabactin resistance (PYR)/PYR1-like (PYL)/regulatory 
component of ABA receptor (RCAR) and protein phosphatase type 2Cs (PP2Cs), 
members of a signaling pathway not present in mammalian systems59,60. Liang 
and coworkers58 identified minimal ABA-binding domains of RCAR and PP2Cs 
for protein fusion and demonstrated ABA-induced gene transcription, protein 
localization, and signal transduction. Compared to an analogous rapamycin-
induced system, ABA-mediated activity was more readily reversed through the 
removal of compound, and higher doses of ABA were also typically required to 
produce signal. 
 
Researchers in the Inoue lab61,62 similarly looked to plant biology for inspiration in 
crafting new dimerization systems. Taking advantage of gibberellin-induced 
interaction of GAD1 with SLR114,15, they discovered that acetoxymethylated 
gibberellin (GA3-AM) is cell permeable and capable of rapidly inducing the 
interaction of GAD1 and SLR1 expressed in mammalian cells. More germane to 
this discussion, a series of systematic truncations yielded uncovered minimal 
domains that maintained similar dimerization efficiency. These researchers 
further demonstrated that the GA3-AM system could be used simultaneously and 
orthogonally to a rapamycin-inducible system, allowing for the construction of a 
simple and rapid “genetic” cellular logic gate61,62. 
! 13!
 
Irreversible Heterodimerizer Interactions 
 
Reversible ligand binding, as has been described above, presents certain 
challenges in the design of heterodimerizing molecules. Disparate ligand-binding 
kinetics between the constituent members of a bifunctional molecule can make 
dimerization efficiency challenging to predict or measure63,64, and certain cellular 
signals can be difficult to detect when induced by transient dimerization. Attempts 
to address these issues have centered on developing tool proteins that 
covalently link to their targets, providing a method for irreversible induction of a 
PPI. 
 
Members of the Johnsson laboratory pioneered early work in this field. Initially 
seeking to provide a method for covalent fluorophore labeling of proteins, they 
identified the human DNA repair protein O6-alkylguanine-DNA alkyltransferase 
(hAGT) as a potential tool for controlled covalent bond formation between a 
unique ligand and a designed protein65. hAGT readily recognizes O6-
benzylguanine derivatives and forms a covalent linkage with the benzylic carbon; 
as a result, hAGT is labeled with any chemical moiety linked to the substrate. 
Subsequent directed evolution of hAGT produced a mutant, commercially 
marketed as the ‘SNAP-tag,’ that displays a 50-fold enhanced activity relative to 
wild type hAGT66. Homodimers of the hAGT substrate were produced that 
demonstrated the ability of this technology to allow for extended, ‘permanent’ 
induced dimerization of target proteins67, and a further extension of this 
technology displayed the ability to modulate gene transcription through covalent 
dimerization of transcription factor domains68. Mimicking the efforts of previous 
researchers, members of Covalys biosciences quickly moved to develop 
orthogonal labeling systems that can be used in combination with the SNAP-tag. 
Termed the ‘CLIP-tag,’ they engineered a SNAP-tag mutant that recognizes and 
covalently links to O2-benzylcytosine derivatives. Notably, the CLIP-tag displayed 
a higher substrate turnover than the SNAP-tag, and the two systems were 
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successfully used in tandem for fluorophore protein-labeling69 and selective 
heterodimerization70.  
 
This methodology was even further expanded with development of the HaloTag, 
a modified dehalogenase enzyme that recognizes chloroalkane moieties71. 
Though this fusion tag is larger in size than the SNAP- or CLIP-tags, with a 
higher potential for interfering with normal protein function through its attachment, 
its use has displayed lowered toxicity and minimized interactions with off-target 
proteins, in addition to requiring a synthetically trivial chemical tag. 
Demonstrating its use as an orthogonal tool to the SNAP-tag, Chidley and 
coworkers72 showed that that the tandem use of bifunctional molecules bearing 
either the Halo or SNAP substrate could be used to localize target proteins to a 
SNAP-Halo fusion protein. Members of the Wymann laboratory73 have designed 
and developed a series of bifunctional molecules that bear both substrates, 
termed HaXS molecules, allowing for an alternative method of protein 
heterodimerization through the expression of two fusions and introduction of a 
single HaXS. Recognizing the potential utility of covalent dimerizers with induced 
reversible activity, they developed a HaXS that incorporates a nitroveratryl group 
in its linker (MeNV-HaXS). While retaining a potent ability for protein 
heterodimerization, MeNV-HaXS is quickly degraded in the presence of near-UV 
light, allowing for a rapid reversal of induced protein localization74.  
 
1.6 Heterodimerizing molecules as tools 
 
Three-hybrid Studies 
 
One of the most powerful and widely used applications of chemical 
heterodimerizing systems is the three-hybrid assay. Using the two-hybrid assay 
for detecting protein-protein interactions as a model, in its initial application Licitra 
and Liu75 took advantage of the modular nature of transcription factors to build a 
model wherein a DNA-binding domain (DBD) and transcriptional activation 
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domain (TAD) are linked through a heterobifunctional molecule (a FK506-
glucocorticoid conjugate. Successful chemical heterodimerization of a DBD and 
TAD results in the transcription of a reporter gene. The application of this 
technology has been widespread and has been reviewed extensively37,41,76,77. 
 
Protein Localization 
 
Inducing protein localization is the focal point of the majority of induced 
dimerization systems. From this standpoint, the possibilities have been versatile 
and well described5,41,42. However, the systems described heretofore rely on the 
utilization of genetically fusing protein tags to localization targets. Recent work by 
Ishida and coworkers has focused on developing ‘self-localizing’ bifunctional 
molecules that recruit target molecules to specific cellular locations78. In 
preliminary experiments, DHFR was successfully localized to microtubules, the 
Golgi, and the nucleus, by synthetically conjugating the DHFR-inhibitor 
trimethoprim to various localizing moieties. This strategy is limited to protein and 
localization targets with defined ligands, but with recent efforts to unearth 
molecular modulators of non-enzymatic targets, this methodology is promising for 
future work on chemically induced protein localization. 
 
Temporal Control Over Enzymatic Activity 
 
The emergence of split-protein systems as reliable tools for detecting PPIs79 has 
led to a surge in the number of available models for enzyme reassembly. This 
has opened up opportunities for using chemically induced dimerization for the 
induction of enzymatic activity. Building off of a similar idea originally pioneered 
in the Muir laboratory80,81, Camacho-Soto and coworkers82 have recently 
developed dimerizer-inducible kinases and phosphatases, relying on rapamycin, 
ABA, or gibberellic acid to localize split enzyme-fusion proteins and trigger 
activity. Their initial efforts suffer from a reliance on high levels of dimerizing 
molecule and a lack of control over enzymatic substrate specificity, but the tools 
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they have initially described allows an orthogonal and (subsequently temporal) 
control over cellular phosphorylation activity that is promising. 
 
1.7. Therapeutic utility of dimerizing molecules 
 
Chemical biologists develop nuanced and intriguing tool compounds to aid 
investigations of biological systems. However, it is important to situate this work 
in the perspective that the ultimate goal of these efforts is towards the 
advancement of therapeutics. The necessity for engineered systems, often 
utilizing large protein tags, precludes much of this work from advancing outside 
of tool compound research. Despite this, several methodologies and targets 
appear particularly amenable to using dimerizing molecules as potential tools in 
therapeutic development. 
 
Inhibiting protein aggregation 
 
Transthyretin, a thyroxine transporter, has been implicated in the pathogenesis of 
several amyloidoses83-85.  Monomeric dissociation and aggregation of this 
normally homotetrameric protein is increased in the presence of destabilizing 
point mutations, with several having demonstrated linkages to clinical 
pathologies84,86,87. Working to develop a molecular stabilizer of homotetrameric 
transthyretin, researchers in Jeffrey Kelly’s laboratory discovered Tafamidis, a 
benzoxazole that decreases transthyretin aggregation and amyloid formation. 
Further studies yielded a crystal structure, detailing how Tafamidis stabilizes the 
oligomeric species by interacting with two thyroxine-binding cavities88. Tafamidis 
has recently been approved in Europe and Japan for use in the treatment of 
familial amyloid neuropathy. 
 
Targeted Antibody Recruitment 
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Triggering selective antibody recruitment to specific cells would be a useful 
method for instigating a native immune system to eliminate tumorigenic species. 
Exploring this idea, members of the Kiessling laboratory89 established an initial 
platform for using bifunctional molecules to induce the localization of antibodies 
to specific cells. Linking a cell surface receptor ligand to a trisaccharide, they 
demonstrated a recruitment of an antibody recognizing the sugar epitope that 
was selective for cells displaying the receptor. O’Reilly and coworkers90 were 
able to utilize a similar strategy to target a B-cell surface receptor, CD22, that 
had proven notoriously difficult to target with small molecules ligands. However, 
the bifunctional ligand-mediated recruitment of antibodies allowed a weak ligand 
to overcome this through an avidity-driven assembly of antibody-CD22 
complexes. Parker and coworkers91 used a similar small molecule epitope linked 
to molecule targeting HIV glycoprotein 20 (gp120). Here they demonstrated that 
binding of gp120 by the small molecule allowed subsequent antibody recruitment 
and cytotoxicity to human cells expressing gp120, and have recently 
demonstrated encouraging success in developing a platform of small molecules 
capable of triggering antibody recruitment92. 
 
Protein Quality Control 
 
A popular alternative to inhibiting a malignant protein’s activity is to instigate its 
degradation. Collaborators in the Crews and Deshaies laboratories have 
pioneered the use of small bifunctional molecules to target specific proteins for 
degradations. Reviewed recently93, their approach has centered on the ability to 
localize ubiquitin E3 ligases to targeted proteins, relying on proximity 
accompanied by this ternary complex to induce ubuitylation of the target and 
subsequent degradation. These molecules, termed proteolysis targeting 
chimeras (PROTACs), initially utilized short peptidic sequences to signal ligase 
recruitment94 but have recently included a Nutlin-based moiety capable of 
targeting the E3 ligase MDM295. Attempting to circumvent the poor efficacy of 
Nutlin-based PROTACs, researchers in the Hashimoto laboratory96,97 have 
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developed an alternative system targeting the E3 ligase cIAP1; however, this 
system similarly suffers from poor potency. Members of the Crews laboratory 
have also uncovered an alternative method of selective protein degradation, 
termed “hydrophobic tagging”98. Here, the covalent linkage of an adamantyl 
group to a HaloTag molecule led to degradation of the protein, though the 
mechanism of this response is still unclear. Further examinations should reveal if 
this strategy can be applied to non-covalent systems, utilizing native ligands 
modified with an adamantyl moiety.  
 
Controlling transcriptional assembly 
 
As stated in section 1.3, nuclear receptors have been well characterized as 
targets for molecule-induced complex formation99. Influenced not just by ligand-
binding7,10 but also post-translational modifications100,101, promoter sequence and 
location102-104, and cellular coregulator levels9,12,105, NR activity is the result of 
processing these complex signals and building defined transcriptional machinery. 
However, the identity of complex members at gene targets is difficult to predict 
and is often still a mystery106,107. Misregulation of complex assembly is a driver in 
the pathogenesis of many diseases10,11,108 and the importance of developing 
methods for directed complex assembly is of the utmost importance. However, it 
is becoming increasingly clear that dynamic control of complex formation is a 
significant undertaking. Recently, several research groups have begun to break 
from the paradigm of using NR ligands to target the LBD to effect wanted 
transcriptional outcomes. These efforts have largely focused on modulating and 
inhibiting the interaction between NRs and coregulators, either through recruited 
steric hindrance109 or through targeting a conserved NR-coregulator interface110-
118. An unprobed strategy for NR activity modulation is the designed assembly of 
transcriptional machinery by using small molecules to localize specific 
coregulators to specific NRs. In lieu of inducing desired PPIs, properly designed 
bifunctional molecules act as PPI surrogates, circumventing allosterically driven 
interactions in favor of designed, predictable interactions, permitting rationally 
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provoked transcriptional profiles. The advancement of chemical 
heterodimerization methods makes this strategy particularly attractive in light of 
the recent expansion of the chemical ‘toolbox’ of probes targeting epigenetic 
proteins119-121. With this knowledge, the rational design of selective bifunctional 
NR ligands will permit a more controlled assembly of transcriptional machinery at 
NR-regulated genes, providing a method to greatly expand our ability to produce 
precise transcriptional profiles. 
 
1.8 Research goals 
 
The primary focus of work outlined in this dissertation is to test the idea of using 
bifunctional ligands as modulators of NR activity in an endogenous context. The 
first goal in the establishment of this strategy is to validate that bifunctional 
steroidal molecules can recruit specific proteins to a DNA-bound receptor. In 
Chapter 2, I discuss the use of several target proteins and evaluate the functional 
effects of their recruitment. The second goal of this work lies in its application of 
this strategy; chiefly, I aim to use designed molecules to produce novel, predicted 
transcriptional outputs dependent on recruitment, and this is the topic of Chapter 
3. A final goal of my graduate work has developed outside of the research 
laboratory, concerning undergraduate biochemistry education at the University of 
Michigan. In Chapter 4, efforts to rationally redesign portions of this course’s 
syllabus through the incorporation of guided-inquiry, and the subsequent results 
thereof, will be discussed.  
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Chapter 2 
 
Using Bifunctional Molecules to Recruit Specific Proteins to a DNA-Bound 
Glucocorticoid Receptor* 
 
 
2.1 Abstract 
 
Nuclear receptors are ligand-induced transcription factors. This family, including 
the sub-class of steroid receptors, responds to specific small molecule hormonal 
stimuli through nuclear translocation and the modulation of regulated-genes. 
Transcriptional outcome is effected through allostery, where ligand shape and 
binding affinity influences receptor conformation and subsequent interaction with 
transcriptional coregulators. Traditional synthetic ligands have sought to take 
advantage of this by inducing specific conformations to produce desired 
transcriptional evidence. However, recent discoveries have shed light on the 
limitations of this approach, including the necessarily constrained suite of 
conformations accessible by the receptor. We have shown that bifunctional 
molecules, aiming to bind both a nuclear receptor and a non-native interaction 
partner, are capable of acting as protein-protein interaction surrogates, localizing 
each target and producing the functional consequence of interaction. This 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!*!This work represents a collaborative effort, portions of which have been published: Højfeldt, 
J.W.; Cruz-Rodriguez, O.; Van Dyke, A.R.; Imaeda, Y.; Carolan, J.P.; Mapp, A.K.; Iñiguez-Lluhí, 
J. Mol. Endocrinol. 2014, 28, 249-259. Compounds described in Figure 2.5 were synthesized J. 
Carolan, J. Højfeldt, Y. Imaeda, and A. Van Dyke. Data in Figures 2.6, 2.9, and 2.11 were 
obtained by O. Cruz-Rodriguez and J. Iñiguez-Lluhí. Data in Figures 2.7 and 2.10 were collected 
with O. Cruz-Rodriguez. Compounds described in Figure 2.12 were synthesized by A. Van Dyke 
and J. Qi. Data in Figure 2.13 were collected by A. Van Dyke. All other experiments were 
performed by J. Carolan. Where indicated, statistical significances are represented as *: p < 0.05; 
**: p < 0.01; ***: p < 0.001.!
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strategy has been applied to the glucocorticoid receptor and the results are 
described here. 
 
2.2 Nuclear receptors are ligand-induced transcription factors 
 
Nuclear receptors (NRs) are a large class of ligand-dependent transcription 
factors typically containing a ligand-binding domain (LBD) and a separate DNA-
binding domain (DBD) capable of recognizing short, often palindromic recognition 
sequences1. Driving the actions of a receptor is a ligand-binding event, wherein a 
NR will typically respond by undergoing a conformational shift and nuclear 
localization. The receptor influences the transcription of a gene by inducing the 
formation of a coregulatory complex at the recognition sequences2,3. Integrating 
directions from DNA sequences4-6, signaling cascades7, and the bound ligand, 
the identity of the members in the transcriptional complex determines subsequent 
up- or down-regulation of a gene8 (Fig. 2.1A). 
 
NRs play a critical role in the signaling pathways of countless physiological 
processes, including embryonic development, maintaining homeostasis, and 
metabolism9. Unsurprisingly, dysregulation of NRs is associated with a variety of 
disease10 and, thus, this protein family has been the focus of numerous drug 
discovery efforts. Currently, NR-targeting synthetic ligands comprise 10-15% of 
marketed pharmaceuticals11.  
 
The canonical mechanism of NR action involves the ligand-induced 
rearrangement of a key α-helix in the LBD, helix 1212-14. It has been believed that 
the orientation of this dynamic surface plays a key role in determining coregulator 
interactions. As such, traditional efforts to develop NR molecular probes and 
drugs have centered on the construction of ligands designed to provoke specific 
conformational shifts within the LBD as a means of gaining greater control over 
produced transcriptional profiles15. Current therapeutics that accomplish this are 
often limited by undesirable side effects or the development of resistance. 
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Recent efforts have often focused on opening pathways to alternative 
mechanisms of transcriptional control16, such as in the development of selective 
estrogen receptor modulators (SERMs) that rely on differential receptor isoform 
expression for selectivity17,18. An alternative, non-canonical method of modulating 
NR action has centered on developing protein-protein interaction (PPI) inhibitors, 
identifying the NR-coregulator interface as a potential point of interference. This 
interaction site has been extensively studied in several NRs, such as the 
estrogen receptor (ER)19 and thyroid receptor (TR)20, and elegantly designed 
peptide probes with high affinity and selectivity for these interactions in vitro have 
been described, termed coactivator-binding inhibitors21-24 (Fig. 2.1B). However, 
several thorough attempts to develop small molecule probes25 targeting this 
interaction have been fraught with the typical difficulties of small molecule 
inhibition of PPIs, namely selectivity and potency26, alongside the inability to 
target proteins interaction at other positions. 
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Many early pharmacological efforts were built on assumptions that NR activity is 
largely moderated through interactions of coregulators with the LBD. However, 
recent biochemical characterizations have helped clarify the roles played by post-
translational modifications7 and DNA-binding sequences5,6, termed hormone 
response elements (HREs), in activity modulation. Further complicating our 
understanding is the discovery that, in many NRs, unstructured portions of the N-
terminal domain organize following HRE binding, allowing for a secondary 
coregulator interaction site; indeed, this site is believed to more significantly 
impact transcriptional activity than the LBD for certain NRs, such as the 
androgen receptor (AR) 27,28.  
Figure 2.1 Ligand-induced NR action. In the top panel (A), the canonical mechanism of NR action is 
depicted. On ligand binding, the NR translocates from the cytoplasm to the nucleus, dimerizes, and 
recruits transcriptional machinery to NR-regulated genes. In B, the actions of a CBI are depicted. Here, 
a peptide probe or small molecule inhibitor prevents the NR helix 12 from recruiting a coactivator, 
inhibiting the assembly of transcriptional machinery. 
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Accounting for this additional information, it is unsurprising that recently designed 
ligands have been unable to elicit the nuanced transcriptional outcomes desired 
by their creators – though desired PPIs at one site are produced, it is difficult to 
predict or control for PPIs formed outside of the allosterically rearranged LBD. 
Acknowledging this, an attractive method of NR control would be through the use 
of ligands capable of recruiting specific coregulators. Designed properly, a 
‘bifunctional’ molecule linking a NR molecule to a coregulator ligand could serve 
as a ‘PPI surrogate,’ bridging the two targets and inducing the functional 
outcomes of association; accordingly, this may serve as an opportunity to unlock 
unique transcriptional profiles (Fig. 2.2).  
 
 
 
Here, we investigate the ability of bifunctional NR ligands to recruit specific 
proteins and the function consequences thereof, utilizing the glucocorticoid 
receptor (GR) as a representative of this family of transcription factors.  
 
2.3 The glucocorticoid receptor as a target for transcriptional modulation 
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Figure 2.2 Bifunctional NR ligands. Where  canonical NR ligands rely on allostery to direct coregulator 
recruitment and direct transcriptional activity, a bifunctional NR ligand is capable of extrinsic, directed 
recruitment, producing unique transcriptional profiles. 
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The glucocorticoid receptor (GR) is a widely expressed transcription factor, and a 
prototype of the steroid receptor (SR) sub-class of the nuclear receptor family. 
Members of this family share a modular structure composed of DNA-binding 
domain (DBD), N-terminal activation domain (AF1), and a C-terminal ligand-
binding domain (LBD) bearing an additional, independently-acting activation 
domain (AF2)29. As with other NRs, GR action is primarily facilitated through the 
binding of its endogenous agonist, cortisol, a steroidal ligand produced in the 
adrenal cortex. Cortisol binding by the GR LBD triggers the disassembly of a GR-
chaperone complex, allowing for nuclear localization of GR. Primary GR 
transcriptional activity occurs as the nuclear-bound GR homodimerizes and binds 
to semi-palindromic, fifteen bp DNA sequences termed glucocorticoid response 
elements (GREs)6. Despite a loose conservation in both GRE sequence and 
location relative to a modulated gene, this interaction often leads to an increase 
in gene transcript levels, termed transactivation, though to varying magnitudes30-
32.  
 
Activated GR can also act to repress the transcription of other genes through 
several mechanisms. One such mechanism involves GR binding to non-GRE 
DNA sequences; here, GR interferes by adopting a conformation that favors 
corepressor recruitment, or, alternatively, by simply interfering with DNA-binding 
by other transcription factors. A related mechanism is implicated in GR action as 
a mediator in anti-inflammatory signaling, where ligand-bound GR is believed to 
physically interact and interfere with the pro-inflammatory transcription factors 
AP-133 and NF-κB34,35. The use of therapeutic glucocorticoids as anti-
inflammatories takes advantage of this GR activity; however, transactivation has 
been linked to the numerous side effects associated with glucocorticoid use36. 
While the GR LBD has been utilized as a successful tool for conducting three-
hybrid assays37, the use of bifunctional glucocorticoids has yet to be exploited for 
regulation of the full length, intact receptor. Though the focus of this project is not 
necessarily to produce dissociated ligands capable of transrepression in the 
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absence of transactivation, this approach will allow for the general production of 
new ligands with unique transcription profiles. 
 
2.4 Recruitment of exogenous proteins to the native glucocorticoid 
receptor 
 
A primary goal of this project is to determine if the principles underlying the three-
hybrid assay can be applied to the full length, native GR; chiefly, we aim to test if 
this approach can be used to recruit specific proteins and direct transcriptional 
outcomes. To this end, we set to determine if a three-hybrid assay could be 
constructed utilizing the native GR. While this is conceptually a small step 
forward, the challenges in this design are considerable. It requires the 
construction of a molecule that is capable of several activities: binding and 
localizing the GR to its GRE consensus sequences; recruiting a secondary 
protein to DNA-bound GR; and localizing that secondary protein in such a 
fashion that it directs transcriptional outcomes over competing interaction 
partners through the GR’s AF1 and AF2. We identified previous three-hybrid 
experiments that have successfully linked GR LBD to the prolyl-isomerase 
protein FK506-binding protein (FKBP) and used these to guide the design of a 
bifunctional molecule37-39. 
 
Synthetic conjugation of a GR- and FKBP-ligand 
 
Dexamethasone (Dex) is a synthetic GR agonist designed to be significantly 
more potent and efficacious than the natural GR ligand, hydrocortisone40, and 
has been used in the construction of many GR-ligand conjugates41-44. Extensive 
mapping of the Dex structure-activity relationship has identified C21 as an 
attachment point least perturbed by modification. Though amide-linkage at this 
point yields the commonly used OxDex compound; however, work surfacing at 
the time of this synthesis indicated that a thioether linkage at this same point 
maintains partial agonistic activity and full efficacy of Dex43,45. We prepared a 
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version of this compound, termed SDex, containing an isothiocyanate moiety, 
SDex-ITC. This functional group allows for a facile reaction with nucleophilic 
linkers (Fig. 2.3A). 
 
As described in Chapter 1, FK50646 is a high-affinity (0.6 nM) inhibitor of the 
prolyl-isomerase protein FKBP47,48. FK506 inhibition of FKBP is mediated 
through the induced dimerization of FKBP with calcineurin, abrogating its ability 
to interact with substrate proteins or other interaction partners49. The first 
chemical inducer of dimerization, described by Spencer and coworkers, was a 
homodimer of FK50650. In this work, the exocyclic allyl substituent was 
functionalized with a nucleophilic N-hydroxysuccinimidyl carbonate group. 
Importantly, this point of modification does not appreciably interfere with the 
FK506-FKBP interaction, though binding to calcineurin is abrogated. We utilized 
this synthetic strategy to produce a functionalized version of FK506, termed 
FK506-NHS (Fig. 2.3C). 
 
Linker length, hydrophobicity, and rigidity all affect a bifunctional molecule’s 
ability to chemically dimerize its targets. Though much work has been performed 
to expand the collective knowledge in this area, it is difficult to determine a priori 
the composition of an ideal linker51. Polyethylene glycol (PEG) linkers are 
particularly attractive because of their flexibility and the added solubility imparted 
by this style of linker. Through a series of optimization experiments, we identified 
a 10-atom PEG-based linker as ideal for these three-hybrid experiments52 and 
prepared it for reaction with SDex-ITC as described (Fig. 2.3B). 
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The functionalized glucocorticoid agonist, SDex-ITC, was conjugated to the 
protected linker compound, Boc-linker, through a simple nucleophilic addition. 
Following cleavage of the tert-butyloxycarbonyl group, mixture with FK506-NHS 
yielded the reacted conjugate molecule, termed SDex-O2-FK506 (Fig. 2.4). 
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Figure 2.3 Functionalization of constituent ligands. Commercially available dexamethasone  (A) and 
FK506  (C) are functionalized to allow for facile conjugation to a commercially available PEG-based 
linker (B). !
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In addition to the constructed bifunctional molecule, we synthesized a 
monofunctional, linker-containing compound SDex-O2-CO2Me to monitor the 
effects of modifying Dex, independent of conjugation. The compounds used in 
subsequent studies have been summarized in Fig. 2.5. 
 
Figure 2.4 Conjugating a GR ligand to FK506. Functionalized Dex (SDex-ITC) is conjugated to a 
linker through thiourea formation. Subsequent linker deprotection allows for conjugation to 
functionalized FK506, forming a carbamate linkage. !
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In order to confirm our hypothesis that this synthetic strategy will minimally 
perturb binding to GR, we utilized a competition assay to determine the binding 
affinity of each described compound for GR. Cellular lysates containing 
expressed GR were incubated with tritium-labeled dexamethasone ([3H]dex) and 
each indicated compound. Following washing, the concentration of remaining 
bound [3H]dex was determined and utilized to determine a binding affinity for 
each compound (Fig. 2.6). Appendage of the synthetic linker resulted in a ~10-
fold loss of binding affinity, as the Kd for unmodified dexamethasone was 
determined to be 4.95 nM while the affinity for the monofunctional compound was 
Figure 2.5 Summary of dexamethasone-based ligands. Compounds used in subsequent studies include 
unmodified dexamethasone, a monofunctional GR ligand-linker compound SDex-O2-CO2Me, and a 
bifunctional SDex-O2-FK506 linking a GR ligand and FKBP ligand. ! 
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determined to be 48.3 nM. Conjugation to FK506 resulted in a further loss in 
affinity, as the Kd of binding for SDex-O2-FK506 for GR was determined to be 
104 nM. However, this may be a complicating factor of utilizing lysates that 
contain FK506-binding proteins.  
 
 
 
Utilizing the full length receptor in a three-hybrid assay 
 
In order to determine if a bifunctional glucocorticoid can recruit a protein to the 
full-length receptor, a modified three-hybrid experiment was constructed, 
depicted in Fig. 2.7A. In place of a GR-Gal4 hybrid and a luciferase plasmid 
containing Gal4 DNA binding sites, 293T cells were transfected with full length 
human GR and a luciferase reporter plasmid containing the endogenous 
enhancer element from the glucocorticoid-sensitive FKBP5 gene, which contains 
two GREs31; in this and subsequent experiments, 293T cells were chosen due to 
this cell line being highly amenable to transfection. Additionally, cells were 
transfected with either an expression plasmid coding for the VP16-FKBP fusion 
protein or a non-fusion FKBP protein for control. The activity of dexamethasone 
Figure 2.6 Conjugate binding to GR. Binding affinities of the utilized conjugate compounds were 
determined utilizing a competition assay with radioisotopically labeled dexamethasone. Synthetic 
modification of dexamethasone mildly perturbs binding to GR. 
oxidase-conjugated antibodies (Pierce) and Super Signal West
Femto chemiluminescence reagents (Pierce).
Results
Design of bifunctional ligands
Using the GR as a paradigm and building on the sig-
nificant experience in structure-activity relationship for
GR ligand conjugates (17, 19, 25–28), we created bifunc-
tional molecules based on the agonist Dex and the antag-
onist RU486. The least perturbing derivative of Dex that
allows facile conjugation with other molecules has been
termed SDex, in which the 21-hydroxyl group is replaced
by thioether linkages (19) (Figure 2). RU486 has been
linked to bile acids through its aniline group and retained
antagonistic activity (28). Using a polyethylene-glycol
linker as a spacer, we have thus conjugated these ligand
derivatives to the natural product FK506 (Figure 2). Our
choice was based on the extensive experience using
FK506 conjugates for ligand-induced protein complex as-
sembly (29, 30). Compounds bearing a linker only were
synthesized as controls (Figure 2).
The binding affinity of the conjugates for full-length
GR was determined in a radiolabeled Dex competition
binding assay. As can be seen in Figure 3A, the affinities of
SDex-O3-OMe and SDex-O2-FK506 are approximately
50 and 100 nM, respectively. Although this is 10- and
20-fold lower than the affinity of Dex (5 nM), these val-
ues are in a range comparable with the affinity of endog-
enous steroids such as cortisol (20 nM). Although the
conjugation of FK506 to SDex lowers the binding affinity
a modest 2-fold, this difference is not due to effects of
binding cellular FK506-binding proteins because binding
studies done in the presence of free FK506 yielded similar
results (data not shown). In the case of the RU486 deriv-
atives, both compounds displayed comparable affinities
(!90 nM), which are less than an order of magnitude
(!6-fold) lower than tha of unmodified RU486 (Figure
3B). From this analysis, it is clear that the synthetic strat-
egy yielded bifunctional ligands that retain a significantly
high affinity for GR.
Figure 2. GR bifunctional ligands. Structures of GR bifunctional
ligands based on the agonist dexamethasone (top panel) or the
antagonist RU486 (bottom panel). Receptor binding, linker, and FK506
moieties are indicated.
A
B
Figure 3. Bifunctional ligands bind to the GR. Competition binding
assays based on displacement of 3lsqb]H]Dex (10 nM) from GR were
carried out as described in Materials and Methods. All curves are fits to
a competitive single binding site model. Values for the calculated
dissociation constant (Kd) are indicated in the inset. A, Competition
using Dex- or SDex-derived ligands. B, Data for RU486-based ligands.
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and the two modified compounds is shown in Figure 2.7B-C, where activity is 
displayed as fold activation over the level expressed in vehicle-treated cells. 
 
 
 
 
In the absence of the VP16-FKBP fusion protein (Fig.2.6B), SDex-O2-CO2Me 
and SDex-O2-FK506 acted as partial agonists, showing both reduced potency 
(by 1-2 orders of magnitude) and efficacy (~ 80%) relative to dexamethasone. 
This is likely due to a reduced GR binding affinity, while the different activities 
between the two SDex-compounds may be caused by increased cell permeability 
by the presence of FK506. The expression of VP16-FKBP has little effect on the 
activity of SDex-O2-CO2Me (Fig. 2.7C). However, in the presence of VP16-
FKBP, SDex-O2-FK506 activated transcription two-fold relative to the maximal 
Figure 2.7 Designed ligand activity in a mammalian three-hybrid assay. In A, the bifunctional molecule 
links GR to a FKBP-fusion protein, driving transcriptional output through the localization of VP16 to 
the reporter gene. In B, the activity of ligands in the absence of fusion protein is shown. In C, the 
activity of ligands in the presence of VP16-FKBP is shown. The bifunctional ligand shows fusion 
protein-dependent activity !
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activation by dexamethasone, while displaying a similar potency (experimental 
EC50 for dexamethasone: 1.6 nM; SDex-O2-FK506: 4.1 nM). The enhanced 
activation by SDex-O2-FK506 in the presence of VP16-FKBP, but not in its 
absence, firmly supports the notion that the molecule is both localizing GR to a 
GRE and recruiting a second protein. 
 
Recruiting VP16-FKBP to native GR-regulated genes 
 
Luciferase reporter experiments provide a platform for rapid screening of multiple 
treatments; however, a transiently transfected reporter plasmid will differ in 
structure and accessibility when compared to a native chromatin environment. To 
demonstrate recruitment of VP16-FKBP to influence the transcription of an 
endogenous gene, 293T cells were transfected with expression plasmids for the 
full-length rat GR and either a plasmid coding for the VP16-FKBP fusion protein 
or a non-fusion FKBP protein for control, then treated with SDex-O2-CO2Me or 
SDex-O2-FK506. Here, the rat isoform of the receptor was utilized due to 
previous experience with this variant. Following treatment, total mRNA from each 
treated sample was isolated. In previous reporter experiments, a reporter plasmid 
containing a promoter sequence from the glucocorticoid-regulated FKBP5 gene 
was used. FKBP5 is a canonical GR-regulated gene, and this characteristic, in 
addition to our desire to maintain continuity with the previously performed 
reporter studies, suggested that it would be an ideal target for monitoring 
transcript levels in response to our bifunctional ligand31,53. RT-qPCR was utilized 
to determine relative quantities of FKBP5 transcript levels in each sample (Fig. 
2.8).  
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In cells expressing the control FKBP protein, SDex-O2-CO2Me and SDex-O2-
FK506 both activated transcription to levels twice that of in cells treated with a 
DMSO vehicle dosing. Unexpectedly, similar activation levels were observed in 
cells expressing the VP16-FKBP fusion. There are several potential explanations 
for this; first, while the dosing time was identical in monitoring reporter expression 
and FKBP5 transcription, the cellular events involved with each occur on different 
time scales. Additionally, a benefit to luciferase reporter experiments is the 
stability of the firefly luciferase protein and its resistance to turnover; however, 
mRNA transcript stability is variable and often does not compare well. An 
alternative explanation is that differences in native chromatin architecture are the 
cause of the disparity in the activity between the two experiments54. In the 
reporter experiment, SDex-O2-FK506 was recruiting VP16-FKBP to a segment of 
DNA just several hundred base pairs (bp) upstream of the luc gene; however, 
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Figure 2.8 Transcriptional modulation of FKBP5.  The effects of the designed ligands on the 
transcription of the endogenous gene FKBP5 are determined through RT-qPCR analysis. Transcript 
quantification was normalized to the housekeeping gene RPL19 and depicted as a fold activation, 
relative to DMSO control, using the ΔΔCT method. Statistical significance was determined using a 
one-tailed student’s t-test. 
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when regulating the transcription of FKBP5, GR likely binds to a GRE located in 
an intronic sequence 26 kilobases from the transcriptional start site54. It is 
possible that architectural differences are central to the observed differences31. 
  
The low inducibility of the FKBP5 gene may also play a role in the lack of 
recruitment-aided activation. In luciferase reporter experiments (Fig. 2.7), 
activation of transcription by the SDex-based compounds reached levels 1-2 
orders of magnitude above those produced in vehicle-treated cells. However, 
induction of native FKBP5 transcription was only 2-3 fold. Observing this, we 
decided to shift focus to an alternative GR-regulated gene. Here, we identified 
the S100P gene55,56; this target codes for a calcium-binding protein that has been 
shown to be potentially oncogenic in prostate cancer. More importantly, this gene 
displays comparatively low basal expression in 293T cells but can be stimulated 
approximately 50-100 fold by dexamethasone in cells expressing GR, indicating 
a large transcriptional dynamic range. With this observation, we reasoned that 
this highly inducible gene is an ideal target gene to observe a recruitment-
dependent effect on transcription. In cells expressing FKBP, SDex-O2-CO2Me 
and SDex-O2-FK506 acted as strong activators of transcription to similar levels 
(Fig. 2.9A). In cells expressing the VP16-FKBP fusion, the bifunctional molecule 
activated transcription to a level approximately 2-3 fold higher than the 
monofunctional SDex-O2-CO2Me, with a similarly higher output when compared 
to the transcript levels measured in cells lacking the fusion protein (Fig. 2.9B). 
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Suppressing transcription through recruitment 
A benefit to the system described heretofore is its modularity; investigating 
alternative bifunctional molecules or recruitment targets is relatively 
straightforward. NR transcriptional repression is commonly facilitated through the 
recruitment of corepressor complexes, so we sought to determine the effects of 
bifunctional molecule-mediated recruitment of a corepressor. Histone deactylase-
1 (HDAC1) acts as a transcriptional repressor both actively, through enzymatic 
deacetylation of histones lysines, and passively, as a scaffold protein that aids in 
the formation of corepressor complexes57. To this end, an expression plasmid for 
an HDAC1-FKBP fusion protein was constructed. 293T cells were transfected 
with a GRE-containing luciferase plasmid, an expression plasmid for the rat GR 
(rGR), and either an expression plasmid for the HDAC1-FKBP fusion protein or a 
plasmid coding for FKBP for control. Cells were treated with one of the indicated 
compounds, and transcriptional activity is displayed in Fig. 2.10 as a function of 
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Figure 2.9 Transcriptional modulation of S100P.  The effects of the designed ligands on the transcription 
of the endogenous gene S100P are determined through RT-qPCR analysis. Transcript quantification was 
normalized to the housekeeping gene RPL19 and depicted as fold activation, relative to DMSO control, 
using the ΔΔCT method. Statistical significance was determined using a one-tailed student’s t-test. 
! 49!
luciferase expressed relative to the levels in vehicle-treated cells. 
 
 
  
In Fig. 2.10A, SDex-O2-CO2Me and SDex-O2-FK506 activated rGR-mediated 
transcription as partial agonists, displaying lower potency (two orders of 
magnitude) and efficacy (achieving ~ 80% maximum activity) relative to 
dexamethasone in cells only transfected with a FKBP expression plasmid, 
comparable with the activation of hGR in Fig. 2.7A. The expression of HDAC1-
FKBP did not affect the activity of SDex-O2-CO2Me (Fig. 2.10B). However, in 
cells expressing this fusion, the maximum transcriptional activity induced by 
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Figure 2.10 Corepressor three-hybrid experiment. A three-hybrid experiment was performed in cells 
expressing FKBP (A), a HDAC1-FKBP fusion (B), or a fusion containing a catalytically weakened 
HDAC1 mutant (C). Transcriptional activity of the bifunctional molecule was fusion-protein 
dependent. 
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SDex-O2-FK506 was lowered approximately 50%, supporting the notion that 
bifunctional molecule recruitment of a corepressor protein can inhibit 
transcriptional activity. It is likely that the residual activation of transcription is 
from competing allosteric recruitment of coactivators by rGR. 
 
Transcription of the S100P gene was affected by the recruitment of VP16-FKBP, 
suggesting that it would be an ideal system for determining the effects of 
HDAC1-FKBP recruitment on the expression of an endogenous gene. 293T cells 
transiently expressing rGR and either FKBP or HDAC1-FKBP were treated with 
the indicated compounds and subsequently lysed. Following total RNA isolation, 
the level of S100P transcripts was quantified and displayed as fold activation 
relative to the transcript level in vehicle-treated cells. As seen in Fig. 2.11A, 
SDex-O2-CO2Me and SDex-O2-FK506 strongly induced the expression of 
S100P in cells expressing FKBP. The expression of HDAC1-FKBP does not 
interfere with the ability of SDex-O2-CO2Me to activate transcription; however, 
activity in cells treated with SDex-O2-FK506 is reduced to approximately 50% of 
the activity level in cells lacking the fusion. Interestingly, whereas activity levels of 
each compound were similar at the dosing concentration indicated (100 nM) in 
reporter experiments (Fig. 2.10B), while transcriptional suppression is only seen 
at high dosing concentration (1 µM), the bifunctional molecule is capable of 
recruitment at a lower concentration in this experiment. This disparity illustrates 
the need for further experimentation monitoring the transcription of alternative 
GR-targets. 
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HDAC1-mediated transcriptional repression proceeds through a number of 
mechanisms, as mentioned prior. In order to determine if the transcriptional 
repression observed as a result of HDAC1-FKBP recruitment is facilitated by 
HDAC1 deacetylase activity or through an alternative mechanism, a fusion 
protein expression plasmid was constructed containing a mutant form of HDAC1, 
HDAC1(D99A)-FKBP. This point mutation severely abrogates HDAC1 enzymatic 
activity, inhibiting its ability to deacetylate lysine substrates and actively repress 
open chromatin conformations58. 293T cells were transfected with expression 
plasmids for rGR and the HDAC1(D99A)-FKBP fusion protein and incubated with 
indicated compounds. As in cells expressing HDAC1-FKBP (Fig. 2.10B), SDex-
O2-FK506 activity was suppressed by approximately 50% in the presence of 
HDAC1(D99A)-FKBP (Fig. 2.10C). It is currently unclear if this suppression is 
simply a factor of steric hindrance inhibiting the recruitment of transcriptional 
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Figure 2.11 Transcriptional modulation of S100P by a corepressor fusion.  The effects of the 
designed ligands on the transcription of the endogenous gene FKBP5 are determined through RT-
qPCR analysis. Transcript quantification was normalized to the housekeeping gene RPL19 and 
depicted as fold activation, relative to DMSO control, using the ΔΔCT method. Statistical significance 
was determined using a one-tailed student’s t-test. ! 
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machinery, or if mutant HDAC1 is continuing to recruit corepressor complexes; a 
similar strategy was employed to sterically hinder the formation of transcriptional 
complexes by ER59 but was ineffective, suggesting that it is likely continued 
contacts between HDAC1 and other corepressors that is mediating suppression. 
However, the difference in size, concentration, and distribution of our recruitment 
target relative to that of Moore and coworkers makes direct comparisons difficult, 
and it is impossible to rule out simple sterics as driving this observation. 
 
2.5 Targeting endogenous coregulators for recruitment 
  
As mentioned previously, a highlight of our system is its modularity. Accordingly, 
it is relatively straightforward to develop alternative bifunctional molecules 
capable of recruiting differing targets. In an effort to identify potential ligands for 
synthetic linkage to dexamethasone, we recognized the potential of (S)-JQ1 (Fig. 
2.12) as a secondary targeting moiety in a bifunctional glucocorticoid. (S)-JQ1 is 
a highly potent inhibitor of the protein bromodomain containing 4 (BRD4)60. 
Bromodomain-containing proteins belong to a diverse family of transcription 
factors, with 41 human variants having been described61,62. However, each 
contains at least one conserved bromodomain, a largely helical protein domain 
capable of recognizing and binding acetylated-lysine molecules. BRD4, as a 
member of the larger BET family, contains two N-terminal bromodomains, each 
of which play a role in substrate binding and specificity. BRD4 has been primarily 
identified for its role as a scaffolding transcription factor, binding specific 
acetylated histone lysines and aiding in the recruitment of P-TEFb, essential for 
the proper positioning of RNA Polymerase II60,63, though it has also been 
demonstrated to bind acetylation marks on alternative transcription factors64,65. 
These responsibilities, along with recent results indicating that BRD4 plays a 
critical role in transcriptional elongation, have spurred efforts to develop and 
molecular modulators of bromodomain-containing proteins such as (S)-JQ1. 
Structural characterization of the (S)-JQ1-BRD4 complex has revealed that C6 of 
the (S)-JQ1 benzodiazepine projects outwards from the protein’s binding site60,66, 
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and follow-up studies show that that enantioretentive substitution at this point 
with a synthetic linker is capable with minimal perturbation of ligand-protein 
binding67. Considering these factors, BRD4 is an ideal target for recruitment to 
DNA-bound GR through a bifunctional molecule. To begin this investigation, we 
synthesized the following molecules (Fig. 2.12): SDex-O3-CO2Me, a 
glucocorticoid molecule appended to a synthetic linker; SDex-O3-(S)-JQ1, a 
bifunctional molecule linking dexamethasone to (S)-JQ1; and SDex-O3-(R)JQ1, 
an inactive diastereomer with no displayed binding to BRD4. 
 
 
 
 
Dimerization of GR and BRD4 
Figure 2.12 Summary of BRD4-targeting ligands. The ligands used in subsequent studies include 
unmodified (S)-JQ1, a monofunctional GR ligand-linker compound SDex-O3-CO2Me, a bifunctional 
SDex-O3-(S)JQ1 , and a bifunctional molecule conjugated to an inactive enantiomer of JQ1 termed 
SDex-O3-(R)JQ1. !
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To first determine if the designed SDex-O3-(S)JQ1 is capable of dimerizing GR 
and BRD4 in the absence of DNA-binding, ligand-induced coimmunoprecipitation 
experiments were performed. The human osteocarcinoma U2OS cell line lacks 
detectable GR expression and was chosen for this study to allow for the potential 
to utilize GR variants in subsequent studies. U2OS cells were transfected with an 
expression plasmid coding for a multiply myc-tagged version of human GR, hGR-
myc6, and incubated with the indicated compound. Samples were subsequently 
lysed and incubated with magnetic beads coated in BRD4-recognizing antibody 
(αBRD4). Bound proteins were eluted and analyzed by Western blot for the 
presence of hGR-myc6 using a myc-recognizing antibody (Fig. 2.13). 
 
 
 
 
SDex-O3-(S)JQ1 induced the coimmunoprecipitation of GR with BRD4. Neither 
the vehicle (DMSO) or linker (SDex-O3-CO2Me) incubated-samples result in the 
coimmunoprecipitation of hGR-myc6, precluding the possibility of a non-specific 
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Figure 2.13 Dimerization of hGR and BRD4. Co-immunoprecipitation experiments were performed 
to detect the ability of the bifunctional molecule to dimerize hGR and BRD4. Cellular lysates were 
incubated bead support coated in a BRD4 recognition antibody on bead support immobilizing BRD4. 
Incubation with bifunctional molecule  co-immunoprecipitated a tagged version of hGR, hGR-myc6, 
as detected by Western blot. Samples, from left to right: DMSO; SDex-O3-CO2Me (steroid-linker); 
SDex-O3-(S)JQ1 (steroid-triangle); SDex-O3-(R)JQ1 (steroid-square). 
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interaction between GR and BRD4. Additionally, the inactive diastereomer, 
SDex-O3-(R)JQ1, was incapable of coimmunoprecipitating hGR-myc6, strongly 
supporting the notion that the observed interaction is being specifically 
modulated through the interaction of each portion of the bifunctional molecule 
with its target-binding pocket. 
 
Functional outcome of BRD4 recruitment 
 
BRD4 interacts with acetylation marks with a rapid ‘on and off’ mode of binding in 
a preferential manner for specific lysines over others68,69. Moreover, though 
BRD4 is thought to primarily aid in transcriptional activation through the 
recruitment of the pTEF-b complex, recent work has shown that BRD4 is capable 
of forming differing, distinct transcriptional complexes with alternative epigenetic 
proteins70, and it is likely that the neighboring chromatin environment plays a role 
in the identity of the complex formed. While established precedent allowed for a 
straightforward prediction of the functional influences of recruiting the activator 
VP16, these outside factors convolute our ability to foresee what outcome BRD4 
recruitment will have on GR-regulated transcription. Further confounding this is 
the recent discovery that at least one BRD4-transcription factor interaction is 
dependent on the ability of BRD4 to recognize an acetylation mark on the 
transcription factor itself, suggesting that recruitment through bifunctionalized 
JQ1 could interfere with necessary PPIs71. 
 
To investigate the effects of bifunctional molecule-facilitated BRD4 recruitment 
on transcription, we initially developed a three-hybrid experiment (depicted in Fig. 
2.14A). This arrangement additionally allows us to confirm that SDex-O3-(S)JQ1 
(hereafter referred to as SDex-O3-JQ1) is capable of chemically dimerizing GR 
and BRD4 in a cellular system.  
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HeLa cells expressing endogenous levels of BRD4 were transfected with a 
luciferase reporter plasmid bearing five Gal4 DNA-binding sites and an 
expression plasmid for a Gal4-GR(LBD) chimera and treated with the indicated 
compounds; here HeLa cells were chosen due to their previous usage in a 
similar model. The resulting activation of transcription is displayed in Fig. 2.13B 
as a fold activation of luciferase produced over the levels in vehicle-controlled 
cells. As expected, the monofunctional SDex-O3-CO2Me acted as an agonist in 
this system, likely activating transcription through its induced rearrangement of 
Figure 2.14 Mammalian three-hybrid assay targeting an endogenous protein. A three-hybrid 
experiment, using a Gal4-GR(LBD) chimera, relying on endogenous BRD4 recruitment to drive 
activity was constructed (A). B: the monofunctional GR ligand acted as a partial agonist, while 
bifunctional ligand strongly and potently activated transcription. C: the enhanced activity of the 
bifunctional molecule was dependent on BRD4 recruitment, as determined by squelching 
experiments. 
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the GR(LBD) AF2 domain. As was seen with the recruitment of VP16-FKBP, the 
bifunctional SDex-O3-JQ1 acts as a ‘superactivator’ of transcription, stimulating 
the expression of luciferase approximately 3-fold higher than the maximum 
activity displayed by SDex-O3-CO2Me. Treatment with (S)-JQ1 negligibly 
affected transcription. 
 
Given (S)-JQ1’s high specificity for BRD460, it is unlikely that an alternative 
protein is being recruited to produce the displayed high activity by SDex-O3-JQ1, 
though we cannot currently rule out the possibility that other proteins are being 
recruited. To confirm that the observed effects are at least dependent on a 
recruitment event, a squelching experiment was performed to determine the 
observed modified transcriptional activity could be attenuated by competing 
ligand. HeLa cells were transfected as above and treated with SDex-O3-JQ1 (1 
µM) along with increasing levels of either (S)-JQ1 or inactive (R)JQ1. As seen in 
Fig. 2.14C, increasing levels of (S)-JQ1 suppressed the transcriptional activity of 
SDex-O3-JQ1 in a dose-dependent fashion, with high concentrations of (S)-JQ1 
(10 µM) suppressing activity approximately 70%. However, co-treatment with 
(R)JQ1 did not produce this effect. This observation supports the hypothesis that 
recruitment is causing the marked difference in activity between SDex-O3-
CO2Me and SDex-O3-JQ1; however, (S)-JQ1 is capable of interfering with 
dexamethasone-induced transcription (unpublished observations) and further 
experiments are necessary to make this claim with more certainty.  
 
Two- and three-hybrid experiments are excellent at demonstrating the potential 
for existing or induced PPIs, but they can occasionally be deceiving if counted on 
for predicting the existence of a functional transcriptional complex72. As with the 
recruitment of FKBP-chimeras, we set out to determine if a bifunctional molecule 
is capable of recruiting endogenous BRD4 to the native, full-length receptor. To 
this end, we evaluated SDex-O3-JQ1’s activity in the system described in Fig. 
2.15A. 
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Initially, U2OS cells were transfected with a reporter plasmid bearing a 
consensus GRE immediately upstream of a promoter driving luciferase 
expression and an expression plasmid coding for human GR. Cells were treated 
with either SDex-O3-CO2Me or SDex-O3-JQ1 (100 nM) for the indicated time. 
Transcriptional activity was determined by monitoring luciferase expression and 
displayed as fold activation over the levels of luciferase in vehicle-treated cells 
(Fig. 2.15B). Both the monofunctional and bifunctional ligands acted as agonists 
of GR-mediated transcription, stimulating activity that increased with increasing 
incubation time. A 16-hour treatment produced the strongest transcriptional 
response and was chosen for further investigations into the activity of SDex-O3-
JQ1. 
Figure 2.15 Recruitment of BRD4 to full-length GR. A reporter experiment was designed utilizing full-
length GR (A). B: the activity of each GR-ligand was time dependent, with maximal observed activity 
occurring at 16 hours of treatment. 
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Figure 2.16 Utilizing alternative GREs in reporter experiments. Full-length GR was utilized in a 
transcriptional reporter experiment, with a reporter plasmid using a consensus GRE (A), FKBP5 GRE 
(B), or GILZ GRE (C). Statistical significances were determined using a two-tailed student’s t-test. 
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U2OS cells were transfected as described earlier and incubated with the 
indicated compound(s) for 16 hours. This measurement of transcriptional activity 
is displayed as a relative percentage normalized to the activity produced by 
dosing with SDex-O3-CO2Me (100 nM) in Fig. 2.16A; data are presented as a 
traditional dose-response curve (left panel) alongside a focused presentation of 
the response to specific doses, including statistical significance analysis (right 
panel). In addition to doses with the monofunctional SDex-O3-CO2Me and 
bifunctional SDex-O3-JQ1, a ‘trans’ addition dosing of equimolar SDex-O3-
CO2Me and a biotinylated form of (S)-JQ1 [(S)-JQ1-biotin] and a ‘squelch’ dosing 
including SDex-O3-JQ1 and an excess (10 µM) of (S)-JQ1-biotin were included. 
The trans addition components were chosen to ensure that transcriptional 
outcomes caused by SDex-O3-JQ1 are not simply additive or synergistic 
responses provoked independently by each moiety in the bifunctional molecule, 
while the squelch dosing is included to confirm that effects are induced through 
recruitment. As expected, SDex-O3-CO2Me acts agonistically to activate GR-
driven transcription, while co-dosing with (S)-JQ1-biotin results in a suppression 
of transcription at high (1 µΜ) concentration, but otherwise minimally affects the 
activity of SDex-O3-CO2Me. Increasing concentrations of SDex-O3-JQ1 result in 
a bell-shaped activity curve, initially increasing at low concentration but declining 
with higher concentrations of compound; at the highest dose (1 µΜ), activity 
levels are approximately 50% of the maximum stimulation level (produced at 10 
nM). The co-addition of excess (S)-JQ1-biotin increases activity in a significanct 
manner, albeit not to the same level as seen with the trans addition treatment. 
The suppression of activity seen with SDex-O3-JQ1, paired with the observation 
that free (S)-JQ1-biotin competes with suppression, strongly suggests that the 
recruitment event is interfering with GR-mediated transcription.  
  
As noted earlier, GREs are loosely conserved sequences, and even single base 
pair differences can effect large differences in the identity of GR binding partners 
and subsequent transcriptional activity6. Given the disparity in activity produced 
by SDex-O3-JQ1 when comparing the results described above, we sought to 
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determine if altering the reporter GRE sequence would result in an altered 
activity profile. U2OS cells were transfected and treated as described earlier; 
however, in lieu of the reporter plasmid bearing a consensus GRE, cells were 
transfected with a reporter plasmid bearing a GRE taken from the FKBP5 gene 
(differing in spacer sequence and at two positions) or a GRE from the GILZ gene 
(differing in spacer sequence and at three positions) immediately upstream of a 
promoter driving luciferase expression. Data are presented as above. As seen in 
Fig. 2.16B, the altered sequence of the FKBP5 GRE was well tolerated, with the 
bifunctional molecule producing a very similar pattern of activity. A similar 
suppression of activity was produced with a high loading of SDex-O3-JQ1, while 
the presence of free (S)-JQ1-biotin again enhanced activation. However, utilizing 
a GILZ GRE sequence (Fig. 2.16C) resulted in a distinct activation pattern. As 
the cellular concentration of SDex-O3-JQ1 is increased, a canonical agonistic 
dose-response curve is produced, and the presence of free (S)-JQ1-biotin does 
not alter transcriptional activation by SDex-O3-JQ1. Despite this altered pattern, 
SDex-O3-JQ1 continues to act as a weaker activator of the full-length GR than 
SDex-O3-CO2Me, in contrast to experiments utilizing Gal4-GR(LBD), suggesting 
an additional mechanism for this lowered transcriptional response.  
 
Recruiting BRD4 to endogenous genes 
 
As displayed earlier, reporter experiments can be poor predictors of the ligand-
induced transcriptional response at endogenous genes. Indeed, even knowledge 
of the chromatin environment surrounding a GRE can be misleading when 
attempting to predict transcriptional responses. To investigate the effects of 
bifunctional molecule treatment on endogenous gene expression, U2OS cells 
were transfected with an expression plasmid for the human GR and treated with 
the indicated compound(s). Following treatment, cells were lysed, total RNA 
isolated, and the indicated transcript was quantified relative to the levels in 
vehicle-treated cells. The transcriptional activity is displayed as fold activation in 
Fig. 2.17. 
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The relative transcript levels of S100P (Fig. 2.17A), FKBP5 (Fig. 2.17B), and 
GILZ (Fig. 2.17C) were determined31,52. SDex-O3-CO2Me treatment activated 
the transcription of each these three GR-target genes. Unlike in reporter 
experiments, co-dosing with (S)-JQ1-biotin did not appreciably alter the activity of 
SDex-O3-CO2Me; this may be a byproduct of a shorter dosing time in RNA 
quantification studies, though the transcriptional response to both 
glucocorticoids73 and (S)-JQ174 is rapid. In comparison to SDex-O3-CO2Me, 
SDex-O3-JQ1 weakly activated transcription of the S100P gene (Fig. 2.17A), 
raising levels to approximately 25% of the maximum level induced by SDex-O3-
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Figure 2.17 Effects of BRD4 recruitment on endogenous gene transcription.  The effects of the 
designed ligands on the transcription of S100P (A), FKBP5 (B), and GILZ (C) in transfected U2OS 
cells are determined through RT-qPCR analysis. Transcript quantification was normalized to the 
housekeeping gene RPL19 and depicted as fold activation, relative to DMSO control, using the ΔΔCT 
method. Statistical significance was determined using a one-tailed student’s t-test. !
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CO2Me. Consistent with the hypothesis that BRD4 recruitment inhibits GR 
activity, the addition of excess (S)-JQ1 allows SDex-O3-JQ1 to activate S100P 
transcription to similar levels as SDex-O3-CO2Me. SDex-O3-JQ1 induced a 
similar, but less pronounced, effect in activating transcription of the FKBP5 gene 
to approximately 60% of the level induced by SDex-O3-CO2Me (Fig. 2.17B). 
Again, addition of excess (S)-JQ1 squelches the suppressed agonism of SDex-
O3-JQ1, raising activity to a level comparable with SDex-O3-CO2Me. 
Interestingly, the transcriptional response at the GILZ gene was even more 
disparate; treatment with SDex-O3-JQ1 alone or in tandem with (S)-JQ1 
produced a near identical activation of GILZ transcription. While further analysis 
of additional targets is necessary prior to making conclusions, the wide range in 
activity induced by the bifunctional glucocorticoid may point to the possibility for 
selectivity in gene expression. 
 
The human adenocarcinoma lung epithelial cell line A549 expresses endogenous 
GR and is commonly used as a model line for the study of GR actions and 
activity31. It has previously been shown that expression levels of GR vary 
between A549 cells and transfected U2OS cells, and this likely influences the 
observed differences in gene expression profiles produced by treatment with 
glucocorticoids2. The effects of SDex-O3-JQ1 treatment on transcriptional activity 
in A549 cells was investigated to determine if similar patterns are displayed in 
cells expressing endogenous levels of GR. Comparing the transcription of S100P 
and GILZ provided the starkest difference in activity mediated by SDex-O3-JQ1 
and provided a template for further studies in A549 cells. Following treatment 
with the indicated compounds, A549 cells were lysed, total RNA was isolated, 
and the indicated transcripts were quantified. Transcriptional activity is displayed 
as fold activation relative to transcript levels in vehicle-treated cells (Fig. 2.18). 
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The activation patterns of S100P (Fig. 2.17A) in A549 cells resemble the profile 
produced in transfected U2OS cells. Treatment with SDex-O3-CO2Me in the 
absence or presence of (S)-JQ1 produced a strong agonistic response, while 
treatment with the bifunctional SDex-O3-JQ1 activated transcription to 
approximately 50% of the level induced by the monofunctional glucocorticoid. As 
observed before, co-treatment of SDex-O3-JQ1 with an excess of (S)-JQ1 
produces transcriptional activity nearly identical to SDex-O3-CO2Me, implying 
that (S)-JQ1 is capable of competing away BRD4 recruitment and causing SDex-
O3-JQ1 to act as its parent, monofunctional ligand. Similarly, the pattern of GILZ 
transcription (Fig. 2.17B) resembled the activities produced in transfected U2OS 
cells, wherein each of the described compounds and combinations produced 
nearly identical responses. These initial observations indicate that the activity 
patterns of the bifunctional molecule may be similar in different cell lines. 
Currently, efforts are underway to expand the list of monitored genes to aid in 
establishing an activity pattern. 
 
Targeting a ligand-sensitive cell line 
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Figure 2.18 Transcriptional modulation in A549 cells.  The effects of the designed ligands on the 
transcription of S100P (A) and GILZ (B) in A549 cells are determined through RT-qPCR analysis. 
Transcript quantification was normalized to the housekeeping gene RPL19 and depicted as fold activation, 
relative to DMSO control, using the ΔΔCT method. Statistical significance was determined using a one-
tailed student’s t-test. 
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(S)-JQ1 has emerged as a potent downregulator of MYC expression, spurring 
investigations into the role it may play in inhibiting the growth of pathogenic 
species driven by c-Myc related oncogenic activity74. Multiple myeloma (MM) is a 
hematological malignancy that has been established as an apt model for c-Myc 
dysregulation53,74,75. Currently, glucocorticoids are commonly used as a 
chemotherapeutic treatment to induce apoptosis in MM cells, but this treatment is 
limited by the rapid development of resistance. Given the dual sensitivity of MM 
cells to both (S)-JQ1 and glucocorticoids, we identified the myeloma cell line 
MM.1S as an ideal model for further evaluation of SDex-O3-JQ1 activity. Unlike 
the related multiple myeloma line MM1.R, a similar line that is believed to have 
suppressed GR expression, we hypothesized that this line may be acutely 
sensitive to modulation with our designed ligand. 
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MM.1S cells were incubated with the compounds indicated prior to total RNA 
isolation. The expression of the target genes FKBP5, GILZ, and MYC was 
monitored in response to treatment; S100P expression in MM.1S cells was not 
detectable, even in response to glucocorticoid. Transcriptional activity is 
displayed as fold activation (Fig. 2.19A and B) or relative mRNA abundance (Fig. 
2.19C) relative to transcript levels in vehicle-treated cells. Induced levels of both 
FKBP5 and GILZ were relatively similar with all treatments, unlike in A549 cells 
and transfected U2OS cells. This convolutes the hypothesis that BRD4 
recruitment is allowable at the FKBP5 GRE but not the GILZ GRE, though a 
Figure 2.19 Transcriptional modulation in a multiple myeloma model. The effects of the designed 
ligands on the transcription of FKBP5 (A), GILZ (B), and MYC (C) in MM.1S cells are determined 
through RT-qPCR analysis. Transcript quantification was normalized to the housekeeping gene RPL19 
and depicted as fold activation, relative to DMSO control, using the ΔΔCT method. ! 
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more detailed analysis of GR and BRD4 levels in each line is necessary. The 
repression of MYC transcription (Fig. 2.19C) was not observed by SDex-O3-
CO2Me, though SDex-O3-JQ1 retained the ability of its parent moiety (S)-JQ1 to 
knockdown the expression of MYC. A trans addition of SDex-O3-CO2Me and 
(S)-JQ1-biotin was more effective at MYC repression; biotinylation will interfere 
with (S)-JQ1’s ability to repress MYC transcription, while this indicates that 
conjugation to SDex may further inhibit that ability. Despite this, the observations 
in Fig. 2.19 indicate that SDex-O3-JQ1 is capable of influencing both GR and c-
Myc signaling pathways. Accordingly, collaborative efforts are currently being 
undertaken to monitor the effects of SDex-O3-JQ1 on multiple myeloma 
proliferation 
 
Effects of a bifunctional molecule on GR transrepression 
 
A key target of GR transrepression is Nuclear Factor kappa-B (NF-κB) 
pathway34,35,76,77, believed to be a primary mechanism of glucocorticoid-induced 
anti-inflammatory responses. Ligand-bound GR acts to physically interact with 
the transcription factor NF-κB, interfering with its ability to recruit the pTEF-b and 
subsequently RNA Polymerase II. To study the effects of BRD4 recruitment to a 
transrepressing GR molecule, a luciferase reporter experiment was conducted 
utilizing a reporter plasmid regulated by NF-κB.  
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U2OS cells were transfected with this reporter plasmid and an expression 
plasmid for GR, and NF-κΒ activity was stimulated with the protein ligand TNF-α. 
NF-κB activity was repressed with the indicated compounds and expressed as a 
percent of activity in cells stimulated with TNF-α alone (Fig. 2.20). SDex-O3-
CO2Me and SDex-O3-JQ1 repressed NF-κB activity with similar potency and 
efficacy. Trans addition of SDex-O3-CO2Me and (S)-JQ1 was the most 
efficacious modulator of repression, reducing NF-κB activity to just 10% of 
stimulated activity. (S)-JQ1 has recently been shown to be capable of repressing 
NF-κB activity as a monofunctional molecule, interfering with the recruitment of 
BRD4 to NF-κB to form a coactivator complex, and as such the additive 
repressive activity by SDex-O3-CO2Me and (S)-JQ1 is expected. The activity 
observed by SDex-O3-JQ1, however, would not be expected if BRD4 is being 
recruited to GR; given that GR transrepression is mediated through a steric 
hindrance mechanism, recruitment of additional proteins to this complex would 
be expected to further suppress transcription. The similarities between 
monofunctional and bifunctional molecule treatment is consistent with NF-κB 
Figure 2.20 GR transrepression of NF-κB activity. The effects of the designed ligands on NF-κB 
activity were tested, where NF-κB activity was stimulated and the effects of the ligands were 
determined in a reporter system. 
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transrepression by SDex-O3-JQ1 is only occurring through the glucocorticoid 
moiety of the molecule. 
 
2.6 Conclusions and discussion 
 
Synthetic linkage of the glucocorticoid agonist dexamethasone to FK506 
provides a method for the recruitment of FKBP-fusion proteins to DNA-bound 
GR. Localization of an activator-FKBP fusion to GR raised the transcriptional 
activation potential past the level produced by a full glucocorticoid agonist. This 
effect was most potently demonstrated at a reporter gene, though it translated to 
the transcription of an endogenous gene modulated by GR. However, 
recruitment is influenced by GRE environment and enhanced activation does not 
occur universally at GR-regulated genes. Alternatively, recruitment of the 
repressor fusion protein HDAC1-FKBP facilitated the downregulation of GR 
transcriptional activity. Investigations into this effect were limited to one 
endogenous gene and, as with the recruitment of VP16-FKBP, this may transpire 
in a gene-specific manner. The transcriptional suppression of a reporter gene 
was only evident at a higher (1 µΜ) concentration of bifunctional molecule, and 
lower concentrations produced a near identical transcriptional response as the 
monofunctional parent molecule. This may be a confounding factor native to all 
chemical dimerization systems, stemming from differences in ligand-protein 
affinities for each moiety of the bifunctional molecule. As such, dimeric GR-ligand 
complexes may be more prevalent than the trimeric FKBP-ligand-GR complex at 
low concentrations, allowing for the glucocorticoid portion of SDex-O2-FK506 to 
act as a simple partial agonist. Alternatively, this effect may be caused by GR’s 
AF1; recruitment of HDAC1-FKBP likely interferes with the recruitment of 
coactivators through AF2, though the independent action of AF1 may overwhelm 
the ability of HDAC1-FKBP to repress transcription at lower concentrations.  
 
The modular design of SDex-O2-FK506 allows for a facile replacement of FKBP 
as a recruitment partner for other targets. Substituting FK506 with (S)-JQ1, the 
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bifunctional SDex-O3-JQ1 demonstrated an ability to recruit BRD4 to GR in 
lysates, at the promoter of a reporter gene, and to an endogenous GRE. BRD4 
binding of acetylated histone lysines is typically associated with upregulation of 
genes in close proximity68; however, SDex-O3-JQ1 was not capable of triggering 
an enhanced level of transcription as was observed with the recruitment of VP16-
FKBP. VP16 is an extremely potent viral activator, and this likely plays a factor in 
the lack of enhanced activation. Another likely explanation is that SDex-O3-JQ1 
is unable to recruit BRD4 in a manner that allows for a transcriptionally favorable 
conformation. Accordingly, this is in line with observations that BRD4 recruitment 
actively inhibits the formation of a favorable transcriptional complex. In luciferase 
reporter studies, the transcriptional response to SDex-O3-JQ1 resembled SDex-
O2-FK506 activity in the presence of HDAC1-FKBP.  As seen with the 
recruitment of FKBP-fusions, it appears that the ability of a bifunctional 
glucocorticoid to recruit secondary proteins, or at very least for those proteins to 
influence transcriptional activity, may be influenced by the chromatin environment 
surrounding a GRE. Our ability to make comparisons between the effects of 
SDex-O3-JQ1 at different genes and in different cell lines is currently limited, but 
a few preliminary conclusions can be made. The S100P gene is responsive to 
glucocorticoid treatment likely due to the presence of a GRE in the S100P 
promoter in close proximity (218 bp) from the gene’s transcriptional start site55. 
This resembles the environment utilized in reporter experiments, wherein each 
GRE was incorporated in close proximity to the luciferase gene; accordingly, this 
may explain the similarity in transcriptional patterns of luciferase and S100P 
expression. This differs starkly from the landscape surrounding the FKBP5 gene, 
where a GRE located in an intronic enhancer 26,000 bp downstream from the 
transcription start site is the putative cause for glucocorticoid responsiveness, 
and the GILZ environment, where transcriptional activity is directed by two GREs 
located 3000 bp upstream of the start site31. Predicting DNA-protein interactions 
in a three-dimensional environment is difficult, and it is unclear currently if the 
location of these GREs allow for a scenario in which recruitment partners can be 
properly positioned. These observations may allow us to predict the ability of 
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bifunctional molecules to differentially regulate genes with GREs located 
immediately upstream of a transcriptional start site; however, it would be 
premature to make this generalization.  Current collaborative efforts are being 
undertaken to profile the effects of SDex-O3-JQ1 on a genomic scale and will 
undoubtedly help guide further conclusions.  
 
The SDex-O3-JQ1 bifunctional molecule maintained the ability of its parent 
ligands to potently inhibit the expression of a NF-κB-regulated gene. Paired with 
a reduced ability to mediate transactivation, this is a desired outcome in anti-
inflammatory signaling. While GR inhibition of NF-κΒ activity is mediated through 
a direct PPI, an enhanced transrepression was not observed by SDex-O3-JQ1 
relative to a trans addition of SDex-O3-CO2Me and (S)-JQ1. Given that both 
glucocorticoids and (S)-JQ1 are independently capable of transrepressing NF-κB 
activity, discerning if BRD4 recruitment is occurring in this scenario is difficult. 
Currently, SDex-O3-JQ1 is being evaluated for its ability to suppress AP-1 
signaling, an additional participant in the inflammation response that has no 
documented response to (S)-JQ1 treatment.  
 
The developments described in Chapter 2 establish the full length GR as a viable 
target of transcriptional modulation by bifunctional ligands. This strategy has 
been used to both enhance activation past full agonist-induced levels and to 
suppress GR from fully activating transcription in manners dependent on 
recruitment. Moreover, this work has demonstrated that much of this activity is 
dependent on the structural environment of a modulated gene, hinting at the 
possibility for selective gene modulation and the production of further unique 
transcriptional outputs. This idea is first progressed in the research described in 
Chapter 3. As more selective, potent ligands of epigenetic proteins continue to be 
developed, the lessons learned here will hopefully guide future efforts to 
chemically induce PPIs and build novel transcriptional complexes. 
 
2.7 Materials and Methods 
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Cell culture and transfections 
HeLa (CCL-2), U2OS (HTB-96), and A549 (CCL-185) cells were purchased from 
ATCC. 293T cells were a gift from J. Iñiguez-Lluhí. Cells were cultured in DMEM 
with 10% FBS at 37°C under 5% CO2. MM1.S cells were a gift from J. Bradner 
and were cultured in RPMI-1640 with 10% FBS under otherwise identical 
conditions. Transient transfections were done using Lipofectamine or 
Lipofectamine 2000 (Invitrogen) with conditions optimized using GFP expression 
plasmid and fluorescent analysis or by using a β-gal expression plasmid and 
activity assay.  
 
Plasmids 
All oligonucleotides for construction of plasmids were purchased from Integrated 
DNA Technologies.  
 
pCMV-β-gal is a β-galactosidase coding plasmid driven by a CMV promoter and 
was generously provided by J. Iñiguez-Lluhí. 
 
pCDNA3 hGR (human GR coding plasmid) and p6R GR (rat GR coding plasmid) 
were gifts from J. Iñiguez-Lluhí. 
 
pVP16-FKBP is a mammalian expression plasmid that encodes a fusion of Gal1-
11 (for efficient expression), NLS from SV40 large T antigen (nuclear localization 
signal), VP16(411-456) (potent activation domain, activation domain 1 from the 
herpes simplex virion protein 16), and human FKBP1A(2-107) (FK506 binding 
protein 1A, 12kDa). It was constructed by cloning of FKBP1A into pAct. The 
coding sequence is shown below, with the elements listed above marked with 
capital letters in brackets: 
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[ATGAAGCTACTGTCTTCTATCGAACAAGCATGC][CCAAAAAAGAAGAGAAA
GGTAGAT]gaattcccgggg[ATCTCGACGGCCCCCCCGACCGATGTCAGCCTGG
GGGACGAGCTCCACTTAGACGGCGAGGACGTGGCGATGGCGCATGCCGA
CGCGCTAGACGATTTCGATCTGGACATGTTGGGGGACGGGGATTCCCCGG
GTCCGGGA]tcgccaggatcc[GGCGTGCAGGTGGAGACTATCTCCCCAGGAGAC
GGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGG
GATGCTTGAAGATGGAAAGAAATTTGATTCCTCCCGGGACAGAAACAAGCC
CTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGG
GGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGA
TTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCAC
TCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAAGATCTGTCGACTTGACG
CGT] 
 
pLIC-FKBP is a cloning vector designed for making fusions to FKBP (and Gal4(1-
11) and SV40 large T NLS). This was made by cutting VP16 out of pVP16-FKBP 
with EcoRI and BamH1, and ligating in an LIC cassette in the form of annealed 
oligos: 5’- AAT TGG GAA GCA CCG GTT CTG GTG ATC -3’ and 5’- GAT CGA 
TCA CCA GAA CCG GTG CTT CCC -3’. To prepare the vector for LIC cloning, it 
was digested with AgeI and processed with T4 DNA polymerase (Novagen) with 
dTTP added as the only nucleotide. Genes to be cloned into the vector were 
PCR amplified with primers that have sequences appended to 5’end of gene 
specific sequence. These appendages are: Sense-primer 5’- 
GGGAAGCACCGGT; Antisense-primer 5’- CACCAGAACCGGT. 
 
pLIC-myc6 is a LIC cloning78 vector to facilitate fusion of genes to six myc-tags in 
a mammalian expression vector. It was prepared by performing site-directed 
mutagenesis to pCS2+MT with the primers: 5’- CAA GCT ACT TGT TCT TTT 
TGC ACC ATG GGA AGC ACC GGT TCT GGT GAG ATG GAG CAA AAG CTC 
ATT TCT G -3’ and 5’- CAG AAA TGA GCT TTT GCT CCA TCT CAC CAG AAC 
CGG TGC TTC CCA TGG TGC AAA AAG AAC AAG TAG CTT G –3’. To 
prepare the vector for LIC cloning, it was digested with AgeI and processed with 
T4 DNA polymerase (Novagen) with dTTP added as the only nucleotide. Genes 
to be cloned into the vector were PCR amplified with primers that have 
sequences appended to 5’end of gene specific sequence. These appendages 
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are: Sense-primer 5’- GGGAAGCACCGGT; Antisense-primer 5’- 
CACCAGAACCGGT. 
 
phGR-myc6 was prepared with LIC of human GR into pLIC-myc6.  
 
pHDAC1-FKBP was constructed by inserting the sequence from mouse histone 
deacetylase-1 into pLIC-FKBP. 
 
pHDAC1(D99A)-FKBP was constructed by single primer site-directed 
mutagenesis using the following primer: 
F-Pr 5’- TGTTGGTGAGGCCTGTCCGGTATTTGATGG -3’ 
 
pConsensus GRE-luc, pFKBP5(GRE)-luc, and pGILZ(GRE)-luc were generously 
provided by K. Yamamoto (UCSF). 
 
pNF-κB-luc was provided generously by G. Nuñez (Univ. of Michigan). 
 
Mammalian three-hybrid assay (Figs. 2.7 and 2.10) 
3,000,000 293T cells were plated in a 10 cm dish in 10 mL DMEM. The following 
day they were transfected by replacing media with transfection mix: 400 ng 
pGBR 6.1 luc, 200 ng pCMV-β gal, 50 ng of p6rGR or pCDNA3 hGRα (as 
indicated), 200 ng of indicated FKBP expression plasmid, 7.1 µg pBSKS, and 16 
µL Lipofectamine in 5 mL serum-free DMEM. After 6 hours, the transfection mix 
was replaced with DMEM + 5% charcoal stripped FBS and allowed to recover 
overnight. The following day, cells were removed by trypsinization and replated 
at a density of 10,000 cells per well in a 96-well dish. Individual wells were 
treated with the indicated compounds to a final DMSO concentration of 0.01%. 
After 16 hours, media was removed and cells were lysed using a passive-lysis 
buffer. β-gal activity was assayed as described previously using a Molecular 
Devices Spectramax plate reader. Luciferase activity was determined as 
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described previously using a Molecular Devices Spectramax L luminometer. 
Standard error from triplicate samples is represented by error bars on graph.  
 
Transcriptional reporter assay (Fig. 2.15 and 2.16) 
U2OS cells were seeded at a density of 250,000 cells per well in a 6-well plate 
with 2 mL DMEM + 10% FBS. The following day, cells were transfected with 1 µg 
of indicated pGRE-luc, 0.5 µg of pCDNA3 hGRα, 0.5 µg of pCMV-β gal, and 5 µL 
of Lipofectamine 2000. After 6 hours, the transfection mix was replaced with 
DMEM + 5% charcoal stripped (CS) FBS and allowed to recover overnight. The 
following day, cells were removed by trypsinization and replated at a density of 
10,000 cells per well in a 96-well dish. Individual wells were treated with the 
indicated compounds to a final DMSO concentration of 0.01%. After 16 hours, 
media was removed and cells were lysed using a passive-lysis buffer. β-gal 
activity was assayed as described previously using a Molecular Devices 
Spectramax plate reader. Luciferase activity was determined as described 
previously using a Molecular Devices Spectramax L luminometer. Standard error 
from triplicate samples is represented by error bars on graph. 
 
RT-qPCR (Figs. 2.10, 2.17, 2.18, and 2.19) 
50,000 transfected U2OS, A549, or MM1.S cells were plated in 24-well plate with 
0.5 mL DMEM + 5% CS FBS. Next day cells were treated with compounds or 
DMSO (0.2% final DMSO for all samples). Total RNA was isolated with Qiagen 
RNAeasy Plus mini kit. cDNA synthesis was done with iScript RT Mastermix 
(Biorad). 20 µL qPCR reaction mix: 2 µL of produced cDNA, 0.2 µL CXR, 0.4 µL 
forward primer (200 nM final), 0.4 µL reverse primer, 7 µL H2O, 10 µL GoTaq 
qPCR master mix (Promega). qPCR was done on ABI StepOne Plus. Products 
were analyzed with melt curve for quality control. Transcript levels were 
normalized to the levels of a housekeeping gene, RPL19. Activation was 
displayed relative to transcript levels in DMSO-treated cells and determined 
using the ΔΔCT method. Primer pairs used:  
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FKBP5: F-Pr 5’- GGAATGGTGAGGAAACGCCG -3’  
FKBP5: R-Pr 5’- CTCTCCTTTCTTCATGGTAGCCACC -3’  
GILZ: F-Pr 5’- CGAACAGGCCATGGATCTGGTGAA -3’  
GILZ: R-Pr 5’- AGAACCACCAGGGGCCTCGG -3’  
S100P: F-Pr 5’- CGGAACTAGAGACAGCCATGGGCAT -3' 
S100P: R-Pr 5’- AGACGTGATTGCAGCCACGAACAC -3’ 
MYC: F-Pr 5’- AAACACAAACTTGAACAGCTAC -3’ 
MYC: R-Pr 5’- ATTTGAGGCAGTTTACATTATGG -3’ 
RPL19: F-Pr 5’- ATGTATCACAGCCTGTACCTG -3’  
RPL19: R-Pr 5’- TTCTTGGTCTCTTCCTCCTTG -3’ 
 
Co-immunoprecipitation (Fig. 2.13) 
α-BRD4 was purchased from Bethyl laboratories (A301). α-myc-HRP was 
purchased from Santa Cruz Biotechnology (9E10). 3,000,000 293T cells were 
seeded in a 10-cm dish in 10 mL of DMEM + 10% FBS. The following day, cells 
were transfected with 4 µg of pCDNA3 and 4 µg of phGR-myc6 with 16 µL of 
Lipofectamine 2000 in 5 mL DMEM + 5% CS FBS. One day following 
transfection, cells were lysed in RIPA buffer including HALT protease inhibitor 
cocktail (Life Technologies), sonicated, and cleared. Lysate protein concentration 
was quantified by BCA assay. 6 µg of α-BRD4 was incubated with 30 µL of 
Protein G Dynabeads and subsequently washed. Antibody-coated beads were 
incubated 100 µg of lysate and the indicated compound, at a final DMSO 
concentration of 0.4% for 2 hours at room temperature. Beads were washed and 
bound proteins were eluted in Laemmli buffer. The presence of hGR-myc6 in 
eluent was detected by Western blot using α-myc-HRP.  
 
Transrepression reporter assay (Fig. 2.20) 
U2OS cells were seeded at a density of 250,000 cells per well in a 6-well plate 
with 2 mL DMEM + 10% FBS. The following day, cells were transfected with 1 µg 
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of indicated pNF-κB-luc, 0.5 µg of pCDNA3 hGRα, and 0.5 µg of pCMV-β gal. 
After 6 hours, the transfection mix was replaced with DMEM + 5% charcoal 
stripped FBS and allowed to recover overnight. The following day, cells were 
removed by trypsinization and replated at a density of 10,000 cells per well in a 
96-well dish. Individual wells were treated with the indicated compounds to a final 
DMSO concentration of 0.01%, along with hTNF-α (Roche) at a final 
concentration of 5 ng/mL. After 16 hours, media was removed and cells were 
lysed using a passive-lysis buffer. β-gal activity was assayed as described 
previously using a Molecular Devices Spectramax plate reader. Luciferase 
activity was determined as described previously using a Molecular Devices 
Spectramax L luminometer. Standard error from triplicate samples is represented 
by error bars on graph. 
 
Chemical synthesis 
FK506 was purchased from LC Laboratories. Dexamethasone was purchased 
from Enzo Life Sciences. Commercially available reagents and solvents were 
used as received. Chromatographic separations were carried out on silica gel 60 
(230-400 mesh, E. Merck) or by reverse phase HPLC on C18 column using the 
indicated eluents. Yields are unoptimized. ESI-MS spectra were obtained on 
Micromass LCT TOF mass spectrometer. High-resolution mass spectra (HRMS) 
were obtained on Micromass AutoSpec Ultima Magnetic sector mass 
spectrometer. 1H-NMR spectra were obtained at 400MHz on a Varian MR-400 
spectrometer. Chemical shifts are given in δ(ppm) values.  
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SDex-ITC was synthesized by J. Carolan and J. Højfeldt following a published 
procedure45. 
Dexamethasone (1.00 g, 2.5 mmol) was dissolved in pyridine (7 mL) and cooled 
to 0°C. Methanesulfonyl chloride (0.26 mL, 3.3 mmol) was added to the mixture 
dropwise over 15 min. After stirring at 0°C for 30 min, the reaction mixture was 
poured into water (300 mL) at 0°C. The precipitation was collected by filtration 
and washed with water. The obtained product and tert-butyl 2-
sulfanylethylcarbamate (1.24 mL, 7.3 mmol) were dissolved in acetone (24 mL). 
Triethylamine (2.05 mL, 7.3 mmol) was added to the solution and then the 
resulting mixture was stirred at room temperature for 15 h. The reaction mixture 
was diluted with water and extracted with ethyl acetate. The extract was washed 
with water and brine, dried over sodium sulfate and concentrated in vacuo. The 
residue was crystallized from ethyl acetate-hexane to give a colorless powder. 
The obtained powder was dissolved in 1.5 M hydrochloric acid in acetic acid (1 
mL) and then the mixture was stirred at room temperature for 15 min. The 
mixture was diluted with water and chloroform and basified with saturated 
aqueous sodium carbonate solution and the slurry was stirred at room 
temperature for 15 min (pH of the slurry should be over 10). Thiophosgene (0.18 
mL, 2.4 mmol) was added to the slurry, and then the resulting mixture was stirred 
at room temperature for 1.5 h. The chloroform layer was separated, and the layer 
was washed with water and brine, dried over sodium sulfate and concentrated in 
vacuo. The residue was purified by silica gel chromatography (ethyl 
acetate/hexane = 1/4 to 1/1) to give product (150 mg, 18%) as a pale yellow 
powder.  1H NMR (400MHz, CDCl3): δ 0.88 (3H, d J = 7.2 Hz), 1.02-1.80 (10H, 
m), 2.01-2.57 (6H, m), 2.81 (2H, t, J = 6.8 Hz), 3.04-3.07 (1H, m), 3.24 (1H, d, J 
= 13.6 Hz), 3.58 (1H, d, J = 14.0 Hz), 3.71 (2H, t, J = 5.8 Hz), 4.34 (2H, d, J = 7.6 
Hz), 6.08 (1H, s), 6.29 (1H, d, J = 8.4 Hz), 7.14 (1H, d, J = 10 Hz). ESI-MS 
calculated for [C25H32FNO4S2 + H]+: 494.1, found 494.0. 
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Boc-linker was synthesized by J. Carolan and A. Van Dyke. 
To a solution of 2-[2-(2-aminoethoxy)ethoxy]ethanamine (5.00 g, 33.7 mmol) in 
ethanol (50 mL) was added a solution of di-tert-butyl dicarbonate (2.45 g, 11.2 
mmol) in dichloromethane (10 mL) dropwise at 0 °C over 2 h. After stirring at 
room temperature for 15 h, the mixture was concentrated in vacuo. The residue 
was diluted with ethyl acetate and acidified with 10% aqueous citric acid solution. 
The aqueous layer was collected, washed with ethyl acetate twice, basified with 
3 M NaOH and extracted with dichloromethane. The extract was dried over 
Na2SO4 and concentrated in vacuo to give Boc-linker (2.02 g, 73%) as a 
colorless oil. 1H NMR (500MHz, CDCl3): d 1.45 (9H, s), 2.89 (2H, t, J = 5.5 Hz), 
3.32-3.34 (2H, m), 3.51-3.57 (4H, m), 3.61-3.64 (4H, m), 5.15 (1H, br s). ESI-MS 
calcd for [C11H24N2O4 + H]+: 249.1, found 249.1. 
 
 
 
 
 
SDex-O2-NH2 was synthesized by J. Carolan and Y. Imaeda. 
A solution of Boc-linker (50 mg, 0.20 mmol) and SDex-ITC (100 mg, 0.20 mmol) 
in dichloromethane (5 mL) was stirred at room temperature for 15 h. After 
concentration in vacuo, the residue was purified by silica gel chromatography 
(ethyl acetate/hexane = 1/3 to 3/1). The product was treated with concentrated 
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hydrochloric acid (1 mL) and ethanol (2 mL) and then stirred at room temperature 
for 1 h. The mixture was basified to pH 12 with 3 M aqueous NaOH solution and 
extracted with dichloromethane twice. The extract was dried over Na2SO4 and 
concentrated in vacuo to give compound 11 (80 mg, 62%) as a pale yellow 
amorphous powder. 1H NMR (400MHz, CDCl3): d 0.82-1.76 (19H, m), 2.09-2.34 
(6H, m), 2.51-2.71 (3H, m), 2.86 (1H, m), 3.03-3.05 (1H, m), 3.41-3.66 (12H, m), 
4.27 (1H, d, J = 10.0 Hz), 5.23 (2H, s), 6.04 (1H, s), 6.25 (1H, d, J = 10.4 Hz), 
7.15 (1H, d, J = 10 Hz). ESI-MS calcd for [C31H48FN3O6S2 + H]+: 642.3, found 
642.3. 
 
 
 
 
 
FK506-NHS-TBS2 was synthesized by J. Carolan and Y. Imaeda following a 
published procedure50. 
To a solution of FK506 (400 mg, 0.50 mmol) and 2,6-lutidine (0.29 mL, 2.5 mmol) 
in dichloromethane (10 mL) was added tert-butyldimethylsilyl 
trifluoromethanesulfonate (TBSOTf; 0.46 mL, 2.0 mmol) dropwise at 0°C under a 
nitrogen atmosphere. After stirring at 0°C for 1 h, the reaction mixture was diluted 
with dichloromethane. The solution was washed with water, 10% aqueous citric 
acid solution and brine then dried over Na2SO4 and concentrated in vacuo. The 
oil product was dissolved in tetrahydrofuran (THF; 16 mL) and water (3.2 mL) 
and charged with 4-methylmorpholine N-oxide (4-NMO; 278 mg, 2.4 mmol) and 
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osmium tetroxide (2.5% wt in tert-butanol; 0.97 mL, 2.4 mmol). After stirring at 
room temperature for 2.5 h, the reaction mixture was diluted with 50% aqueous 
methanol (4.8 mL). Sodium periodate (1.02 g, 4.8 mmol) was added to the 
mixture and stirred at room temperature for 1 h. The mixture was extracted with 
diethyl ether. The extract was washed with brine, dried over Na2SO4, and 
concentrated in vacuo. The resulting product was dissolved in THF (16 mL) and 
treated with LiAlH(OCEt3)3 solution (0.5M in THF; 1.42 mL, 0.71 mmol) at  –78°C. 
After stirring for 40 min, the reaction was quenched with saturated aqueous 
ammonium chloride (1.6 mL), dried over Na2SO4 and concentrated in vacuo. The 
product was then dissolved in acetonitrile, 2,6-lutidine (1.11 mL, 9.5 mmol) and 
N,N’-disuccimidyl carbonate were added. After stirring at room temperature for 
18 h, the reaction mixture was concentrated in vacuo. The residue was diluted 
with ethyl acetate, washed with water, 5% aqueous citric acid solution, and brine, 
dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica 
gel chromatography (ethyl acetate/hexane = 1/3 to 2/5) to give compound 
FK506-NHS-TBS2 (350 mg, 63%) as a pale yellow film. 1H NMR (400MHz, 
CDCl3): d 0.00-0.12 (12H, m), 0.84-1.06 (22H, m), 1.28-2.37 (44H, m), 2.87-2.89 
(3H, m), 2.98 (1H, m), 3.35-3.63 (10H, m), 3.82-5.27 (8H, m). ESI-MS calcd for 
[C60H100N2O17Si2 + Na]+: 1199.6, found 1199.6. 
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SDex-O2-FK506 was synthesized by J. Carolan and Y. Imaeda, adapting a 
published procedure50. 
A mixture of SDex-O2-NH2 (16 mg, 0.025 mmol), FK506-NHS-TBS2 (30 mg, 
0.025 mmol) and N,N-diisopropylethylamine (0.009 mL, 0.050 mmol) in 
dichloromethane (0.5 mL) and DMF (0.5 mL) was stirred at room temperature for 
3 days. The mixture was diluted with dichloromethane, washed with water, 5% 
aqueous citric acid solution, and brine, dried over Na2SO4 and concentrated in 
vacuo. The residue was purified by silica gel chromatography (ethyl 
acetate/hexane = 1/3 to 4/1) to give the TBS protected product (10 mg). The 
product (5 mg) was treated with 1.5 M HCl in AcOH (0.5 mL) and water (0.1 mL) 
and then stirred at room temperature for 30 min. The mixture was neutralized 
with NaHCO3 powder and suspended in acetonitrile. The mixture was filtered and 
the filtrate was concentrated in vacuo. The residue was purified by HPLC (0.1% 
aqueous TFA/acetonitrile = 45/55 to 25/75) to give compound SDex-O2-FK506 
(1.8 mg, 42%) as a colorless amorphous powder, calculated to be 95% pure 
through peak integration. 1H NMR (400MHz, CD3OD): d 0.86-1.12 (19H, m), 
1.22-2.35 (50H, m), 2.76 (3H, br s), 3.04-3.15 (3H, m), 3.38-4.25 (33H, m), 5.08-
5.22 (3H, m), 6.07 (1H, s), 6.26-6.29 (1H, m), 7.40 (1H, m). HRMS (ESI) calcd for 
[C75H115FN4O20S2 + Na]+: 1497.7422, found 1497.7415. HPLC chromatogram of 
purified product is displayed below: 
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SDex-O2-CO2Me was synthesized by A. Van Dyke. 
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SDex-O3-CO2Me was synthesized by A. Van Dyke. 
 
 
 
 
 
SDex-O3-(S)JQ1 was synthesized by A. Van Dyke and J.Qi. 
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SDex-O3-(R)JQ1 was synthesized by A. Van Dyke and J. Qi. 
 
2.8 References 
 
(1) Nagy, L.; Schwabe, J. W. R. Mechanism of the Nuclear Receptor 
Molecular Switch. Trends in Biochemical Sciences 2004, 29, 317–324. 
 
(2) Rogatsky, I.; Wang, J.-C.; Derynck, M. K.; Nonaka, D. F.; Khodabakhsh, 
D. B.; Haqq, C. M.; Darimont, B. D.; Garabedian, M. J.; Yamamoto, K. R. 
Target-Specific Utilization of Transcriptional Regulatory Surfaces by the 
Glucocorticoid Receptor. Proceedings of the National Academy of 
Sciences 2003, 100, 13845–13850. 
 
(3) Johnson, A. B.; O’Malley, B. W. Steroid Receptor Coactivators 1, 2, and 
3: Critical Regulators of Nuclear Receptor Activity and Steroid Receptor 
Modulator (SRM)-Based Cancer Therapy. Molecular and Cellular 
Endocrinology 2012, 348, 430–439. 
 
(4) Dahlman-Wright, K.; Siltala-Roos, H.; Carlstedt-Duke, J.; Gustafsson, J.-
A. Protein-Protein Interactions Facilitate DNA Binding by the 
Glucocorticoid Receptor DNA-Binding Domain. Journal of Biological 
Chemistry 1990, 265, 14030–14035. 
 
(5) Wood, J. R.; Greene, G. L.; Nardulli, A. M. Estrogen Response Elements 
Function as Allosteric Modulators of Estrogen Receptor Conformation. 
Molecular and Cellular Biology 1998, 18, 1927–1934. 
 
(6) Meijsing, S. H.; Pufall, M. A.; So, A. Y.; Bates, D. L.; Chen, L.; 
Yamamoto, K. R. DNA Binding Site Sequence Directs Glucocorticoid 
Receptor Structure and Activity. Science 2009, 324, 407–410. 
 
SDex-O3-(R)JQ1
N
H
S
S
O
H
HF
HO
HO
O
N
N
S
N NO
Cl
O
O
ON
H
NH
! 86!
(7) Ismaili, N.; Garabedian, M. J. Modulation of Glucocorticoid Receptor 
Function via Phosphorylation. Annals of the New York Academy of 
Sciences 2004, 1024, 86–101. 
 
(8) Yamamoto, K. R.; Darimont, B. D.; Wagner, R. L.; Iniguez-Lluhi, J. 
Building Transcriptional Regulatory Complexes: Signals and Surfaces. 
Cold Spring Harbor Symposia on Quantitative Biology 1998, 63, 587–
598. 
 
(9) Evans, R. M. The Steroid and Thyroid Hormone Receptor Superfamily. 
Science 1988, 240, 889–895. 
 
(10) Love, J. D. Nuclear Receptors and Disease. In Encyclopedia of Life 
Sciences; John Wiley & Sons, Ltd: Chichester, UK, 2005; pp. 1–5. 
 
(11) Ottow, E.; Weinmann, H. Nuclear Receptors as Drug Targets: a Historical 
Perspective of Modern Drug Discovery. In Nuclear Receptors as Drug 
Targets; Ottow, E.; Weinmann, H., Eds.; 2008; pp. 1–23. 
 
(12) Bledsoe, R. K.; Montana, V. G.; Stanley, T. B.; Delves, C. J.; Apolito, C. 
J.; McKee, D. D.; Consler, T. G.; Parks, D. J.; Stewart, E. L.; Willson, T. 
M.; et al. Crystal Structure of the Glucocorticoid Receptor Ligand Binding 
Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator 
Recognition. Cell 2002, 110, 93–105. 
 
(13) Stevens, A.; Garside, H.; Berry, A.; Waters, C.; White, A.; Ray, D. 
Dissociation of Steroid Receptor Coactivator 1 and Nuclear Receptor 
Corepressor Recruitment to the Human Glucocorticoid Receptor by 
Modification of the Ligand-Receptor Interface: the Role of Tyrosine 735. 
Molecular Endocrinology 2003, 17, 845–859. 
 
(14) Yoshikawa, N.; Yamamoto, K.; Shimizu, N.; Yamada, S.; Morimoto, C.; 
Tanaka, H. The Distinct Agonistic Properties of the Phenylpyrazolosteroid 
Cortivazol Reveal Interdomain Communication Within the Glucocorticoid 
Receptor. Molecular Endocrinology 2005, 19, 1110–1124. 
 
(15) Schäcke, H.; Rehwinkel, H.; Asadullah, K. Dissociated Glucocorticoid 
Ligands: Compounds with an Improved Therapeutic Index. Current 
Opinion in Investigational Drugs 2004, 101, 15603–15608. 
 
(16) Burris, T. P.; Solt, L. A.; Wang, Y.; Crumbley, C.; Banerjee, S.; Griffett, K.; 
Lundasen, T.; Hughes, T.; Kojetin, D. J. Nuclear Receptors and Their 
Selective Pharmacologic Modulators. Pharmacological Reviews 2013, 65, 
710–778. 
 
(17) Lewis, J. S.; Jordan, V. C. Selective Estrogen Receptor Modulators 
! 87!
(SERMs): Mechanisms of Anticarcinogenesis and Drug Resistance. 
Mutation Research 2005, 591, 247–263. 
 
(18) Maximov, P. Y.; Lee, T. M.; Jordan, V. C. The Discovery and 
Development of Selective Estrogen Receptor Modulators (SERMs) for 
Clinical Practice. Current Clinical Pharmacology 2013, 8, 135–155. 
 
(19) Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, 
D. A.; Greene, G. L. The Structural Basis of Estrogen 
Receptor/Coactivator Recognition and the Antagonism of This Interaction 
by Tamoxifen. Cell 1998, 95, 927–937. 
 
(20) Ribeiro, R. C. J.; Apriletti, J. W.; Wagner, R. L.; Feng, W.; Kushner, P. J.; 
Nilsson, S.; Scanlan, T. S.; West, B. L.; Fletterick, R. J.; Baxter, J. D. X-
Ray Crystallographic and Functional Studies of Thyroid Hormone 
Receptor. Journal of Steroid Biochemistry and Molecular Biology 1998, 
65, 133–141. 
 
(21) Chang, C.-Y.; Norris, J. D.; Grøn, H.; Paige, L. A.; Hamilton, P. T.; Kenan, 
D. J.; Fowlkes, D.; McDonell, D. P. Dissection of the LXXLL Nuclear 
Receptor-Coactivator Interaction Motif Using Combinatorial Peptide 
Libraries: Discovery of Peptide Antagonists of Estrogen Receptors Α and 
Β. Molecular and Cellular Biology 1999, 19, 8226–8239. 
 
(22) Geistlinger, T. R.; Guy, R. K. An Inhibitor of the Interaction of Thyroid 
Hormone Receptor Β and Glucocorticoid Interacting Protein 1. J. Am. 
Chem. Soc. 2001, 123, 1525–1526. 
 
(23) Leduc, A.-M.; Trent, J. O.; Wittliff, J. L.; Bramlett, K. S.; Briggs, S. L.; 
Chirgadze, N. Y.; Wang, Y.; Burris, T. P.; Spatola, A. F. Helix-Stabilized 
Cyclic Peptides as Selective Inhibitors of Steroid Receptor–Coactivator 
Interactions. Proceedings of the National Academy of Sciences 2003, 
100, 11273–11278. 
 
(24) Geistlinger, T. R.; McReynolds, A. C.; Guy, R. K. Ligand-Selective 
Inhibition of the Interaction of Steroid Receptor Coactivators and 
Estrogen Receptor Isoforms. Chemistry & Biology 2004, 11, 273–281. 
 
(25) Steger, D. J.; Haswell, E. S.; Miller, A. L.; Wente, S. R.; OShea, E. K. 
Regulation of Chromatin Remodeling by Inositol Polyphosphates. 
Science 2003, 299, 114–116. 
 
(26) Watson, P. J.; Fairall, L.; Santos, G. M.; Schwabe, J. W. R. Structure of 
HDAC3 Bound to Co-Repressor and Inositol Tetraphosphate. Nature 
2013, 481, 335–340. 
 
! 88!
(27) Bevan, C. L.; Hoare, S.; Claessens, F.; Heery, D. M.; Parker, M. G. The 
AF1 and AF2 Domains of the Androgen Receptor Interact with Distinct 
Regions of SRC1. Molecular and Cellular Biology 1999, 19, 8363–8392. 
 
(28) Lavery, D. N.; McEwan, I. J. The Human Androgen Receptor AF1 
Transactivation Domain: Interactions with Transcription Factor IIF and 
Molten-Globule-Like Structural Characteristics. Biochemical Society 
Transactions, 2006, 34, 1054–1057. 
 
(29) Zhou, J.; Cidlowski, J. A. The Human Glucocorticoid Receptor: One 
Gene, Multiple Proteins and Diverse Responses. Steroids 2005, 70, 407–
417. 
 
(30) Wang, J.-C.; Derynck, M. K.; Nonaka, D. F.; Khodabakhsh, D. B.; Haqq, 
C. M.; Yamamoto, K. R. Chromatin Immunoprecipitation (ChIP) Scanning 
Identifies Primary Glucocorticoid Receptortarget Genes. Proceedings of 
the National Academy of Sciences 2004, 101, 15603–15608. 
 
(31) So, A. Y.-L.; Chaivorapol, C.; Bolton, E. C.; Li, H.; Yamamoto, K. R. 
Determinants of Cell- and Gene-Specific Transcriptional Regulation by 
the Glucocorticoid Receptor. PLoS Genet 2007, 3, e94. 
 
(32) So, A. Y.-L.; Cooper, S. B.; Feldman, B. J.; Manuchehri, M.; Yamamoto, 
K. R. Conservation Analysis Predicts in Vivo Occupancy of Glucocorticoid 
Receptor-Binding Sequences at Glucocorticoid-Induced Genes. 
Proceedings of the National Academy of Scienes 2008, 105, 5745–5749. 
 
(33) König, H.; Ponta, H.; Rahmsdorf, H. J.; Herrlich, P. Interference Between 
Pathway-Specific Transcription Factors: Glucocorticoids Antagonize 
Phorbol Ester-Induced AP-1 Activity Without Altering AP-1 Site 
Occupation In Vivo. The EMBO Journal 1992, 11, 2241–2246. 
 
(34) Nissen, R. M.; Yamamoto, K. R. The Glucocorticoid Receptor Inhibits 
NFkB by Interfering with Serine-2 Phosphorylation of the RNA 
Polymerase II Carboxy-Terminal Domain. Genes Development 2000, 14, 
2314–2329. 
 
(35) Luecke, H. F.; Yamamoto, K. R. The Glucocorticoid Receptor Blocks P-
TEFb Recruitment by NFBto Effect Promoter-Specific Transcriptional 
Repression. Genes Development 2005, 19, 1116–1127. 
 
(36) Stahn, C.; Löwenberg, M.; Hommes, D. W.; Buttgereit, F. Molecular 
Mechanisms of Glucocorticoid Action and Selective Glucocorticoid 
Receptor Agonists. Molecular and Cellular Endocrinology 2007, 275, 71–
78. 
 
! 89!
(37) Gestwicki, J. E.; Kumar, A. Two- and Three-Hybrid Systems; John Wiley 
& Sons, Inc.: Hoboken, NJ, USA, 2007. 
 
(38) Licitra, E. J.; Liu, J. O. A Three-Hybrid System for Detecting Small 
Ligand–Protein Receptor Interactions. Proceedings of the National 
Academy of Sciences 1996, 93, 12817–12821. 
 
(39) Henthorn, D. C.; Jaxa-Chamiec, A. A.; Meldrum, E. A GAL4-Based Yeast 
Three-Hybrid System for the Identification of Small Molecule-Target 
Protein Interactions. Biochemical Pharmacology 2002, 63, 1619–1628. 
 
(40) Arth, G. E.; Johnston, D. B. R.; Fried, J.; Spooncer, W. W.; Hoff, D. R.; 
Sarett, L. H. 16-Methylated Steroids. Ii. 16-Methyl Analogs of Cortisone, a 
New Group of Anti-Inflammatory Steroids. 9-Halo Derivatives. J. Am. 
Chem. Soc. 1958, 80, 3161–3163. 
 
(41) Acedo, M.; Tarrason, G.; Piulats, J.; Mann, M.; Wilm, M.; Eritja, R. 
Preparation of Oligonucleotide-Dexamethasone Conjugates. Bioorganic 
Medicinal Chemistry Letters 1995, 5, 1577–1580. 
 
(42) Rebuffat, A. G. Gene Delivery by a Steroid-Peptide Nucleic Acid 
Conjugate. The FASEB Journal 2002. 
 
(43) Liu, B.; Kodadek, T. Investigation of the Relative Cellular Permeability of 
DNA-Binding Pyrrole−Imidazole Polyamides. J. Med. Chem. 2009, 52, 
4604–4612. 
 
(44) Li, N.-N.; Lin, J.; Di Gao; Zhang, L.-M. A Macromolecular Prodrug 
Strategy for Combinatorial Drug Delivery. Journal of Colloid and Interface 
Science 2014, 417, 301–309. 
 
(45) Lopez, S.; Simons, S. S., Jr. Dexamethasone 21-(Β-Isothiocyanatoethyl) 
Thioether: a New Affinity Label for Glucocorticoid Receptors. J. Med. 
Chem. 1991, 34, 1762–1767. 
 
(46) Tanaka, H.; Kuroda, A.; Marusawa, H.; Hatanaka, H.; Kino, T.; Goto, T.; 
Hashimoto, M. Structure of FK506: a Novel Immunosuppressant Isolated 
From Streptomyces. J. Am. Chem. Soc. 1987, 109, 5031–5033. 
 
(47) Siekierka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, C. S.; Sigal, N. H. A 
Cytosolic Binding Protein for the Immunosuppressant FK506 Has 
Peptidyl-Prolyl Isomerase Activity but Is Distinct From Cyclophilin. Nature 
1989, 341, 755–757. 
 
(48) Harding, M. W.; Galat, A.; Uehling, D. E.; Schreiber, S. L. A Receptor for 
the Immunosuppressant FK506 Is a Cis-Trans Peptidyl-Prolyl Isomerase. 
! 90!
Nature 1989, 341, 758–760. 
 
(49) Schreiber, S. L.; Crabtree, G. R. The Mechanism of Action of 
cyclosporinA and FK506. Immunology Today 1992, 13, 136–142. 
 
(50) Spencer, D. M.; Wandless, T. J.; Schreiber, S. L.; Crabtree, G. R. 
Controlling Signal Transduction with Synthetic Ligands. Science 1993, 
262, 1019–1024. 
 
(51) Portoghese, P. S. From Models to Molecules: Opioid Receptor Dimers, 
Bivalent Ligands, and Selective Opioid Receptor Probes. J. Med. Chem. 
2001, 44, 2259–2269. 
 
(52) Højfeldt, J. W.; Cruz-Rodríguez, O.; Imaeda, Y.; Van Dyke, A. R.; 
Carolan, J. P.; Mapp, A. K.; Iñiguez-Lluhí, J. A. Bifunctional Ligands Allow 
Deliberate Extrinsic Reprogramming of the Glucocorticoid Receptor. 
Molecular Endocrinology 2014, 28, 249–259. 
 
(53) Chauhan, D.; Auclair, D.; Robinson, E. K.; Hideshima, T.; Li, G. 
Identification of Genes Regulated by Dexamethasone in Multiple 
Myeloma Cells Using Oligonucleotide Arrays. Oncogene 2002, 21, 1346–
1358. 
 
(54) Paakinaho, V.; Makkonen, H.; Jääskeläinen, T.; Palvimo, J. J. 
Glucocorticoid Receptor Activates Poised FKBP51 Locus Through Long-
Distance Interactions. Molecular Endocrinology 2010, 24, 511–525. 
 
(55) Gibadulinova, A.; Oveckova, I.; Parkkila, S.; Pastorekova, S.; Pastorek, J. 
Key Promoter Elements Involved in Transcriptional Activation of the 
Cancer-Related Gene Coding for S100P Calcium-Binding Protein. 
Oncology Reports 2008, 20, 391–396. 
 
(56) Tothova, V.; Isola, J.; Parkkila, S.; Kopacek, J.; Pastorek, J.; 
Pastorekova, S.; Gibadulinova, A. Glucocorticoid Receptor-Mediated 
Transcriptional Activation of S100P Gene Coding for Cancer-Related 
Calcium-Binding Protein. J. Cell. Biochem. 2011, 112, 3373–3384. 
 
(57) Ropero, S.; Esteller, M. The Role of Histone Deacetylases (HDACs) in 
Human Cancer. Molecular Oncology 2007, 1, 19–25. 
 
(58) Weerasinghe, S. V. W.; Estiu, G.; Wiest, O.; Pflum, M. K. H. Residues in 
the 11 Å Channel of Histone Deacetylase 1 Promote Catalytic Activity: 
Implications for Designing Isoform-Selective Histone Deacetylase 
Inhibitors. J. Med. Chem. 2008, 51, 5542–5551. 
 
(59) Moore, T. W.; Gunther, J. R.; Katzenellenbogen, J. A. Probing the 
! 91!
Topological Tolerance of Multimeric Protein Interactions: Evaluation of an 
Estrogen/Synthetic Ligand for FK506 Binding Protein Conjugate. 
Bioconjugate Chem. 2010, 21, 1880–1889. 
 
(60) Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, 
O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; et al. Selective 
Inhibition of BET Bromodomains. Nature 2011, 468, 1067–1073. 
 
(61) Muller, S.; Filippakopoulos, P.; Knapp, S. Bromodomains as Therapeutic 
Targets. Expert Rev. Mol. Med. 2011, 13, e29. 
 
(62) Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J.-P.; 
Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Muller, S.; Pawson, T.; et al. 
Histone Recognition and Large-Scale Structural Analysis of the Human 
Bromodomain Family. Cell 2012, 149, 214–231. 
 
(63) Brès, V.; Yoh, S. M.; Jones, K. A. The Multi-Tasking P-TEFb Complex. 
Current Opinion in Cell Biology 2008, 20, 334–340. 
 
(64) Zou, Z.; Huang, B.; Wu, X.; Zhang, H.; Qi, J.; Bradner, J.; Nair, S.; Chen, 
L.-F. Brd4 Maintains Constitutively Active NF-Kappa;B in Cancer Cells by 
Binding to Acetylated RelA. 2013, 33, 2395–2404. 
 
(65) Shi, J.; Wang, Y.; Zeng, L.; Wu, Y.; Deng, J.; Zhang, Q.; Lin, Y.; Li, J.; 
Kang, T.; Tao, M.; et al. Disrupting the Interaction of BRD4 with 
Diacetylated Twist Suppresses Tumorigenesis in Basal-Like Breast 
Cancer. Cancer Cell 2014, 25, 210–225. 
 
(66) Matzuk, M. M.; McKeown, M. R.; Filippakopoulos, P.; Li, Q.; Ma, L.; Agno, 
J. E.; Lemieux, M. E.; Picaud, S.; Yu, R. N.; Qi, J.; et al. Small-Molecule 
Inhibition of BRDT for Male Contraception. Cell 2012, 150, 673–684. 
 
(67) Anders, L.; Guenther, M. G.; Qi, J.; Fan, Z. P.; Marineau, J. J.; Rahl, P. 
B.; n, J. L. E.; Sigova, A. A.; Smith, W. B.; Lee, T. I.; et al. Genome-Wide 
Localization of Small Molecules. Nature Biotechnology 2013, 32, 92–96. 
 
(68) Dey, A.; Chitsaz, F.; Abbasi, A.; Misteli, T.; Ozato, K. The Double 
Bromodomain Protein Brd4 Binds to Acetylated Chromatin During 
Interphase and Mitosis. Proceedings of the National Academy of 
Sciences 2003, 100, 8758–8763. 
 
(69) Nishiyama, A.; Dey, A.; Miyazaka, J.; Ozato, K. Brd4 Is Required for 
Recovery From Antimicrotubule Drug-Induced Mitotic Arrest: Preservation 
of Acetylated Chromatin. Molecular Biology of the Cell 2006, 17, 814–
823. 
 
! 92!
(70) Rahman, S.; Sowa, M. E.; Ottinger, M.; Smith, J. A.; Shi, Y.; Harper, J. 
W.; Howley, P. M. The Brd4 Extraterminal Domain Confers Transcription 
Activation Independent of pTEFb by Recruiting Multiple Proteins, 
Including NSD3. Molecular and Cellular Biology 2011, 31, 2641–2652. 
 
(71) Zou, Z.; Huang, B.; Wu, X.; Zhang, H.; Qi, J.; Bradner, J.; Nair, S.; Chen, 
L.-F. Brd4 Maintains Constitutively Active NF-kappaB in Cancer Cells by 
Binding to Acetylated RelA. 2013, 33, 2395–2404. 
 
(72) Luo, M.; Lu, X.; Zhu, R.; Zhang, Z.; Chow, C. C.; Li, R.; Simons, S. S., Jr. 
A Conserved Protein Motif Is Required for Full Modulatory Activity of 
Negative Elongation Factor Subunits NELF-a and NELF-B in Modifying 
Glucocorticoid Receptor-Regulated Gene Induction Properties. Journal of 
Biological Chemistry 2013, 288, 34055–34072. 
 
(73) Charmandari, E.; Kino, T. Chrousos Syndrome: a Seminal Report, a 
Phylogenetic Enigma and the Clinical Implications of Glucocorticoid 
Signalling Changes. European Journal of Clinical Investigation 2010, 40, 
932–942. 
 
(74) Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, 
H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; et al. BET 
Bromodomain Inhibition as a Therapeutic Strategy to Target C-Myc. Cell 
2011, 146, 904–917. 
 
(75) Moalli, P. A.; Pillay, S.; Weiner, D.; Leikin, R.; Rosen, S. T. A Mechanism 
of Resistance to Glucocorticoids in Multiple Myeloma: Transient 
Expression of a Truncated Glucocorticoid Receptor mRNA. Blood 1992, 
79, 213–222. 
 
(76) Scheinman, R. I.; Gualberto, A.; Jewell, C. M.; Cidlowski, J. A.; Baldwin, 
A. S., Jr. Characterization of Mechanisms Involved in Transrepression of 
NF-kB by Activated Glucocorticoid Receptors. Molecular and Cellular 
Biology 1995, 15, 943–953. 
 
(77) De Bosscher, K.; Vanden Berghe, W.; Vermeulen, L.; Plaisance, S.; 
Boone, E.; Haegemen, G. Glucocorticoids Repress NF-kB-Driven Genes 
by Disturbing the Interaction of P65 with the Basal Transcription 
Machinery, Irrespective of Coactivator Levels in the Cell. Proceedings of 
the National Academy of Sciences 2000, 97, 3919–3924. 
 
(78) Aslanidis, C.; de Jong, P. J. Ligation-Independent Cloning of PCR 
Products (LIC-PCR). Nucleic Acids Research 1990, 18, 6069–6074. 
 
 
! 93!
 
 
 
 
Chapter 3 
 
Functional Agonism by a Glucocorticoid Antagonist-Based  
Bifunctional Molecule* 
 
3.1 Abstract 
 
Glucococorticoids, such as dexamethasone and prednisolone, are commonly 
used anti-inflammatory and immunosuppressive drugs prescribed for the 
treatment of such maladies as asthma, arthritis, and various allergic disorders. 
Long-term use of this class of therapeutics is limited by mild to severe side 
effects, believed to be through alternative receptor actions. Current efforts to 
produce ligands capable of dissociating desirable from undesirable actions have 
been unsuccessful. Bifunctional glucocorticoids, acting through mechanisms 
distinct from classical glucocorticoid ligands, are capable of producing altered 
transcriptional profiles that may prove useful in this endeavor. Here, we 
characterize the actions of a bifunctional molecule constructed from a 
glucocorticoid antagonist, RU486, that instigates novel glucocorticoid receptor 
activity. 
 
3.2 Limitations of current glucocorticoid ligands 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!*!The work described in this chapter is the product of collaborative efforts. J. Carolan, A. Van 
Dyke, J. Bradner, and A. Mapp conceived of the experiments described. The compounds 
described in Figure 3.2 were synthesized by J. Carolan, J. Højfeldt, A. Van Dyke, and J. Qi.The 
data presented in Fig. 3.3 were collected by A. Van Dyke. All other experiments were performed 
by J. Carolan. Where indicated, statistical significances are represented as *: p < 0.05; **: p < 
0.01; ***: p < 0.001.!
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It is well established that the glucocorticoid receptor (GR) regulates the 
transcription of genes as a response to ligand-interaction1,2 through two distinct 
mechanisms: transactivation, involving the formation of multiprotein complexes at 
GR-binding sequences (Fig. 3.1A) 3-5; and transrepression, involving the indirect 
or direct activation disruption by other transcription factors (Fig. 3.1B) 6-11. GR 
has been identified as central to perturbing the inflammation response, and many 
have recognized that this proceeds largely through GR transrepression12-14. 
Given this pivotal role in repressing inflammation, innumerable pharmaceutical 
efforts have been devoted to producing novel glucocorticoid ligands as anti-
inflammatory therapeutics. Many potent glucocorticoids have been described15-18 
that differ in pharmacokinetic and pharmacodynamics properties; however, they 
largely share the same mechanism of action and universally produce similar 
undesirable side effects. A paradigm has arisen wherein it is believed that many 
of these effects arise through GR transactivation, and, as such, glucocorticoids 
with the highest therapeutic indices would be those that best dissociate GR 
transrepression from transactivation15. Accordingly, many efforts of the past 
decade to selectively modulate GR activity have focused on producing novel 
ligands that induce GR conformations capable of separating these responses19-
22. 
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There have been successful structural characterizations of individual GR 
domains, helping guide the synthesis of new ligands9,23. However, structural data 
has been limited for the full-length receptor24, making it difficult to predict the 
global allosteric effects of ligand binding. Recent biochemical characterizations 
have established that, despite its modularity, GR is a structurally plastic protein 
and its activities are highly dependent on total protein conformation2,25,26. This 
realization helped guide the landmark discovery that the short, six base pair (bp) 
half-sequence of a glucocorticoid response element (GRE) is capable of serving 
as an allosteric ligand in and of itself4.  
 
Figure 3.1 Distinct mechanisms of GR action. A: GR transactivation occurs following GR 
ligand binding, causing DNA-binding and increased transcription of regulated genes. B: GR 
transrepression occurs through several mechanisms, such as with the NF-κB pathway, where GR 
directly interferes with recruitment of the transcriptional machinery to DNA-bound NF-κB. !
! ! NR 
coregulator ! ! ! ! !!! !!!! !!
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Several additional insights regarding the non-ligand regulation of GR activity 
have further complicated efforts to rationally design GR modulators. GR is 
subject to varying post-translational modifications (PTMs) 27,28, including 
phosphorylation29-31, acetylation32, sumoylation33, and ubiquitylation34,35, 
alongside varying, cell-specific levels of modification, that influence resultant GR 
activity36,37. Moreover, the long-held belief that GR activity is modulated through 
a single splice isoform, GRα, has recently been disputed; transcriptional activities 
have begun to be attributed to alternative GR splice isoforms2,38. It has also been 
discovered that the GR coding gene, NR3C1, harbors multiple non-traditional 
transcriptional start sites, resulting in the production of alternative GRα protein 
products, each with similar ligand-binding capabilities though producing distinct 
transcriptional profiles2,4,38,39. Proceeding from these discoveries, over 350 
coregulators have been detected as potential interaction-partners with members 
of the GR family40,41.  
 
This collected knowledge reveals insights into why there has been limited 
success in producing ligands that produce desirable therapeutic outcomes solely 
through allosteric rearrangement of the GR ligand-binding domain (LBD). 
Importantly, this may expose limitations into the transactivation/transrepression 
dissociation model as the gold standard for GR modulation, a realization 
compounded by recent reports of certain anti-inflammatory gene products being 
produced through GR transactivation42,43. Accordingly, we need new methods for 
targeting GR, not new ligands. 
 
In Chapter 2, we demonstrated our ability to produce novel GR transcriptional 
profiles by synthetically modifying an existing glucocorticoid molecule. Learning 
from recent insights into GR function and inflammation, we reason that the 
selective activation of GR-regulated genes is of high importance, and this may be 
accomplished through the use of a ligand ordinarily incapable of activation. Here, 
we describe work to develop an antagonist-based bifunctional molecule to 
accomplish this goal. 
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3.3 Developing an antagonist-based bifunctional ligand 
 
As mentioned above, pharmaceutical efforts have been fruitful in developing 
synthetic glucocorticoid agonists. Surprisingly, there is only one clinically 
prescribed antiglucorticoid44. RU486 (clinically known as mifepristone) was 
developed by scientists at Roussel-Uclaf in the 1980’s45. Maintaining a high 
binding affinity for GR, this synthetic steroid antagonizes glucocorticoid binding44. 
Interestingly, RU486 is capable of inducing GR nuclear translocation46, 
manifesting in a low transactivation potential47 believed to be dependent on 
context through the GR AF1 domain48, though this is disputed49. However, 
RU486 bears a dimethylaniline moiety stemming from C11 of the steroidal core 
that projects from the GR LBD, disrupting helix 12 from forming an active 
coactivator-recruiting conformation9; limited evidence supports the notion that 
this disruption may induce helix 12-facilitated recruitment of corepressor 
proteins48.  
 
Owing to its antiglucocorticoid activity, RU486 is frequently used to treat 
Cushing’s syndrome, a set of symptoms that typically emerge in response to 
long-term glucocorticoid use or adrenal gland hyperactivity causing elevated 
cortisol-release50. As a therapeutic, RU486 suffers limitations in use because of 
pan-steroidal anti-activity; indeed, it was originally developed as an abortifacient 
through an anti-progestin mechanism, antagonizing progesterone receptor (PR) 
activity, and it maintains weak androgen receptor (AR) activity51. While this 
promiscuity curbs therapeutic RU486 use, it marks it as a potentially appealing 
tool to investigate the effects of bifunctional molecule-mediated recruitment on a 
variety of NRs while also expanding our collective ability to modulate GR activity 
through alternative mechanisms.  
 
The amino group of the dimethylaniline moiety has previously been used as a 
conjugation point for the synthetic linkage of RU486 to a variety of targeting 
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groups, including glucoronic acid52 and bile acid53,54, as a method for cell-specific 
localization of anti-glucocorticoid activity. Despite this chemical modification, 
RU486-conjugates maintain a high affinity for GR53. Accordingly, we developed a 
similar strategy to synthetically link RU486 to FK506. While we noted a marked 
(~10-fold) decrease in binding affinity for the receptor following conjugation, with 
the Kd of binding GR for RU486 to be 13 nM whereas conjugates displayed Kd’s 
determined to be 83.6-93.9 nM, the bifunctionalized RU486 molecule was able to 
recruit FKBP-fusion proteins to GR, resulting in an effect on the transcription of 
both reporter and endogenous genes55. Encouragingly, when recruiting VP16-
FKBP, this effect manifested as an activation of transcription; in essence, 
synthetically converting RU486 allowed for a reprogramming of its intrinsic, 
antagonistic nature, initiating its actions as an agonist-like glucocorticoid.  
 
This prior work established that the intrinsic properties of a GR ligand can be 
dissociated from consequent functional effects through extrinsic recruitment, and, 
more importantly, established RU486 as a building block for additional 
bifunctional ligands. If we can effect a similar antagonist-to-agonist 
reprogramming through the recruitment of an endogenous cellular target, this 
exponentially increases the potential matrix of modules available for bifunctional 
molecule design and, subsequently, the potential for unique transcriptional 
profiles. 
 
3.4 Recruitment of BRD4 by an antagonist-based bifunctional ligand 
 
In the work described in Chapter 2, we established that synthetically tethering a 
glucocorticoid agonist to the bromodomain inhibitor (S)-JQ156 allows for the 
targeted recruitment of BRD4, though this appeared to be a gene-specific event. 
Moreover, the functional effects of BRD4 recruitment appeared to significantly 
vary based on the nature of the utilized receptor; whereas recruitment to a 
truncated GR containing only the GR led to robust transcriptional activation, the 
recruitment of BRD4 to a full length GR resulted in the production of a more 
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nuanced transcriptional profile. These observations made it difficult to predict the 
functional outcomes of recruiting BRD4 to antagonist-bound GR, compounded by 
the unclarity regarding whether a disrupted helix 12 will accommodate chemical 
dimerization with BRD4. To begin this investigation, we synthesized the following 
molecules (Fig. 3.2): RU-O3-N3, a glucocorticoid antagonist appended to a 
synthetic linker; and RU-O3-JQ1, a bifunctional molecule linking RU486 to (S)-
JQ1. 
 
 
 
The synthesized bifunctional molecule was demonstrated to display a modest 
(~10-fold) loss in binding affinity for BRD4 in an in vitro assay (unpublished 
observations, collected by Jun Qi).  
 
BRD4 recruitment in a traditional three-hybrid experiment 
 
Figure 3.2 Bifunctional antagonist-based molecules. A monofunctional GR antagonist-linker 
molecule, RU-O3-N3, was constructed, along with the bifunctional RU-O3-JQ1. 
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To investigate the effects of antagonist-facilitated BRD4 recruitment on 
transcription, we employed a traditional three-hybrid experiment (depicted in Fig. 
3.3A). This arrangement additionally allows us to confirm that RU-O3-JQ1 is 
capable of chemically dimerizing GR and BRD4 in a cellular system. 
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HeLa cells expressing endogenous levels of BRD4 were transfected with a 
luciferase reporter plasmid bearing five Gal4 DNA-binding sites and an 
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Figure 3.3 Recruitment of endogenous BRD4 in a traditional three-hybrid experiment. A: a traditional 
three-hybrid design, using a Gal4-GR(LBD) chimera, was modified to be responsive to the recruitment 
of endogenous BRD4. B: In this three-hybrid experiment, the monofuctional molecule negligibly 
activated transcription, while the bifunctional molecule acted as a strong activator of transcription. C: 
Co-addition of the bifunctional molecule and free (S)-JQ1 in a squelching experiment attenuated the 
activation capability of RU-O3-JQ1, supporting the belief that the bifunctional molecule’s activity was 
dependent on BRD4 recruitment. 
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expression plasmid for a Gal4-GR(LBD) chimera and treated with the indicated 
compounds; here, HeLa cells were chosen owing to previous experience with 
this cell line while conducting three-hybrid experiments. The resulting activation 
of transcription is displayed in Fig. 3.3B as a fold activation of luciferase 
produced over the levels in vehicle-controlled cells. As expected, the 
monofunctional RU-O3-N3 minimally affected GR activity relative to the DMSO 
control treatment; the lack of an appreciable partial agonistic effect can likely be 
attributed to the lack of the GR AF1 domain in this system, believed to play a 
large role in RU486-induced transactivation. Interestingly, the ‘trans’ addition of 
RU-O3-N3 and unconjugated (S)-JQ1 produced a small increase in activation; 
this was unexpected, as the co-treatment of (S)-JQ1 with a glucocorticoid agonist 
has been shown to suppress GR activity (data not shown). Treatment of these 
transfected cells with the bifunctional RU-O3-JQ1 led to a sharp, dose-dependent 
increase in transcription, similar to the effect produced by the agonist-based 
SDex-O3-JQ1. At high concentrations, this effect dissipates; this observation 
would be in accordance with BRD4 recruitment facilitating the activation of 
transcription, as high levels of bifunctional molecule serve to saturate each 
protein binding partner, favoring dimeric species over trimeric complexes and 
lowering the effective concentration of BRD4 localized to DNA. However, cellular 
viability was lowered at high (5 µΜ) dosing of RU-O3-JQ1, confounding this 
conclusion. 
 
As an alternative means of confirming that BRD4 recruitment is occurring and is 
instigating transactivation, a squelching experiment was performed (Fig. 3.3C). 
HeLa cells were transfected as above and treated with RU-O3-JQ1 (0.5 µM) 
along with increasing levels of (S)-JQ1. In the absence of competing inhibitor, 
RU-O3-JQ1 treatment produced a 30-fold activation of transcription relative to 
levels in DMSO-treated cells. However, co-treatment with (S)-JQ1 (0.05 µΜ) 
resulted in attenuated activity with 7-fold activation relative to levels in control-
treated cells, approximately 25% of the activity produced in the absence of 
competing ligand. Equimolar treatment with unconjugated (S)-JQ1 produced a 
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nearly full attenuation of activity. These data firmly support the premise that RU-
O3-JQ1 is acting as a protein-protein surrogate to induce an interaction between 
GR and BRD4, and, as was seen in three-hybrid experiments evaluating SDex-
O3-JQ1 activity, this results in transcriptional activation.  
 
Recruitment to the full-length receptor 
 
The data presented in Fig. 3.3B demonstrates that RU-O3-JQ1 is capable of 
bridging the GR LBD and BRD4, and the localization of BRD4 to a reporter gene 
in this context results in strong activation. However, this does not reveal any 
insights into whether RU-O3-JQ1 maintains its parent ligand’s ability to induce 
GR nuclear translocation, or if the presence of the GR DBD and AF1 will interfere 
with BRD4-facilitated upregulation. We developed a luciferase reporter assay in 
order to investigate this, depicted in Fig. 3.4A.  
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Figure 3.4 Recruitment of BRD4 to full-length rat GR. A: A transcriptional reporter assay was 
designed to monitor the effects of BRD4 recruitment on transcriptional activity by full-length GR.  The 
activity of the indicated ligands was measured utilizing a reporter plasmid containing a GRE from the 
GILZ gene (B) and the FKBP5 gene (C). 
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U2OS cells were transfected with a reporter plasmid bearing one of the indicated 
glucocorticoid response elements (GREs)4 immediately upstream of a promoter 
driving luciferase expression and an expression plasmid coding for rat GR (rGR), 
utilizing rGR due to previous experience with this GR variant. In this and 
subsequent experiments, U2OS cells were utilized due to their negligible 
expression of GR, allowing for the introduction of GR variants through 
transfection. Cells were treated RU-O3-N3, RU-O3-JQ1, or a trans addition of 
RU-O3-N3 and (S)-JQ1 at the indicated concentrations. Transcriptional activity 
was determined by monitoring luciferase expression and displayed as fold 
activation over the levels of luciferase in vehicle-treated cells. The data displayed 
in Fig. 3.4B reflects cells transfected with a reporter plasmid bearing a GRE 
sequence from the GILZ gene. In this system, the monofunctional ligand acted as 
weak agonist in the presence and absence of unconjugated (S)-JQ1. The 
bifunctional ligand, however, activated transcription in a dose-dependent fashion, 
inducing activity levels 8-fold higher than DMSO-treated cells and approximately 
200% of the activity levels induced by RU-O3-N3. High levels of (S)-JQ1, either 
unconjugated or as a part of RU-O3-JQ1, result in a loss of viability. In contrast, 
cells transfected with a reporter plasmid bearing a GRE from the FKBP5 gene 
(Fig. 3.4C) were weakly stimulated to equivalent transcriptional levels by all three 
dosing combinations. This data suggests that the role of the GRE may determine 
if BRD4 recruitment is sterically permissible, or if BRD4 recruitment serves to 
activate transcription in the presence of other, GRE-determined complexation 
partners. As mentioned above, GRE sequence plays a determining role in GR 
transactivation, acting as an allosteric ligand that aids in dictating GR binding 
partners and, subsequently, the magnitude of transcriptional activation. The GILZ 
and FKBP5 GREs share an identical AGAACA half sequence, identical to the 
most consistently present GR binding sequence57. However, they differ in both 
the spacers between half sequences and, more importantly, in the second half 
sequences. Whereas the FKBP5 GRE bears a second half sequence that is 
perfectly palindromic with its first half sequence (TGTTCT), the GILZ GRE is a 
loosely conserved semi-palindrome, utilizing the nucleotide sequence GGTTCC 
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as its second GR binding site. This imperfect palindromic sequence may disfavor 
GR dimerization at the GRE, allowing for the recruitment of BRD4 and 
successive transcriptional upregulation. However, a more nuanced analysis of 
GR in complex with this is necessary in order to determine the mechanism of the 
activation selectivity observed here. 
 
As stated above, several variables were introduced when transitioning from a 
traditional three-hybrid system to a reporter system using the full-length receptor; 
GRE sequence is accountable for solely one of these variables. In Chapter 2, it 
was hypothesized that the presence of AF1 in the full-length receptor, and the 
additional protein contacts present therein, may play a fundamental role in 
producing the disparate activity profiles observed when comparing SDex-O3-JQ1 
activity in each reporter system26. To better explore the responsibilities borne by 
AF1 and AF2, two mutant rGR expression plasmids were constructed, 
introducing mutations into the AF1 (E219K/F220L/W234R) or AF2 (E773R) that 
have been demonstrated to attenuate the activation capability of each respective 
domain4,36,58 (Fig. 3.5A). 
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U2OS cells were transfected as above with the indicated GRE-containing 
reporter plasmid and a mutated AF-1 rGR (mut-AF1) or AF-2 rGR (mut-AF2) 
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Figure 3.5 Effects of GR mutations on bifunctional molecule activity. A: GR is a multidomain protein, 
including two activating functions, AF1 and AF2, and a DBD. The indicated mutations abrogate the 
activation capability of the indicated AF domain. The effects of the indicated compounds on the activity 
of mutant full-length rGR were monitored under several conditions: mutant AF1 at reporter plasmid 
using a GILZ GRE (B); mutant AF2 activity at the GILZ GRE (C); mutant AF1 activity at the FKBP5 
GRE (D); and mutant AF2 activity at the FKBP5 GRE (E). Statistical significance is determined using a 
one-tailed student’s t-test. 
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expression plasmid. Following transfection recovery, cells were treated as 
indicated above and assessed for levels of produced luciferase, displayed as 
transcriptional activity relative to a treatment control. In contrast to cells 
expressing the wild type receptor, cells expressing mut-AF1 did not display 
appreciable activity levels in response to the monofunctional glucocorticoid 
antagonist at either the GILZ (Fig. 3.5B) or FKBP5 (Fig. 3.5D) GREs, supporting 
the theory that RU486-facilitated transactivation occurs largely as a result of AF-1 
activity. Despite the attenuated AF-1 activity, RU-O3-JQ1 is able to still act as a 
dose-dependent transcriptional activator of the GILZ-based reporter, triggering 
luciferase production levels 3-fold higher than in DMSO-treated cells and 
approximately 150% of the levels produced in cells treated with the 
monofunctional compound. Notably, RU-O3-JQ1 similarly triggered a response 
150% the level of that produced in response to RU-O3-N3 at the FKBP5-based 
reporter, contrasting with the response produced by the native rGR; however, 
AF-1 mutation attenuated activity universally at this promoter, confounding 
interpretation of the significance of this data. Mutation of AF-2 appeared to 
negligibly affect the activities of RU-O3-N3 or RU-O3-JQ1 at the GILZ promoter 
(Fig. 3.5C); the monofunctional compound continued to act as a weak 
transcriptional agonist, while RU-O3-JQ1 produced a dose-dependent activation 
with a maximal response approximately 200% that of the RU-O3-N3 response. 
The GR conformation induced by binding the GILZ(GRE) likely does not favor the 
interaction with coregulators that would impede BRD4 recruitment, evidence by 
the near identical responses of rGR and mut-AF2 to RU-O3-JQ1 treatment. 
Fascinatingly, RU-O3-N3 was incapable of inducing mut-AF2 transactivation (Fig. 
3.5E) of the FKBP5(GRE)-driven reporter, though RU-O3-JQ1 produced a weak 
agonistic response; this provide an example of activation that is both sequence- 
and coregulator-context specific, and may provide a path to investigating if RU-
O3-JQ1 acts as a more potent activator in systems expressing low levels of AF-
2-recruited coregulators. 
 
Modulating human GR activity 
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The rat glucocorticoid receptor has been extensively characterized, providing the 
opportunity to exploit this expanded knowledge base to conduct nuanced 
mechanistic investigations. The 795 amino acid rGR shares a high level of 
sequence homology (88%) with the dominant human glucocorticoid receptor, the 
777 amino acid isoform α (hGRα). However, though the two receptors are 
frequently used interchangeably in the literature, they often display different 
activities and produce different transcriptional profiles when evaluated in identical 
systems, likely due to differences in post-translational modifications29 and the 
presence of an expanded polyglutamine tract in the rGR AF1. 
 
Acknowledging the potential for species-specific differences in response, the 
activities of the antagonist-based molecules were evaluated in a reporter system 
utilizing the human receptor. 
 
! 110!
 
 
U2OS cells were transfected with an expression plasmid coding for hGRα and a 
luciferase reporter plasmid driven by a promoter containing a consensus GRE 
(Fig. 3.6A), a GRE from the FKBP5 sequence (Fig. 3.6B), or a GRE from the 
GILZ promoter (Fig. 3.6C). Signifying a brief departure from previous 
experiments, the ‘trans’ addition employed in this set of trials contained a 
biotinylated version of (S)-JQ1, acknowledging its utility as a better mimic of the 
effects of synthetic conjugation on (S)-JQ1. Following treatment, cells were lysed 
and luciferase levels were quantified and displayed relative to those in vehicle-
Figure 3.6 Transcriptional activity of full-length hGR. The effects of the indicated compounds on the 
transcriptional activity of hGR were measured at reporter plasmids containing several different GREs, 
including a consensus GRE (A), a FKBP5 GRE (B), and a GILZ GRE (C). Statistical differences 
were determined using a one-tailed student’s t-test. 
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treated cells. The results marked a departure from the observations collected 
utilizing rGR. Regardless of the GRE employed, the monofunctional ligand RU-
O3-N3 failed to appreciably elevate transcription of luciferase in both the 
absence and presence of (S)-JQ1-biotin. However, the bifunctional ligand 
produced a dose-dependent activation of transcription in all three systems, 
significantly raising transcriptional levels at concentrations as low as 0.1 µΜ. 
While the magnitude of this activation ranged from 145% of the RU-O3-N3 
produced level (Fig. 3.6C) to 165% (Fig. 3.6B), the absolute activation was less 
than 2-fold higher than that produced in response to DMSO, considerably lower 
than the responses observed utilizing rGR. Though these two receptors have 
been used relatively interchangeably in the literature, results like this highlight 
differences in activity that are imperative to note in future efforts. !!
In Fig. 3.5, we observed that mutation of the rat AF2 did not significantly alter 
RU-O3-JQ1’s ability to act as an agonistic transcriptional modulator. In human 
pathology, numerous clinical cases of glucocorticoid resistance have presented 
in response to mutations in the AF2 of hGR. “Primary Generalized Familial or 
Sporadic Glucocorticoid Resistance,” recently renamed as Chrousos syndrome59, 
is typified by a broad range of symptoms, extending from mild hypertension to 
severe fatiguing and hypoglycemia. In cases where the biochemical mechanism 
driving the development of this syndrome has been elucidated, the presence of a 
single point mutation at a variety of positions throughout AF2 results in lowered 
ligand affinity, increased nuclear translocation times, and/or aberrant interactions 
with coactivators. As the RU-O3-JQ1 molecule was designed to act as a protein-
protein interaction surrogate, we sought to investigate if the bifunctional molecule 
could ‘rescue’ the activity of impaired GRs incapable of normal coactivator 
interactions. Three representative receptors were chosen from the literature, 
described in Table 3.1, and expression plasmids coding for each were 
constructed. 
 ! !
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Table 3.1: Glucocorticoid Receptor Mutations Resulting in Chrousos 
Syndrome59 
Point Mutation   
cDNA Protein Genotype Characteristics 
N/A hGRα homozygous normal transactivation 
normal ligand Affinity 
nuclear translocation: 12 min 
normal coactivator interactions 
A1922T60 D641V homozygous transactivation decreased 
lowered ligand affinity (3x) 
nuclear translocation: 22 min 
aberrant coactivator interactions 
G2185A61 V729I homozygous transactivation down 
lowered ligand affinity (2x) 
nuclear translocation: 120 min 
aberrant coactivator interactions 
T2209C62 F737L heterozygous transactivation decreased 
lowered ligand affinity (1.5x) 
nuclear translocation: 180 min 
 
 
U2OS cells were transfected with a luciferase reporter plasmid driven by a 
promoter containing a GRE, along with an expression plasmid for one of the 
indicated mutant hGR isoforms (Fig. 3.7). Cells were treated with RU-O3-N3 or 
RU-O3-JQ1, lysed, and luciferase levels were quantified and displayed as 
transcriptional activity relative to levels produced in vehicle-treated cells. 
 
! 113!
 
 
While the introduction of each point mutation lowered the transactivation 
capability of dexamethasone (data not shown), the synthetic agonist was still 
capable of potently and effectively (30- to 40-fold activation, 0.01 µΜ dosing) 
induce GR activity; accordingly, it was unlikely that the weakly activating RU-O3-
JQ1 would be able to rescue impaired GR activity.  
 
Interestingly, the monofunctional ligand, in contrast to what was observed with 
the native receptor, weakly activated each of the mutant receptors. The 
bifunctional ligand also served to activate each of the mutants; however, 
individual mutations appeared to effect its ability to recruit BRD4 as it was only 
capable of activating the D641V and F737L point mutants to levels above that 
produced by RU-O3-N3 (140%, Fig. 3.7A; and 160%, Fig. 3.7C, respectively). 
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Figure 3.7 Mutational effects on hGR transcriptional activity.  The transcriptional activity induced by 
the indicated compounds was measured in cells expressing hGR variants containing different point 
mutations that affect AF2 activity, including the point mutation D641V (A), V729I (B), and F737L 
(C). Statistical significance was determined using a one-tailed student’s t-test. 
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RU-O3-N3 and RU-O3-JQ1 produced similar responses in cells expressing the 
V729I mutant (Fig. 3.7B). The mutant-specific effects here may follow from 
altered LBD structures caused by the introduced mutations – the protein 
architecture may impair the ability of the RU-O3-JQ1 molecule to present the 
JQ1 moiety for effective BRD4 recruitment, or alternatively there may be 
hindrances introduced by the LBD. Further experimentation is necessary to 
define the roles that each mutation is playing in dictating whether the bifunctional 
ligand is capable of recruitment-mediated activation, though this knowledge may 
shed further light on the altered receptors themselves. Accordingly, though the 
antagonist-based ligands did not find utility as activity rescuers, they may find a 
use in further probing the functional effects of ligand binding by these 
therapeutically relevant receptor molecules.  
 
Recruitment to endogenous genes 
 
Previous work has demonstrated that luciferase reporter systems are more 
readily capable of amplifying transcriptional activity to detectable levels than 
experiments involving the quantification of endogenous transcripts. As observed 
in Fig. 3.6, the activation levels in a reporter system utilizing hGR were 
considerably lower than those produced by the agonist-based compounds 
described in Chapter 2. Surprisingly, we have not yet been able to discover a 
gene that is activated in a recruitment-based fashion by the bifunctional RU-O3-
JQ1. However, these initial experiments have been limited to monitoring the 
production of three transcripts (FKBP5, GILZ, and S100P) 55,63 in only two 
different cellular systems (A549 cells expressing endogenous levels of hGR, and 
U2OS cells transfected with a hGR expression plasmid), so it is possible that, as 
was seen with SDex-O3-JQ1, recruitment-facilitated transcriptional activity is 
gene-specific and we merely have not monitored the expression of an ideal 
candidate gene. Current efforts include transcriptomic profiling in response to 
RU-O3-N3 and RU-O3-JQ1 treatment to identify genes capable of harboring 
BRD4 recruitment. 
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Bifunctional-ligand induced transrepression 
 
As has been discussed above and in Chapter 2, GR transrepression of NF-κΒ 
activity is believed to be key signal in anti-inflammatory responses. RU486 has 
long been believed to be unable of downregulating the NF-κB pathway; though 
there is evidence that RU486 continues to trigger an interaction between GR and 
NF-κB64,65, it does not arrange the two proteins in a transcriptionally defunct 
complex10. Recent work has shown that RU486 may even be capable of 
activating NF-κB activity in certain contexts66. Though the mechanism of this is 
unclear, it may arise through a recently discovered context-dependent synergism 
of activation observed between GR and NF-κB67.  
 
If RU486 is indeed incapable of repressing NF-κB signaling due to an inability to 
interfere with pTEF-b recruitment11, BRD4 recruitment may provide a mechanism 
to disrupt the formation of a transcriptionally active complex. Alternatively, the 
presence of (S)-JQ1 in a bifunctional molecule, a moiety previously shown to 
inhibit NF-κB signaling68, may provide a means for NF-κB transrepression. To 
this end we utilized the luciferase reporter assay described in Chapter 2 to 
monitor the effects of the antagonist-based molecules on NF-κB activity.!!
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U2OS cells were transfected with an expression plasmid for hGRα and a reporter 
plasmid driven by a promoter containing five NF-κB binding sites. Following 
transfection recovery, NF-κB activity was stimulated by its ligand hTNF-α, and 
cells were dosed with vehicle or the indicated compounds at a final concentration 
of 1 µΜ. Transcriptional activity is displayed as a measure of quantified luciferase 
relative to the levels in cells treated with vehicle and hTNF-α alone (Fig. 3.8). 
Expectedly, dexamethasone served to efficaciously repress NF-κB activity to 
24% of that observed in vehicle-treated cells, while (S)-JQ1 mildly repressed 
activity to 65% of vehicle. Unexpectedly, the monofunctional RU-O3-N3 acted to 
repress activity to a level 45% of that observed in vehicle-treated cells. The 
bifunctional molecule also acted in a near identical fashion, repressing activity to 
similar levels as the linker-containing antagonist. 
 
While it was unexpected to see the level of transrepression produced by RU-O3-
N3, it was unclear if this activity would similarly occur in the NF-κB-driven 
expression of endogenous genes. The IL-8 gene codes for the interleukin-8 
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Figure 3.8 Transrepression of NF-κB activity in a reporter assay. The effects of the indicated 
compounds on hTNF-α stimulated NF-κB activity were measured in a transcriptional reporter 
system. Statistical significance was determined using a one-tailed student’s t-test. 
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protein, a key cytokine in the inflammation response69. IL-8 expression is 
extremely sensitive to both TNF-α induction (through the activation of NF-κB) and 
to glucocorticoid agonist-induced transrepression, establishing it as a model 
gene for analyzing the effects of glucocorticoid ligands on transrepressive 
activities.  
 
 
 
The human adenocarcinoma lung epithelial cell line A549 has been well 
established as a model cell line for investigating GR-mediated transrepressive 
transcriptional activities37. A549 cells were stimulated with the NF-κB ligand 
hTNF-α and incubated with vehicle or the indicated compounds at a final 
concentration of 1 µΜ (Fig. 3.9). Following treatment, transcript levels of IL-8 
were quantified and expressed relative to the levels produced in A549 cells 
stimulated with hTNF-α and treated with vehicle. As was seen in reporter 
experiments, dexamethasone acted as an effective transrepressor ligand. In 
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Figure 3.9 Transrepression of a NF-κB-regulated gene. The effects of the indicated compounds on the 
modulation of a NF-κB-regulated gene, IL-8, in hTNF-α stimulated cells were monitored. IL-8 levels 
were normalized between samples through comparison to the housekeeping gene RPL19 and effects of 
each compound on IL-8 production were determined relative to DMSO-treatment via the ΔΔCT 
method. !
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contrast to what was observed in Fig. 3.8, and seemingly mimicking what has 
been established in the literature, RU-O3-N3 did not act as a transcriptional 
repressor. However, the bifunctional molecule capably repressed the levels of IL-
8 to levels approximately 50% of those in vehicle-treated cells. Further 
experiments are necessary to discern if this mechanism is through ligand-
facilitated recruitment of BRD4 to sterically hinder complex formation, though it is 
likely that this is simply occurring as a result of the (S)-JQ1-mediated inhibition of 
BRD4-NF-κB interaction.  
 
3.5 Recruitment to the androgen receptor 
 
While a therapeutic limitation, a benefit to utilizing RU486 as a building block for 
creating bifunctional tool compounds is its promiscuity for NRs. One potential 
alternative target is the androgen receptor (AR)51. This aberrant activity of this 
member of the NR family is central to prostate cancer pathology, marking it as an 
important therapeutic target70. As with GR, traditional approaches to modulate 
AR activities have centered on developing novel small molecules that sculpt the 
AR LBD surface in fashions that disfavor the expression of AR-controlled 
oncogenes71. This is confounded by observations that tumorigenic AR is prone to 
developing mutations in its LBD and coregulator binding surface, contributing to 
the development of resistance to therapeutic antiandrogens72,73.  
 
Acknowledging the limitations of the traditional approach described above, a 
recent focus shift has centered on the production of alternatively acting steroid-
conjugates to combat this malady. Downregulating AR activity through the 
targeted recruitment of coregulators is an innovative strategy to accomplish this 
goal. In initial reporter experiments, we have observed that RU-O3-N3 acts as a 
mild (EC50: 190 nM) partial agonist of AR transactivation while RU-O3-JQ1 is 
incapable of activating transcription, though currently, much further 
characterization is necessary. 
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3.6 Conclusions and discussion 
 
Synthetic linkage of the glucocorticoid antagonist RU486 to the bromodomain 
inhibitor (S)-JQ1 provides a method for the recruitment of bromodomain-
containing BRD4 to DNA-bound GR. In a three-hybrid experiment utilizing a Gal4 
DBD and GR LBD chimera, this resulted in a potent, recruitment-dependent 
activation of transcription. However, in a reporter system absent of a Gal4 DBD 
to anchor GR to DNA, and instead resting on the inherent ability of full length GR 
to recognize and bind GREs, this effect is severely dampened. 
 
The antagonist-based bifunctional ligand, RU-O3-JQ1, appeared to display both 
a species- and GRE-dependent ability to effect GR transactivation. The 
dampened transactivation induction of rGR by RU-O3-JQ1 was further magnified 
when characterizing the activation response by hGR, as RU-O3-JQ1 only weakly 
induced hGR transactivation. Further differences were observed regarding the 
GRE-dependent response to RU-O3-JQ1; whereas a stark difference in rGR 
activity was observed when utilizing alternative reporter plasmids bearing 
different GREs, swapping GREs did not appreciably perturb the responses in 
cells expressing hGR. While hGR and rGR have been presumptively 
interchanged in characterization studies, with relatively few comparative works 
described, these results seem to magnify the differences between the two, 
shedding light on the potential folly of assuming equivalence. 
 
Despite the activity differences of rGR and hGR in reporter experiments, each 
isoform was capable of utilizing RU-O3-JQ1 agonistically while bearing 
mutation(s) in the respective AF2. By disrupting the rGR AF2, RU-O3-JQ1 was 
capable of activating mut-AF2 in both GRE-contexts investigated. In an 
alternative line of experiments, disruption of hGR AF2 resulted in a set of 
heterogeneous responses, where the ability of RU-O3-JQ1 to continue acting as 
an activator through recruitment was dependent on the location of the 
perturbation. The knowledge base regarding GR-coregulator interactions, and 
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the role that DNA sequence plays in determining these interactions, is rapidly 
expanding4,5 and molecular tools are necessary to further dissect the effects of 
altering AF2 topology, a therapeutically relevant occurrence59. As such, the utility 
for compounds such as RU-O3-JQ1, capable of inducing novel GR-coregulator 
interactions, will similarly expand.  
 
As discussed above, pharmaceutical efforts to develop anti-inflammatories has 
been driven by the paradigm of separating transactivation from transrepression, 
a viewpoint that may be myopic given recent indications of the role GR 
transactivation plays in the anti-inflammation response. Acknowledging this 
limitation, the observation that RU-O3-JQ1 is capable of repressing NF-κB 
signaling while inducing a transactivation profile distinct from traditional GR 
agonists is a significant development. However, coordinating the inflammation 
response involves the up- and down-regulation of numerous pathways, notably 
the similarly GR-repressed AP-1 network. As such, these initial results provide 
encouragement to continue to determine the effects of RU-O3-JQ1 treatment on 
the expression of other genes in the inflammation network. 
 
The developments described in Chapter 3 further validate bifunctional GR 
ligands as viable probes for studying this important receptor and as tools for 
producing novel transcriptional outputs. Notably, this strategy was applied to 
execute a change in a GR ligand’s fundamental, intrinsic nature, employing 
extrinsic recruitment to convert an antagonist into a functional agonist. The 
transcriptional responses elicited by the bifunctional ligand display a selectivity 
that has not been observed in other steroidal modulators, providing excitement 
for additional characterization and, eventually, expanding this class of ligands to 
produce even further refined transcriptional responses.  
 
3.7 Materials and Methods 
 
Cell culture and transfections 
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U2OS (HTB-96) and A549 (CCL-185) cells were purchased from ATCC. Cells 
were cultured in DMEM with 10% FBS at 37°C under 5% CO2. Transient 
transfections were done using Lipofectamine or Lipofectamine 2000 (Invitrogen) 
with conditions optimized using GFP expression plasmid and fluorescent analysis 
or by using a β-gal expression plasmid and activity assay.  
 
Plasmids 
All oligonucleotides for construction of plasmids were purchased from Integrated 
DNA Technologies.  
 
pCMV-β-gal is a β-galactosidase coding plasmid driven by a CMV promoter and 
was generously provided by J. Iñiguez-Lluhí. 
 
pCDNA3 hGR (human GR coding plasmid) and p6R GR (rat GR coding plasmid) 
were gifts from J. Iñiguez-Lluhí. 
 
Coding plasmids for rat GR containing AF1 and AF2 mutations were constructed 
by A. Van Dyke. 
 
pConsensus GRE-luc, pFKBP5(GRE)-luc, and pGILZ(GRE)-luc were generously 
provided by K. Yamamoto (UCSF). 
 
Mutant hGR coding plasmids were constructed using the Stratagene Quikchange 
method. Relevant primers for each mutation were constructed and amplified 
using pCDNA3 hGR as a template. Following PCR amplification, synthetic 
plasmids were treated with DpnI restriction enzyme to remove template and 
transformed into E. coli. The primers for each mutation are as listed: 
 
D641V F-Pr: 5’- ACTCTACCCTGCATGTACGTCCAATGTAAACACATGCTG -3’ 
D641V R-Pr: 5’- CAGCATGTGTTTACATTGGACGTACATGCAGGGTAGAGT -3’ 
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V729I F-Pr: 5’- GATTCTATGCATGAAGTGATTGAAAATCTCCTTAACT -3’ 
V729I R-Pr: 5’- AGTTAAGGAGATTTTCAATCACTTCATGCATAGAATC -3’ 
 
pNF-κB-luc was generously provided by G. Nuñez (Univ. of Michigan). 
 
Transcriptional reporter assay (Figs. 3.4, 3.5, 3.6, 3.7) 
U2OS cells were seeded at a density of 250,000 cells per well in a 6-well plate 
with 2 mL DMEM + 10% FBS. The following day, cells were transfected with 1 µg 
of indicated pGRE-luc, 0.5 µg of pCMV-β gal, 5 µL of Lipofectamine 2000, and 
0.5 µg of the indicated GR coding plasmid. After 6 hours, the transfection mix 
was replaced with DMEM + 5% charcoal stripped (CS) FBS and allowed to 
recover overnight. The following day, cells were removed by trypsinization and 
replated at a density of 10,000 cells per well in a 96-well dish. Individual wells 
were treated with the indicated compounds to a final DMSO concentration of 
0.01%. After 16 hours, media was removed and cells were lysed using a passive-
lysis buffer. β-gal activity was assayed as described previously using a Molecular 
Devices Spectramax plate reader. Luciferase activity was determined as 
described previously using a Molecular Devices Spectramax L luminometer. 
Standard error from triplicate samples is represented by error bars on graph. 
 
Transrepression reporter assay (Fig. 3.8) 
U2OS cells were seeded at a density of 250,000 cells per well in a 6-well plate 
with 2 mL DMEM + 10% FBS. The following day, cells were transfected with 1 µg 
of indicated pNF-κB-luc, 0.5 µg of pCDNA3 hGRα, and 0.5 µg of pCMV-β gal. 
After 6 hours, the transfection mix was replaced with DMEM + 5% charcoal 
stripped FBS and allowed to recover overnight. The following day, cells were 
removed by trypsinization and replated at a density of 10,000 cells per well in a 
96-well dish. Individual wells were treated with the indicated compounds to a final 
DMSO concentration of 0.01%, along with hTNF-α (Roche) at a final 
concentration of 5 ng/mL. After 16 hours, media was removed and cells were 
lysed using a passive-lysis buffer. β-gal activity was assayed as described 
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previously using a Molecular Devices Spectramax plate reader. Luciferase 
activity was determined as described previously using a Molecular Devices 
Spectramax L luminometer. Standard error from triplicate samples is represented 
by error bars on graph. 
 
RT-qPCR (Figs. 3.9) 
50,000 transfected U2OS, A549, or MM1.S cells were plated in 24-well plate with 
0.5 mL DMEM + 5% CS FBS. Next day, cells were treated with compounds or 
DMSO (0.2% final DMSO for all samples), along with hTNF-α (Roche) at a final 
concentration of 5 ng/mL. Total RNA was isolated with Qiagen RNAeasy Plus 
mini kit. cDNA synthesis was done with iScript RT Mastermix (Biorad). 20 µL 
qPCR reaction mix: 2 µL of produced cDNA, 0.2 µL CXR, 0.4 µL forward primer 
(200 nM final), 0.4 µL reverse primer, 7 µL H2O, 10 µL GoTaq qPCR master mix 
(Promega). qPCR was done on ABI StepOne Plus. Products were analyzed with 
melt curve for quality control. Transcript levels were normalized to the levels of a 
housekeeping gene, RPL19. Activation was displayed relative to transcript levels 
in DMSO-treated cells and determined using the ΔΔCT method. Primer pairs 
used:  
 
IL-8: F-Pr 5’- ATGACTTCCAAGCTGGCCGTGGCT -3’  
IL-8: R-Pr 5’- TCTCAGCCCTCTTCAAAAACTTCT -3’  
RPL19: F-Pr 5’- ATGTATCACAGCCTGTACCTG -3’  
RPL19: R-Pr 5’- TTCTTGGTCTCTTCCTCCTTG -3’ 
 
Chemical synthesis 
RU486 (Mifepristone) was purchased from Sigma-Aldrich. Commercially 
available reagents and solvents were used as received. Chromatographic 
separations were carried out on silica gel 60 (230-400 mesh, E. Merck) or by 
reverse phase HPLC on C18 column using the indicated eluents. Yields are 
unoptimized. ESI-MS spectra were obtained on Micromass LCT TOF mass 
spectrometer. High-resolution mass spectra (HRMS) were obtained on 
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Micromass AutoSpec Ultima Magnetic sector mass spectrometer. 1H-NMR 
spectra were obtained at 400MHz on a Varian MR-400 spectrometer. Chemical 
shifts are given in δ(ppm) values.  
 
 
 
RU486(-CH3) was synthesized by A. Van Dyke. 
To a solution of RU486 (500 mg, 1.2 mmol) in dichloromethane (10 mL) was 
added NMO (0.61 g, 5.2 mmol) and tetrapropylammonium perruthenate (TPAP; 
41 mg, 0.12 mmol). After stirring at room temperature for 22 h, additional TPAP 
(41 mg, 0.12 mmol) and NMO (0.61 g, 5.2 mmol) were added. After stirring at 
room temperature for 15 h, the reaction mixture was quenched with saturated 
aqueous NaHSO3 solution. The dichloromethane was removed in vacuo and 
extracted with ethyl acetate. The extract was washed with brine, dried over 
Na2SO4 and concentrated in vacuo. The product was suspended in 1 M 
hydrochloric acid (10 mL) and methanol (10 mL) and heated at 55°C for 40 h. 
The mixture was neutralized with aqueous NaHCO3 solution and extracted with 
dichloromethane. The extract was washed with brine, dried over Na2SO4, and 
concentrated in vacuo. The residue was purified by silica gel chromatography 
(ethyl acetate/hexane = 4/1) to give compound RU486(-CH3). ESI-MS calced for 
[C28H33NO2 + H+] = 415.3; found 416.2. 
 
O
OH
H
H
N
RU486(-CH3)
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RU-O3-N3 was synthesized by J. Carolan and J. Højfeldt. 
To a mixture of RU486(-CH3) (22 mg, 0.053 mmol) and 2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethan-1-amine (19 mg, 0.064 mmol) in acetonitrile (5 
mL) in a sealed tube was added sodium iodide (10 mg, 0.064 mmol) and N,N-
diisopropylethylamine (0.03 mL, 0.16 mmol). The reaction was heated to 100°C 
for 60 h. After concentration in vacuo, the residue was purified by silica gel 
chromatography (ethyl acetate/hexane = 4/6 to 6/4) to give compound RU486-
O3-N3 (22 mg, 67%) as a yellow sticky oil. The product was further purified by 
HPLC (0.1% aqueous TFA/acetonitrile = 80/20 to 65/35) to give the trifluoroacetic 
acid salt of RU486-O3-N3 as a colorless amorphous powder, calculated to be 
100% pure through peak integration. 1H NMR (400MHz, CDCl3): d 0.53 (3H, s), 
1.31-1.47 (2H, m), 1.65-1.78 (3H, m), 1.88 (3H, s), 1.89-2.03 (2H, m), 2.18-2.47 
(7H, m), 2.55 (2H, m), 2.74-2.77 (1H, m), 2.93 (3H, s), 3.36-3.78 (2H, m), 3.46-
3.48 (1H, m), 3.59-3.66 (12H, m), 4.32 (1H, d, J = 6.8 Hz), 5.74 (1H, s), 6.61 (2H, 
d, J = 8.8 Hz), 6.97 (2H, d, J = 8.4 Hz). HRMS (ESI) calcd for [C36H48N4O5 + H]+: 
617.3697, found 617.3699. HPLC chromatogram of purified product is displayed 
below: 
 
O
OH
H
N
O O O N3
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RU-O3-JQ1 was synthesized by A. Van Dyke and J. Qi. 
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Chapter 4 
 
Introduction of a Guided-Inquiry Experimental Module into an 
Undergraduate Biochemistry Syllabus* 
 
4.1 Abstract 
 
The past two decades have seen the science education community define and 
develop several instructional methods that aim to increase cognition and long-
term understanding in undergraduate science courses, such as a problem-based 
learning and peer-led teaching. Many of these methods have identified inquiry as 
a key component to transforming educative activities from low-level to high-level 
by Bloom’s taxonomy of learning. Here, we describe efforts to incorporate 
guided-inquiry into the undergraduate biochemistry course syllabus at the 
University of Michigan through the development of a novel experimental module. 
Based on student feedback and performance, this module was an effective tool 
for raising student engagement and understanding, and it is easily modifiable for 
incorporation into curricula at other institutions. 
 
4.2 The role of inquiry in undergraduate laboratory courses 
 
Laboratory instruction allows young scientists-in-training to engage in practices 
reflective of trained specialists in a given discipline. Deriving from classical 
apprenticeships and constructivist theory and supported by Lave’s work in !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
* The experimental module described here was designed by J. Carolan and K. Nolta. Assessment 
activities were designed by J. Carolan and influenced through discussions with B. Coppola and A. 
Mapp. Implementation and assessment activities were administered by K. Nolta and graduate 
student instructors associated with CHEM352. 
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situated learning1, laboratory courses have historically been constructed to 
prepare students for future work through the repetition of established procedures. 
The limitations to this style of instruction have been noted frequently2,3, but 
widespread attempts to address this have been often been met without requisite 
enthusiasm. Despite good intentions, innovatively designed curricula were often 
simply spliced with existing methodology and practices, limiting or abrogating any 
potential efficacy4. 
 
Within the larger educational community, recent outlooks on reform have focused 
on decreasing instructional-centered models of teaching in favor of focusing on 
enhancing the learning process of individual students5. This shift in mindset was 
reflected in the standards and recommendations recently released by the 
National Research Council6, highlighting the importance of incorporating inquiry 
into student practices as a means of increasing scientific literacy and 
understanding of scientific processing. This is amplified in laboratory settings, 
where it is important to convey to students the differences between learning 
science and doing science, and the goals associated with each process. As a 
result, in laboratory courses, this has manifested in multiple described efforts to 
incorporate student-driven inquiry into experiments. These examples belong in a 
continuum of loosely distinct styles of instruction that share in their goal of 
increasing active learning and vary in their level of inquiry incorporation2,7,8, best 
described by Domin2 for chemistry laboratories but applicable for other fields. 
 
Expository learning 
 
Recent meta-analyses of undergraduate laboratory experiments have uncovered 
that a vast majority in scientific disciplines are expository in nature, despite this 
style being the most heavily criticized7,8. Expository laboratories define problems 
and procedures for students, who subsequently investigate an issue in order to 
define a known result. These experiments do allow for rote memorization and low 
level problem solving9, but they do so at the expense of higher order planning 
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and processing. However, their widespread use derives from ease of use, 
reproducibility, and lowered material costs, and in departments without financial 
flexibility or resources, this style is commonly the only available option. 
 
Guided inquiry learning 
 
Guided inquiry laboratories expand on the framework of expository 
experimentation by enlarging the responsibility thrust upon the students. While 
students are presented a problem and protocols to navigate towards a solution, it 
is largely up to the student to develop an overall method towards this destination 
and to determine an optimal method of communicating conclusions. Transitioning 
towards a more inductive method of learning, this style of instruction situates the 
student as the driver in his own learning, aiding deeper understanding10,11. 
Unfortunately, even this limited incorporation of student-driven activity 
necessitates a significantly higher level of teacher effort, limiting its 
implementation. 
 
Problem-based learning 
 
Trained researchers identify and define problems, often with guidance from peers 
and advisors, and then approach those problems through self-constructed 
methodology. Problem-based learning (PBL) has emerged as an attractive style 
of instruction, across many disciplines, that emulates this style of inquisition. 
Here, instructors provide a concrete background of knowledge surrounding a 
concept alongside a loose framework for potential projects, but it is the students 
who are tasked with constructing a problem and developing the methods to solve 
it. Again, this approach serves to imitate that of a trained scientist, but in this 
scenario it is the methods of problem-solving that are emphasized over the 
solving of the problem itself. Accordingly, this approach is demonstrated to be 
more effective at developing many of the higher cognitive skills described in 
Bloom’s taxonomy2,9,12. The benefits described are paired with difficulties in 
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implementation – PBL requires substantively more effort on the part of both 
instructor and class, and the openness afforded to students yields significantly 
higher material costs. 
 
4.3 Rationale for this work 
 
Undergraduate biochemistry laboratory course have long provided an opportunity 
for students to connect the nebulous techniques learned in lecture to actual, 
“wet” application. As we evaluated the syllabus for the University of Michigan’s 
undergraduate laboratory course, CHEM352, we identified a set of key 
experiments that relied heavily on expository methods and, as such, were an 
ideal target for improvement. 
 
Protein production, purification, and characterization form the nucleus of 
countless efforts in the biochemical laboratory. Navigating these techniques often 
requires a keen understanding of concepts like chromatography, protein-antibody 
recognition, or enzymatic catalysis, validating their importance in any 
biochemistry syllabus. Accordingly, recombinant protein characterization has 
been the subject of several academic efforts to produce more effective 
coursework13-16. However, these efforts can be difficult to adapt because they 
often require a full semester of instruction12,17-21 or expensive instrumentation22-
25. Above, we described the benefits of utilizing guided-inquiry as a means of 
enhancing laboratory instruction – keeping true with a constructivist view of 
chemical education wherein student scientists must construct learning via their 
own frameworks, guided-inquiry allows students to benefit from their own built 
inquisitions, developing their abilities to plan, infer, and critically analyze. We 
aimed to address the above limitations by developing an improved laboratory 
experiment that is brief and can be completed by large amounts of students in a 
financially reasonable fashion. Here, we describe a two-week experimental 
module centering on protein separation and identification that aims to improve on 
student engagement and learning through guided inquiry.  
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4.4 Incorporating inquiry into the biochemistry laboratory 
 
The goals for this experiment center on introducing students to 1) the 
fundamentals and difficulties associated with separating proteins and 2) the 
necessity for different methods in identifying separated proteins, while gaining 
the benefits of a guided inquiry format26,27. In this exercise, students are provided 
a designed mixture of proteins and are asked to determine a way to isolate and 
ascertain the molecular weight of each component. To represent different protein 
classes and features, each component is distinguishable either visually, by 
enzymatic assay, or by immunoassay. Following size-exclusion chromatographic 
separation, students determine which of their collected fractions contains each 
protein using these techniques. Each assay is tailored to provide data rapidly for 
student analysis. Students utilize SDS-PAGE and convoluted mass spectra of 
each protein component as alternative methods for molecular weight 
determination and must rationalize any conflicts in their collected data.  
 
This two week experimental module was easily incorporated into the University of 
Michigan’s biochemistry laboratory course, composed of students majoring in a 
range of disciplines (including biochemistry and chemistry, but also several 
majors associated with health professions) who typically had previously or were 
concurrently taking a biochemistry lecture course, though several students had 
no supplementary knowledge provided through this source. This module was 
optimized for a large (~ 90-110) group of students per implementation, and 
requires no uncommon instrumentation. It is easily incorporated into introductory 
biochemistry laboratory course curricula and serves as a valuable method for 
introducing students to protein separations and identifications.  
 
4.5 Experimental details  
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Students work in groups of two to four depending on material limitations. This 
experiment was performed over two, 4 h periods following a one-hour lecture 
occurring during the week prior. During the lecture period, students are 
introduced to the concepts governing each potential portion of the experiment 
(chromatographic separations, protein-protein interactions, etc.), along with a 
generic background on each of the proteins they will be separating. Prior to 
beginning the experiment, students are provided with protocols for conducting 
each individual technique (Figure 4.8). The experiment is divided into two parts, 
allowing for a break to occur between sessions after completing Part I, and is 
summarized in Table 4.1. 
!! !
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Table 4.1: Experimental workflow 
 
Lab Activity 
Part I (Week 1) • Students are provided a protein mixture 
• Separation by column chromatography 
• Visual analysis identifies fractions containing 
cytochrome c 
• Analysis by ELISA immunoassay indicates 
fractions containing BSA 
• Colorimetric assay identifies the presence of 
β-gal in fractions 
 
 
Part II  
(Likely Week 2) 
• Students perform SDS-PAGE to aid in 
protein size determination 
• Using collected data and provided MS 
spectra, students determine size of protein 
components 
• Students describe, justify their methods, 
process, and conclusions 
 
 
Part I: Separation and Identification of Proteins 
 
Students are provided a mixture of proteins including cytochrome c, bovine 
serum albumin (BSA), and E. coli β-galactosidase (β-gal), along with a mixture of 
yellow riboflavin and blue dextran for determining maximum and minimum 
column elution volumes. Using a size-exclusion column, students collect fractions 
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of eluent using the dyed molecules as beginning and end point indicators (Fig. 
4.1). 
 
 
 
At this point, students attempt to determine which fractions contain each 
individual protein. Fractions containing cytochrome c are readily identifiable by a 
visible red tint. To identify fractions containing β-gal, students utilize a 
colorimetric assay fitted to β-gal detection (Figure 4.2A). Chlorophenol red-β-D-
galactoside (CPRG) is a substrate for β-gal that provides a quantitative and 
readibly visible color change in buffer medium and is frequently utilized to detect 
the presence of β-gal. Additionally, we have tailored an enzyme-linked 
immunosorbent assay (ELISA) to compatibility with a BSA-recognizing antibody 
Figure 4.1 Students separate a mixture of proteins using column chromatography. Cytochrome c 
(red band) migration through the column is monitored visually, while riboflavin (yellow) and 
blue dextran (blue) serve as visual indicators for column total volume and void volume 
(respectively). 
! 143!
to produce an immunoassay for BSA detection (Fig. 4.2B). Students utilize these 
three methods to determine which fractions contain each component of their 
mixture. Students typically collect more fractions than there are wells available in 
a provided polyacrylamide gel for SDS-PAGE. As such, prior to continuing to Part 
II, students must process their data in order to determine which fractions to 
assess via SDS-PAGE. 
 
 
Part II: Size Determination of Each Protein  
 
Students prepare samples for loading on to a polyacrylamide gel by mixing with a 
provided loading dye and denaturing with high heat. After sample preparation, 
students load and run gels. Following the SDS-PAGE separation, students stain 
their gels in Coumassie solution and proceed to destain the gels for visualization. 
Figure 4.2 Visualization of each utilized assay. In the top panel (A), results of a β-galactosidase 
assay are depicted. +, -, and each number represent positive control, negative control, and 
reactions with samples from each indicated fraction, respectively. Red color change signifies the 
presence of β-gal. In the bottom panel (B), results of an ELISA assay are depicted. Development 
of blue color (as seen with a sample from fraction 6) indicates the presence of BSA in the 
collected fraction.! 
A 
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Students determine molecular weights by measuring migration distances of 
marker proteins, constructing a standard line, and comparing migration distances 
of their sample proteins (Figure 4.3). 
 
  
 
Prior to the beginning of the lab, mass spectra for each protein were collected 
(or, when unavailable, a representative spectrum was constructed). At this point, 
students are provided these, with each spectrum only labeled with the position in 
which the protein eluted. Students are tasked with utilizing the differing (and 
potentially conflicting) data collected from assaying, electrophoresis, and mass 
spectrometry in order to determine protein elution order and molecular weight.  
 
After completing the experimental portion of this module, students report the 
determined size of each protein in their mixture. This report includes a detailed 
explanation of how they came to each determination,  how they reconciled and 
prioritized any potential conflicting data, and a discussion of the benefits and 
limitations of each technique that contributed to their final results. 
Figure 4.3 SDS-PAGE results displaying electrophoresed collected fractions. Following gel stain 
with coumassie blue, proteins were visualized. The annotation by each set of bands indicates the 
protein identitiy. 
β,Gal !! !!!!!BSA !!!!!!! ! ! cyt$c 
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4.6 Results  
 
A majority of students (69 of 87) attempting this experiment were able to 
successfully design a path to complete the module and provide an acceptable 
rationale for their determined protein molecular weights. One common error 
arose from the β-gal protein existing as a homotetramer, so molecular weight 
information obtained from SDS-PAGE yields a deceptively small mass; a majority 
were able to identify this and provide an attempted explanation, but a significant 
minority were unable to reconcile the mass differences. One common technical 
mistake performed was protein mixture dilution prior to column entry; this often 
resulted in difficulty monitoring the visible components of the mixture during 
separation and an excessive number of collected fractions. Second, many 
students reported having difficulty interpreting ELISA results; color development 
is time sensitive and it is likely that slow reagent addition played a role. However, 
the β-gal activity assay used proved extremely robust and, with access to a plate 
reader, a quantitative component could be readily incorporated into this module.  
 
4.7 Discussion 
 
Following an informal implementation, a formal implementatin was conducted 
where three sections of 28-32 students completed this experiment. 
Chromatographic separations, ELISAs, and protein mass spectrometry were 
typically introduced in separate experiments prior to this and students often had 
trouble connecting the utility of each technique to solving larger problems. 
Student response to this laboratory module was highly favorable. To assess the 
impact of incorporating guided inquiry, students engaged in a group retrospective 
analysis28,29 to rate and rank this experimental module in addition to others in the 
course (questions are provided in 4.9), including experiments that focused on: 
pipetting; titrating an amino acid; restriction mapping; determining protein 
concentrations; characterizing forms of hemoglobin using spectrophotometry; 
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enzyme kinetics; and protein isolation and assaying. Ratings were collected as 
numerical inputs to signify how well a group of students believed each 
experiment was able to accomplish an educational goal, with a rating of ‘7’ 
signifying that this was significantly accomplished and a rating of ‘1’ signifying 
that this was not accomplished at all. Rankings were utilized to validate the data 
collected from rating questions, and the inverted numerical scale, purposefully 
inserted, prevent students from simply transcribing answers from the paired 
question. The results of the ratings, including standard error of the mean and a 
statistical p value, are displayed in Table 4.2. P values were determined utilizing 
a two-tailed student’s t-test assuming equal variance that compared collected 
rankings against a hypothetical, purely neutral rating. 
 
! !
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Table 4.2: Average Ratings Score of Each Experiment as it Accomplishes 
an Educational Goal 
 
Educational Goal 
Experiment Utility/Relevance 
Mimics Biochemical 
Research 
Critically Evaluate 
Data 
Pipetting/Buffer 
Preparation 5.83 (0.26), 0.00000 5.93 (0.44), 0.00015 2.80 (0.42), 0.00750 
Amino Acid Titration 4.47 (0.42), 0.28031 4.27 (0.38), 0.49290 4.53 (0.39), 0.18096 
Analysis of 
DNA/Restriction 
Mapping 
5.80 (0.33), 0.00001 5.93 (0.32), 0.00000 6.07 (0.33), 0.00000 
Determining Protein 
Concentrations 5.87 (0.27), 0.00000 6.27 (0.21), 0.00000 6.20 (0.28), 0.00000 
Characterizing 
Forms of 
Hemoglobin 
5.00 (0.34), 
0.006232 5.07 (0.36), 0.00592 5.33 (0.27), 0.00003 
Enzyme Kinetics 4.00 (0.40), 1.00000 4.33 (0.41), 0.42328 5.13 (0.58), 0.06262 
Protein 
Isolation/Assaying 6.03 (0.29), 0.00000 6.60 (0.16), 0.00000 5.67 (0.41), 0.00035 
 
Several interesting observations are revealed in Table 4.2, but of most significant 
importance is that student groups indicated that this new experimental module 
had high utility and relevance and was able to significantly prepare them for work 
in a research environment. Additionally, this module was able to accomplish 
these more capably than other experiments in the course. However, this module 
falls short when evaluating our desire for students to feel as if they are 
generating and critically evaluating data. This may have been a linguistic design 
flaw in the construction of our post-laboratory solicitation of feedback – it was 
later identified that many students disconnected the colorimetric results from the 
assays they performed as data, whereas this was not the case in experiments 
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that dealt with collected numerical outputs (such as in determining the 
concentration of a protein spectrophotmetrically). 
 
As a means of assessing long-term cognitive impact of this experimental module 
and the ability of students completing it to reappropriate their knowledge in new 
settings, an end of semester assessment was conducted. Students were tasked 
with providing written feedback and responses to challenges built off of 
techniques and concepts learned throughout the course, including an 
assessment module built off of concepts learned in this described experiment 
(Figure 4.10). This assessment was constructed not as an attempt to elicit 
‘correct’ responses from students, but rather to determine if students are able to 
re-conceptualize concepts and apply them to new problems (as they would in a 
research setting); as such, detailed analysis of the assessment results is difficult. 
However, an indepedent member of the chemistry department rated and ranked 
student responses to this module, and we were encouraged to find that 82% of 
responding students (72 of 88) were able to provide adequate responses, and 
40% (35 of 88) were able to provide exceptional responses. 
 
From a student’s perspective, there are many benefits from completing this 
module. Though not using cellular lysates, students are introduced to the 
difficulties and limitations of protein purification. Students also gain familiarity with 
several protein identification techniques and how protein characteristics 
necessitate different methods in different situations. This also illustrates disparate 
sensitivities and reliabilities from one method to the next (e.g. comparing an 
enzymatic assay to an immunoassay). 
 
Finally, students benefit from situating this experiment in the context of a guided 
inquiry. Presented with different techniques and tasked with determining the best 
method to tackle their problem, students have described this module as feeling 
more like a research project than other experimental modules. Connecting data 
collected from different sources helps contextualize the techniques introduced in 
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this module to laboratory settings outside of the course, increasing student 
interest and engagement. The benefits of completing this laboratory were 
acknowledged as this experiment has been incorporated into the syllabus and, 
as of April 2015, has been implemented by instructors independent of those 
behind the design of the module. Based on the positive reception described 
herein, the implementation of this module and subsequent results are being 
prepared for communication with the larger chemical education audience through 
publication. 
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4.8 Student protocol 
 
Chemistry 352 – Techniques in Biochemistry  
Experiment 9 
Separation, Identification, and Analysis of Proteins  
 
 
Protein purification is one of the most important facets of biochemical 
investigation. A successful purification procedure may require a number of 
different techniques.  Chromatographic methods are some of the most common 
(and most successful) tools that a protein chemist can use.  A wide variety of 
chromatographic techniques have been developed, and each utilizes a different 
means of discriminating between proteins (i.e. size, affinity for a particular ligand, 
pI, etc.).  Gel filtration, which is used to separate proteins based on their native 
size, is among the most common, and you will be performing that procedure in 
the lab. 
 
Identification of proteins following separation by chromatography is an integral 
step in purification. Most proteins are not visible in solution and indirect methods 
necessary for detecting the presence of a given specific protein. Common 
methods for protein identification include enzymatic assays and immunogenic 
assays, two indirect methods of determining the presence of a protein. During 
this experiment, you will utilize both types of assays to identify the presence of 
two distinct proteins in your column fractions. 
 
Electrophoretic techniques are also quite useful when isolating and 
characterizing proteins.  It can also be an attractive method to identify proteins 
when no identification assay is readily available. Like gel filtration, it can separate 
proteins based on size (or relative molecular weight, Mr), but it is often done 
under denaturing conditions. You will analyze the size, composition, and purity of 
various proteins separated from a mixture using SDS-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE), which is one of the most commonly used 
electrophoretic techniques for analyzing proteins.  
 
Background  
Suggested reading: Lehninger, 3.3; Voet & Voet, 6-3B, 6-4B,C  
 
Gel filtration chromatography (gel permeation or size exclusion chromatography) 
uses a matrix (gel) of semi-porous microscopic beads to effect separation of 
molecules on the basis of size (and also shape). Such beads are typically made 
from hydrated polymers of dextran, acrylamide, or agarose, and they can be 
used to separate molecules ranging in size from molecular weight (Mr) ~ 100 to 
Mr ~ 10,000,000, depending on the size of the beads. Specific beads will have 
specific ranges of molecular weight that can be separated; solvent and molecules 
in this range will freely enter the beads while molecules outside the range are 
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eluted from the beads entirely. Molecules of sizes in a bead’s range spend part of 
the time within the bead and part of the time excluded. The elution volume of 
molecules from the column therefore depends on how much time a molecule 
spends within the pores of the bead—larger molecules spend less time in the 
pores and thus elute faster.  
 
  
 
Remember that gel filtration chromatography is usually run under native 
conditions: proteins remain folded in their native confirmations and are able to 
interact with each other. Proteins that consist of more than one polypeptide chain 
(complexes) remain intact and run at the size of the complex, not the size of the 
individual components. Polyacrylamide gel electrophoresis (PAGE) uses a gel-
based matrix to size proteins, but the proteins move through the gel based on 
their charge as well as effective size. Denaturing SDS-PAGE, in contrast, uses 
the detergent SDS (and often reducing agents) to denature proteins completely, 
breaking complexes apart. Each individual subunit will be coated with the 
detergent, giving each polypeptide a negative charge.  Proteins will move 
through the gel due to this charge, but become hung up on the gel matrix based 
on their individual sizes. The relative distance that a protein migrates in the gel is 
inversely proportional to its molecular weight. By comparing the distance 
migrated by an unknown protein to a set of protein standards of known molecular 
weight (the standard “ladder”), the molecular weight of the denatured protein can 
be estimated.  
 
 
ELISA (enzyme-linked immunosorbent assay) is a powerful tool for detecting the 
presence of very specific target molecules, often being able to detect incredibly 
small amounts of molecule. This method traditionally relies on the use of 
antibody-protein binding interactions, but it can and has been used in a much 
wider variety of general ligand binding tests.  The ELISA method has been used 
for years as a diagnostic tool in medicine and it is widely used in industry as a 
means of checking quality control.  It is such a practical tool that many consumer-
oriented products have been developed from it (i.e. pregnancy tests).  This 
method (with other immunoassay techniques like radioimmunoassay) is one of 
the most powerful biotechnological tools to have come out of the biochemical 
sciences. 
 
 
Enzymatic assays provide another method to study and characterize specific 
proteins. Though limited in that a specific assay can only be used for a specific 
protein, an appropriate enzymatic assay can be a very powerful method to study 
that enzyme. Oftentimes, a reagent that mimics an enzyme’s natural substrate 
can be used as a tool for study. One commonly used enzymatic assay is the β-
galactosidase assay. Chlorophenyl red-β-D-galactopyranoside (CPRG) is a 
modified galactoside sugar that is chemically linked to a red dye. In the presence 
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of β-galactosidase, the enzyme cleaves the dye from the sugar and a red color is 
produced in solution. This assay is frequently used to determine the presence 
and concentration of β-galactosidase and is representative of similar colorimetric 
enzymatic assays. 
 
 
Experiment 9 Goal: 
You will be given a mixture of three proteins and are tasked with separating, 
identifying, and determining the molecular weight of each protein using the 
techniques described above.  
 
 
Experimental Design  
You are provided with the following:  
 
• A column of sephacryl S300 filtration material, bed volume ~10 mL, 
equilibrated in PBS buffer – this column matrix can separate molecules 
between 10 and 1500 kDa 
• A concentrated solution of the following mix of proteins:  
• Cytochrome C, a pink/red heme-containing protein involved in 
electron transfer  
• A galactosidase, a colorless enzyme that hydrolyzes galactosides 
into monosaccharides 
• A serum albumin, a colorless protein that binds lipids in blood  
• A solution of blue dextran (a large colored sugar with a Mr ~ 2,000 kDa) and 
riboflavin (a brightly colored small molecule that will spend a maximal 
amount of time on the column)  
 
Running the column  
To get the best separation, the sample volume (the “load”) should be no more 
than 1% of the column volume; loading the sample properly is the key to attaining 
good chromatographic separation. To help keep your protein sample 
concentrated, you may add your blue dextran/riboflavin mixture to the column 
prior to adding your protein sample. To do this, it’s important to allow the buffer 
above your column to run to just above the column matrix. At this point, add the 
mixture, allow the mixture to run into the column, and add a small amount of PBS 
to further allow the column. When the mixture has fully entered the column, 
repeat this process with the protein sample; the aim is to have sample enter as a 
tight band with minimal dilution. When the protein sample has fully entered the 
column, top up the column with PBS, taking care to not disturb the column matrix. 
It is important to maintain a level of PBS above the column, never allowing it to 
dry. 
 
Collect PBS in a graduated cylinder until you are ready to begin collecting 
fractions (hint: when will this be? what should be coming off the column first?). It 
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is up to you to determine fraction size - more fractions will result in better 
separation of proteins, but there are limits to how many fractions you can assay.  
 
 
It is likely that you will have too many fractions to analyze on a single SDS-PAGE 
gel. To help narrow down which fractions to run on your gel, you have the option 
of performing a galactosidase assay and an ELISA assay designed to detect the 
serum albumin protein. 
 
 
Identification by enzymatic activity – running the galactosidase assay 
In order to determine which fractions contain your galactosidase protein, you will 
be utilizing an enzymatic assay that specifically detects the presence of this 
protein.  
• Add 50 µL of positive control, negative control, or of your fraction to 
your microplate strip 
• Add 150 µL of assay buffer to each well 
• Monitor for color change and record which wells/fractions tested 
positive 
Using this will allow you to determine which fractions contain your protein and 
can be used, along with the SDS-PAGE gel results, to determine the size of 
galactosidase. Note – this is a time sensitive assay, so be sure to add assay 
buffer quickly. 
 
Identification by an immunogenic assay – running the ELISA 
ELISA assays can be tailored to detect different proteins using different primary 
antibodies. You have an antibody that recognizes this serum albumin protein and 
can utilize it in an ELISA assay to determine which fractions contain this protein. 
 
• Add 50 µL of positive control, negative control, or of your fraction to a well 
in your microplate strip 
• After 5 minutes, dump out your wells by inverting them onto a stack of 
paper towels and gently tapping them.  Add 150 µL of wash buffer to each 
of your wells.  Discard your wash buffer.  Repeat, but allow your wash 
buffer to sit in the wells for 5 minutes.  The wash buffer will wash away 
any unbound proteins and block unoccupied binding sites. 
• Add 50 µL of primary antibody to your wells.  Allow it to bind for 5 minutes, 
after which time, dump out the antibody solution and wash 2x with wash 
buffer. You no longer need to incubate the wells with wash buffer. 
• Add 50 µL of HRP-conjugated secondary antibody.  Allow it to bind for 5 
minutes, after which time, dump out the antibody solution and wash 2x 
with wash buffer. 
• Add 100 µL of enzyme substrate to the wells.  
• Monitor for color change and record which wells/fractions tested positive. 
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Analysis by SDS-PAGE - right after the column or in the following week  
Your GSI will help you load and run your gel.  If you are unfamiliar with running 
SDS-PAGE gels, get help before you start. 
 
• Pipet 10 µL from each fraction into a separate eppendorf tube and add 10 
µL of 2X gel loading buffer. 
• Mix the sample, cap the tube and heat at 95 oC in a heating block for 5 
min. (Question: what does heating in loading buffer do to the proteins?).   
• During this time, set up your gel apparatus.  Make sure you position the 
gel carefully to avoid leaking buffer. And don’t forget – remove the tape 
from the bottom of the gel before setting up the apparatus. 
• To run the gel, carefully load ~15 µL (this will be based on the well 
capacity) of each sample into one of the sample wells on the top edge of 
the gel—use a pipetman to do this and make sure the wells are 
completely submerged with buffer before loading. Include a “ladder” lane 
of standards (10 µL of ladder should be fine).   
• Run the gel at ~180V until the blue marker dye is about 5 mm from the 
bottom edge of the gel.  
• Carefully remove the gel cassette and pry apart the plates.  
• Remove the gel—it can rip quite easily so be gentle—and transfer it to a 
container. Submerge the gel in enough Coomassie solution so that it 
completely covers the gel.    
• Once the Coomassie dye has penetrated the gel, (~10-30 min or until the 
entire gel is a deep deep blue), pour the Coomassie dye back into the 
bottle it came from and rinse the gel once with diH2O.   
• Pour the water in the appropriate waste and pour in enough destaining 
solution to completely submerge the gel.  You can add a couple of balled-
up Kimwipes in with your gel as the Kimwipes have an affinity for 
Coomassie and will help with the destain process.   
• As unbound stain diffuses out of the gel, protein bands should become 
visible. If necessary, your gel may be left to destain until the next lab 
session, when you can photograph your gels to include as part of your 
results.  Label your gel if you want to leave it over the week. 
• When you are ready to analyze band migration, place your gel on a 
lightbox and measure the distance traveled by each band, including each 
band in your ladder 
 ! !
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!
The following mass spectra were obtained to aid in precise protein size 
determination: 
 
The last protein to elute from the column: !!
!
The second protein to elute from the column: !
!
 
 
 
 
 
 
 
 
!
!
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 The first protein to elute from the column: 
!!
 ! !
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Write-up 
In your post-lab write up, include the following: 
 
• a digitized version of your gel including: 
o distances migrated for each band (including each band in your 
protein ladder) 
o a standard curve constructed using your protein ladder band 
migrations 
• the determined molecular weights for cytochrome C, BSA, and β-
galactosidase 
• a detailed description of how you determined the molecular weight for 
each protein, including: 
o which data you utilized in your determination, noting any 
inconsistencies in information collected from different sources 
o how you prioritized data collected from different sources, and, more 
importantly, why 
o include an explanation of why you disregarded, if applicable, certain 
data sets 
• a brief discussion of the benefits and limitations of each utilized technique 
(MS, size-exclusion chromatography, and each assay) – this will likely tie 
into your discussion on data prioritization 
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4.9 Student feedback handout 
 
Experimental,Evaluations,
!
!
We!are!constantly!striving!to!improve!the!designs!of!each!experimental!project!in!CHEM352,!
aiming!to!enhance!both!the!scientific!design!and!the!educational!utility!of!each!lab.!In!order!to!
aid!in!this!process,!we!are!asking!that!you!help!provide!feedback!so!that!future!versions!of!this!
course!can!benefit.!!
!
The!following!questions!ask!you!about!your!experience!with!each!laboratory!in!CHEM352!and!
how!you!felt!they!helped!accomplish!course!educational!goals.!
!
In!place!of!individual!survey,!you!will!be!working!in!groups!to!provide!these!assessments.!It!is!
imperative!that!each!group!member!is!vocal!and!included;!collective!responses!about!past!
experiments!will!help!provide!much!more!useful!feedback.!With!the!other!lab!members!at!your!
bench,!work!together!to!provide!consensus!responses,!using!reasoned!arguments!to!describe!
your!answers.!In!the!event!of!a!disagreement,!work!together!to!provide!the!best!possible!
consensus!response.!
! !
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Question,1:!An!important!part!of!any!undergraduate!laboratory!course!is!introducing!students!
to!techniques!that!are!relevant!and!useful!(i.e.!potentially!used!in!a!research!setting).!To!what!
degree!do!you!feel!that!each!experiment!accomplished!this?!
! ! ! ! !
! ! ! ! ! !!Not!at!all!!!!!!!!! ! !!!!!!!!Neutral!!!!!!!!!!!!!!Significantly!
Pipetting/buffers:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Amino!acid!titration:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Analysis!of!DNA/GMOs:!! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Protein!concentrations/spectrophotometry:! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Hemoglobin!separation:! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Enzyme!kinetics:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Protein!isolation/assaying:! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
!
Question,2:!Rank!each!experiment!in!terms!of!how!each!accomplished!this!goal;!1!=!most!
significantly!accomplished,!7!=!least!significantly!accomplished!
!
Pipetting/buffers:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Amino!acid!titration:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Analysis!of!DNA/GMOs:!! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Protein!concentrations/spectrophotometry:! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Hemoglobin!separation:! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Enzyme!kinetics:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Protein!isolation/assaying:! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
!
!
Include,any,comments/reasoning,below:,
, ,
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Question,3:!Unlike!lecture!courses,!laboratory!courses!provide!an!opportunity!for!“situated!
learning,”!allowing!students!to!learn!through!doing!by!mimicking!research!activities.!Though!it’s!
unlikely!any!person!can!gain!mastery!of!a!skill/technique!after!one!use,!it!is!a!goal!of!this!course!
to!introduce!students!to!techniques!in!a!setting!that!they!would!then!be!able!to!envision!
applying!those!techniques!to!alternative!settings!(such!as!to!solving!problems!in!a!research!lab).!
To!what!degree!do!you!feel!each!experiment!provided!opportunities!that!would!better!prepare!
you!for!working!in!a!research!environment?!!
! ! ! ! !
! ! ! ! ! !!Not!at!all!!!!!!!!! ! !!!!!!!!Neutral!!!!!!!!!!!!!!Significantly!
Pipetting/buffers:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Amino!acid!titration:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Analysis!of!DNA/GMOs:!! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Protein!concentrations/spectrophotometry:! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Hemoglobin!separation:! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Enzyme!kinetics:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Protein!isolation/assaying:! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
!
Question,4:!rank!each!experiment!in!terms!of!how!each!accomplished!this!goal;!1!=!most!
significantly!accomplished,!7!=!least!significantly!accomplished!
!
Pipetting/buffers:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Amino!acid!titration:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Analysis!of!DNA/GMOs:!! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Protein!concentrations/spectrophotometry:! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Hemoglobin!separation:! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Enzyme!kinetics:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Protein!isolation/assaying:! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
!
!
Include,any,comments/reasoning,below:,
, ,
! 161!
Question,5:!Laboratory!courses!provide!an!opportunity!to!produce!real!data.!A!goal!of!this!
course!is!to!provide!an!opportunity!to!critique!and!evaluate!data.!Occasionally,!it!may!even!be!
necessary!to!assess!and!reconcile!conflicting!data!in!order!to!come!to!an!experimental!
conclusion.!To!what!degree!do!you!feel!did!each!experiment!aid!in!your!ability!to!critically!
evaluate!data?!
! ! ! ! !
! ! ! ! ! !!Not!at!all!!!!!!!!! ! !!!!!!!!Neutral!!!!!!!!!!!!!!Significantly!
Pipetting/buffers:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Amino!acid!titration:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Analysis!of!DNA/GMOs:!! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Protein!concentrations/spectrophotometry:! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Hemoglobin!separation:! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Enzyme!kinetics:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Protein!isolation/assaying:! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
!
Question,6:!rank!each!experiment!in!terms!of!how!each!accomplished!this!goal;!1!=!most!
significantly!accomplished,!7!=!least!significantly!accomplished!
!
Pipetting/buffers:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Amino!acid!titration:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Analysis!of!DNA/GMOs:!! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Protein!concentrations/spectrophotometry:! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Hemoglobin!separation:! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Enzyme!kinetics:! ! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
Protein!isolation/assaying:! ! ! 1!!!!!!!!!!!2!!!!!!!!!!!!3!!!!!!!!!!!!4!!!!!!!!!!!!5!!!!!!!!!!!!6!!!!!!!!!!!!7!
!
!
Include,any,comments/reasoning,below:,
,  
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Question,7:!Are!there!other!learning!goals!that!you!believe!CHEM352!should!be!aiming!to!
achieve?!Please!list!any!below.!
!
!
!
!
!
!
!
!
!
!
,
,
Question,8:!If!you!have!any!other!critiques!that!you!wish!to!include,!please!list!them!below.!
! !
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4.10 End of semester assessment 
 Module!2:!Protein!Isolation!Scenario:!In!your!research!lab,!you!have!been!attempting!to!purify!a!specific!NADH,oxidizing!enzyme!to!study!in#vitro.!You!believe!you!have!isolated!this!enzyme!from!cellular!lysate,!but!when!you!run!a!SDS,PAGE!gel!analyzing!your!protein,!you!notice!an!extra!band!that!indicates!an!impurity!smaller!than!your!desired!protein.!You!have!a!few!hypotheses!as!to!why!you!may!be!seeing!two!bands!instead!of!one;!suggest!a!method!for!testing!each!hypothesis:!!
• the!enzyme!is!a!heterodimer!!!!!
• your!purification!method!isolated!an!extra!NADH,oxidizing!enzyme,!giving!you!a!mixture!of!two!different!dehydrogenases!!!!!
• a!truncated!version!of!the!protein!was!also!produced,!missing!a!part!of!the!C,terminus;!according!to!the!literature,!the!C,terminus!is!where!the!catalytic!site!of!the!enzyme!is!
! !
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Chapter 5 
 
Conclusions and Future Directions 
 
5.1 Design and characterization of bifunctional glucocorticoids 
 
Conclusions 
 
The glucocorticoid receptor (GR) has been a drug target for the better part of a 
century, with early drugs even predating the first expression of a nuclear receptor 
by several decades1,2, but the strategies to target this class of transcription 
factors have largely been stagnant in their methodology. Obtaining a crystal 
structure of the GR ligand-binding domain (LBD)3 was a breakthrough that 
allowed researchers to break away from traditional structure-activity relationships 
to guide ligand design4,  but these efforts have overwhelming subscribed to a 
paradigm of targeting the LBD alone5,6, ignoring discoveries that indicate factors 
outside the LBD play key roles in determining GR activity7-9. At the outset of my 
dissertation research, I set out to validate an alternative method of modulating 
GR activity. Chemical inducers of dimerization have been established as a novel, 
straightforward method for selectively inducing protein-protein interactions 
(PPIs)10,11 and provided an attractive method for guiding the construction of 
transcriptional complexes at GR-regulated genes. 
 
Preliminary efforts focused on adapting the well established yeast three-hybrid 
assay12 to a mammalian system utilizing human GR. In a standard three-hybrid 
assay, a Gal4 DNA-binding domain (DBD) is fused to a GR LBD, removing the 
need for a GR ligand to induce nuclear translocation (and effectively removing a 
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variable), while the removal of the GR N-terminal domain (AF1) removes 
potential PPIs from confounding an otherwise straightforward transcriptional 
output13. Despite these differences, we were able to develop a three-hybrid 
reporter system wherein transcriptional output was dependent on a bifunctional 
molecule bridging full-length GR and a fusion protein and dictated by the nature 
of the fusion. While the recruitment of a fusion-activator triggered sharp 
transcriptional activation, consistent with traditional three-hybrid experiments12,14, 
it was especially promising to see that a corepressor fusion protein was able to 
inhibit transcription when recruited. 
 
Extensive efforts were devoted to recreating recruitment-dependent 
transcriptional activity at GR-regulated genes. We were encouraged to find that 
the S100P gene appeared to be particularly sensitive to recruitment, but it was 
unclear why we were not able to reproduce similar activities at other genes. We 
were met with similar limitations when evaluating the activity of our BRD4-
targeting bifunctional molecule. Recruitment-dependent effects on the 
transcription of certain endogenous genes appeared be evident, but we were 
unable to make any certain conclusions about the susceptibility of a gene to 
transcriptional modulation by a recruited target. Predicting the activity of 
glucocorticoid-bound GR is difficult15-17, and our understanding of GR interactions 
within the larger environment of complex chromatin architecture is still in its 
infancy. These factors make it difficult to determine a priori when recruitment at 
endogenous genes is a possibility, but as sequencing technologies continue to 
develop and become more prevalent, our future ability to predict the 
transcriptional outcome of bifunctional molecule treatment will grow. 
 
During the initial characterization of the functional effects of BRD4-recruitment to 
the GR LBD, it appeared that recruitment, in the absence of competing factors 
through other GR domains13,18,19, could yield potent transactivation. This 
consequence did not translate to activity produced by full-length GR, but it 
nonetheless indicated that, under certain conditions, BRD4-recruitment might 
! 169!
result in transactivation. Following from this, we sought to determine if BRD4-
recruitment to antagonist-bound GR, lacking appreciable activation capabilities, 
would result in GR transactivation. The rationale for this was two-fold: the 
production of novel GR transcriptional outputs, as would be a predicted result by 
this molecule, is desirable, and the functional conversion of an antagonistic 
molecule to an acting agonistic as a result of extrinsic recruitment would be a 
powerful display of the potential of this system. As was the case with our agonist-
based bifunctional molecules, the activities stimulated by an antagonist-based 
bifunctional molecule were difficult to predict but highly encouraging. In a variety 
of systems, this molecule acted as a transcriptional activator relative to its parent 
antagonist. Investigating this molecule’s interactions with abnormal GR isoforms, 
an interesting pattern of selectivity in activation induction emerged, hinting at the 
possibility for future mechanistic studies on recruitment. Most encouragingly, 
however, was the observation that this molecule is capable of potent 
transrepression. The exact mechanism of GR-mediated suppression of 
inflammation is still elusive, but it has become clear that an ideal transcriptional 
response involves a profile reflecting a mixture of transactivation and 
transrepression20,21, hinting at the unique utility of this bifunctional molecule. 
 
Future directions 
 
Development of glucocorticoid-FK506 conjugates, preliminarily, was performed 
as a necessary step in confirming that full-length GR is a suitable partner in 
further three-hybrid studies, prior towards developing conjugates that target 
endogenous proteins. However, the success we achieved in recruitment of fusion 
proteins to GR, and subsequently affecting its activity, mark this as a potential 
method for monitoring the effects of recruiting alternative protein modulators to 
GR22. Advanced bifunctional ligands have been developed that recruit ubiquitin 
E3 ligases to targets, inducing the ubiquitylation of bound proteins23; however, 
similar strategies to effect other post-translational modifications have largely 
been unexplored. The modularity of our system allows for the facile replacement 
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of recruited moieties, making the recruitment of kinase-, acetylase-, or 
sumoylating-fusion proteins, to name just a few potential partners, a possibility 
(Figure 5.1). Though modification of GR in vitro is a straightforward process, the 
ability to trigger modification through the introduction of an extracellular stimulus 
is intriguing and provides a new method for mechanistic studies of GR. 
 
 
 
One observation that bore out from our three-hybrid studies was that recruitment-
dependent activity seemed to be dependent on cellular levels of GR. It is unclear 
if modulating levels of BRD4 will accordingly result in differential effects on GR 
activity following bifunctional molecule-treatment. In preliminary experiments, 
even slight overexpression of BRD4 lead to considerable cellular cytotoxicity, 
precluding an investigation into the role of BRD4 expression levels on 
! ! !! !
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! !! ! kinase FKBP 
GR 
! 
! ! !! !
! ! 
! 
! Altered transcriptional.
profile? 
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Figure 5.1 Inducible post-translational modification. The recruitment of specific fusion proteins to GR provides a potential 
method for triggering post-translational modifications, such as phosphorylation, in response to an extracellular stimulus by 
localizing relevant enzymatic proteins to the receptor. 
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recruitment. If it bears out that recruitment and, subsequently, transcriptional 
suppression of GR is weakened in cells expressing lower levels of BRD4 (or 
alternatively, strengthened in highly expressing cells), this may provide a method 
for further selectivity in action. This concept, moreover, may provide additional 
layers of complexity regarding selectivity in action. Throughout the work 
described here, several different cell lines were utilized for varying reasons as 
indicated. Ligand-mediated recruitment is likely an event that is affected by 
competitive intrinsic interactions, and differences in coregulator expression levels 
among different cell lines and tissue types likely plays a role in the ability for and 
outcome of recruitment. Accordingly, it would be naïve to assume that our 
bifunctional ligands would effect similar outcomes across a variety of cell lines. 
As such, it will be important to expand our studies to include multiple cellular 
environments to cast light on the effects that this variable plays within our 
system. 
 
In the construction of each bifunctional ligand, dexamethasone was chosen as a 
constituent member owing to its high affinity for GR and propensity for effective 
stimulation of nuclear translocation. As our investigations uncovered that BRD4 
recruitment is a method for suppressing GR activity, however, it became evident 
that many of the initial qualities that made dexamethasone attractive could 
potentially be detrimental. Though likely not the sole cause, the strength of the 
dexamethasone-GR interaction relative to the JQ1-BRD4 interaction may provide 
an explanation for the persistent activation capabilities of our bifunctional ligand 
at low dosing concentrations. Prednisolone and methylprednisolone are less 
potent glucocorticoids that are established conjugation candidates24 that could be 
used in the construction of ligands that provoke even further specialized 
transcriptional profiles, likely with low transactivation potential but maintained 
transrepression. 
 
Though the antagonist-based bifunctional molecule was incapable of ‘rescuing’ 
the activity of defective receptors implicated in glucocorticoid resistance, this 
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molecule may provide a key towards targeting an alternative instigator of 
glucocorticoid resistance. The NR3C1 gene is known to produce at least nine 
physiologically relevant GR isoforms25, and though the α-isoform, described 
throughout this thesis, is believed to be the dominant receptor, a single 
alternative isoform, hGRβ26, is believed to be expressed at significant levels in 
many, if not all, tissues. Produced by an alternative splicing splicing event, hGRβ 
has a truncated LBD containing fifteen unique residues relative to hGRα (Figure 
5.2). Canonically, hGRβ is incapable of ligand binding and serves simply as a 
dominant-negative receptor, serving to inhibit hGRα activity when overexpressed. 
However, recent reports have indicated that this isoform binds RU486 and 
undergoes nuclear translocation27, though this observation is in some dispute28. 
If hGRβ does indeed bind RU486, the antagonist-based bifunctional molecule 
would provide a unique method of modulating this isoform’s transcriptional 
activity, a highly desirable outcome given its believed role in the development of 
resistance in cancers such as multiple myeloma29. 
 
 
 
Figure 5.2 Glucocorticoid receptor isoforms. A: the glucocorticoid receptor is multidomain protein, consisting of a N-terminal 
domain (NTD), DNA-binding domain (DBD), and a ligand-binding domain (LBD). B and C illustrate the similarities between 
the dominantly expressed human GR isoforms, hGRα and hGRβ. Numbers represent standard notation for exons of the NR3C1 
gene. The divergence of hGRα and hGRβ arises from a splice variation, with each isoform incorporating a different ninth exon.   
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Many of these ideas touch on potential therapeutic applications for using our 
designed bifunctional steroids. However, the greatest power of this platform rests 
in the underlying modularity of the designed ligands and the proteins they target. 
Picking new targets and synthetically appending new ligands is relatively 
straightforward, and our ability to produce distinct transcriptional profiles 
accordingly is magnified exponentially relative to efforts that attempt to achieve 
this outcome through new monofunctional ligands. Currently, the prevailing 
limitation to this method is in our ability to predict the outcome of gene-specific 
regulation – it is highly beneficial that only certain genes are acutely sensitive to 
recruitment-dependent modulation, but we are currently unable to predict which 
factors contribute to this state. Despite this, we have demonstrated the much-
needed development of molecules capable of producing complex, novel 
transcriptional profiles. As we expand our ability to predict genes sensitive to this 
effect, we will be able to better design bifunctional ligands that provoke desired 
activation and suppression states of sensitive targets across the genome. 
Expanding beyond our system, future efforts will focus on using this knowledge in 
the design of new ligands, expanding our matrix of utilized constituent ligands 
and exponentially increasing our ability to induce novel transcriptional profiles. 
 
5.2 Effects of incorporating guided-inquiry into an educational laboratory 
 
Conclusions 
 
The course syllabus for CHEM352 at the University of Michigan, Biochemistry 
Techniques, is designed to provide students a broad immersion into techniques 
commonly performed in biochemical and molecular biological research 
laboratories. This design, coupled with rotating instructors for the course and 
limited resources for reform, precludes students from engaging in higher level 
cognitive activities30 in a biochemical environment. Though a small step forward 
from the expository design, the guided-inquiry laboratory style has been 
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demonstrated to provide significantly expanded benefits for students, raising 
engagement, understanding, and long-term cognition in a variety of settings31-36.  
 
Identifying a three-week portion of a previous syllabus that had been identified as 
underwhelming by students and instructors, we aimed to reform the experiments 
therein by introducing students to the same techniques (protein chromatography, 
mass spectrometric analysis of proteins, protein electrophoresis, and 
immunoassays) in the form of a guided-inquiry investigation. Extensive 
optimization of the module yielded a reproducible experiment capable of being 
administered to large (> 75) groups of students reliably without necessitating the 
purchase of any prohibitively expensive reagents; indeed, the most expensive 
reagent, a primary antibody recognizing bovine serum albumin, was purchased 
inexpensively ($135) at a quantity that is estimated to be adequate for six 
hundred students.  
 
Informal student response to the module was overwhelmingly positive, with 
students commonly remarking that it was enjoyable to engage in an experiment 
where there was a perception of problem solving. Formal elicited feedback 
confirmed this, as students identified the laboratory as engaging and containing a 
higher level of utility (i.e. transferability of skills to a non-educational setting). In 
an end of term assessment, a majority of students were capable of transferring 
learned skills in the module to the design of methods for investigating related 
‘research’ questions. As a result of this response, the experimental module has 
been formally incorporated into the course syllabus and is currently (April, 2015) 
being implemented by an instructor not involved with the design of the module. 
 
The reproducibility of this module, paired with the relative low cost of performing 
it by large groups of students, marks it as especially attractive for incorporation 
by educators at institutions similar to the University of Michigan, where efforts for 
substantive renovation can be difficult. 
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Future directions  
 
The construction of this laboratory module marked an important step forward in 
progressing towards a more significant overhaul of the CHEM352 syllabus, but 
there are still opportunities to continue to modify this experiment, raising its utility. 
For example, the experiment was intentionally designed to provide for a level of 
ambiguity to results obtained from the immunoassay portion of the module, 
believing this to be an appropriate method for students to have to interpret and 
reconcile unclear data. However, a significant portion of students met this with 
result by simply shutting down, believing the experiment itself to be flawed and 
without utility. This shed light on an important observation – many students 
observe experimental protocols as sacrosanct and do not have to go through the 
rigor of repeating and refining techniques, providing an inadequate impression of 
actual research. Though difficult to implement, allowing students to engage in 
method refinement would be an important way to further develop this module, 
and I believe the subsequent cognitive benefits would make the work well worth 
the effort.  
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